The 46th Annual Meeting of Taiwanese Dermatological Association by derma.tda

SCIENTIFIC PROGRAM

Table of Contents

Welcome address..............................................................................

Organizing committee........................................................................

General information..........................................................................

Registration..............................................................................

Transportation..............................................................................

Floor plan.........................................................................................

Program at glance...........................................................................

Professor Lu Yau-Chin Memorial Lectureship....................................

Speakers & Abstracts........................................................................

Free Papers..............................................................................

Case Reports..............................................................................

E-posters..............................................................................

Sponsors...................................................................................

Welcome Message Dear Friends and Colleagues, It is with great pleasure that we welcome you all to this exciting joint meeting hosted by the Taiwanese Dermatological Association (TDA), the East Asia Vitiligo Association (EAVA), and the Asian Society of Dermatopathology (ASD) at the Kaohsiung Exhibition Center, Kaohsiung, Taiwan, from Friday November 13 to Sunday November 15, 2020. We are honored to organize this special event during this extraordinary time. While the pandemic still looms around the globe, we are most fortunate to host this hybrid meeting. With our domestic colleagues enjoying the physical meeting and our foreign friends sharing their latest academic and clinical advances via the latest internet technology, we are able to bring the experts from EAVA and ASD to Taiwan! This year, in addition to the medical and aesthetic sessions covering all aspects of our specialty, we also included sessions covering medical education and evidence-based medicine with special focus on COVID-19 into our program. It is our hope that this meeting not only provides insights on recent advancements in the field of dermatology, but also includes important topics that are relevant to the medical society in general. For our friends who cannot be here in Kaohsiung physically, we thank you for your support and contribution to the success of this meeting. For our colleagues who are here in Kaohsiung for the meeting, we promise you a fantastic scientific program and an opportunity to meet up with colleagues during this extraordinary time. Please remember all the precautions we must practice in the time of this pandemic. Stay safe, stay healthy, and look forward to an excellent event! Cheng-Che E. Lan, MD, PhD President The 46 th Annual Meeting of Taiwanese Dermatological Association The 3 rd Meeting of East Asia Vitiligo Association

Dear Distinguished Guests, Colleagues, and Friends, Itâ&#x20AC;&#x2122;s our great pressure to welcome you to join the 2nd Annual Meeting of the Asian Society of Dermatopathology (ASD) at the Kaohsiung International Convention Center on November 13-15, 2020. ASD is a young society but has given tremendous efforts in the education of dermatopathology. In 2020, we started biannual basic course for young doctors and advanced topic-oriented monthly webinar for systematic learning. The annual meeting is another important event we can share and learn new information together. Despite the travel restriction due to COVID-19, we successfully invite experts in Asia, Europe, Africa, and US and organize comprehensive updates in dermatopathology in this meeting. We deeply appreciate for all speakerâ&#x20AC;&#x2122;s help to pre-record their lectures and we can provide a high-quality conference as usual. In this two-and-half day virtual meeting, there are self-assessment, interactive case discussion, keynote speeches, lectures, oral presentation in free communication, and posters exhibition. We hope all participants can discuss and acquire knowledge together to enhance the quality of patient care. Finally, we would like to acknowledge all organizing staff and participants for their efforts and commitment. I wish the convention every success and all the best to everyone.

Sincerely, Yu-Hung Wu MD President, Asian Society of Dermatopathology

Organizing Committee TDA Organizer濣Taiwanese Dermatological Association (TDA) Co-organizer濣Kaohsiung Medical University Chung-Ho Memorial Hospital Honorary President濣Hsin-Su YU ( ὀ⹟⏟ ), Gwo-Shing CHEN ( 晚⛲䅶 ) President濣Cheng-Che E. LAN ( 喴㔦ⓙ ) Secretary-General濣Wei-Tai YU ( ὀ䶔㳗 ) (Medical) , Nai-Jen HSU ( 娘ḪẨ ) (Aesthetic) Committee of Medical session濣Shih-Tsung CHENG ( 愔婐⭾ ), Stephen Chu-Sung HU ( 僈㥁㝥 ), Yin-Chun CHEN ( 晚䚯␂ ), Sheng-Yiao LIN( 㝾倽⠖ ), Yang-Yi CHEN ( 晚㳘ự ), Chi-Ling LIN ( 㝾嵞侵 ), Ching-Ying WU ( ␚朹䨵 ), Shiang-Yu YANG ( 㤱侻⭮ ), Tzu-Hung HUANG ( 溪⬷洢 ), Szu Hao CHIU ( 悘〄屑 ), Ting-Ting YANG ( 㤱ẔẔ ), Li-Wen CHIU ( 悘印曖 ), Yng SUN ( ⭒䅹 ), Wei Cheng FANG ( 㖠䄹䧲 ), Wei-Yao WANG ( 䍲‰俧 ), Huei-Jing WANG ( 䍲㙰㙖 ) Committee of Aesthetic session濣Chung-Jen TSENG ( 㛥⿇Ẩ ), Teh-Yang CHENG ( 危⾞㏁ ), Chao-Chin WANG ( 䍲㘔㬤 ), Pin-Chi CHIU ( 悘⒨漱 )

ASD Organizer濣Asian Society of Dermatopathology (ASD) President濣Yu-Hung WU (Taipei) Vice-president濣M RAMAM (New Delhi) Secretary-General濣Thuy L. PHUNG (Houston) Treasurer濣TAN Suat Hoon (Singapore) Education Committee濣Joyce LEE (Chair, Singapore), Sujay KHANDPUR (New Delhi), Daisuke TSURUTA (Osaka), Sook Jung YUN (Gwangju), Wei ZHANG (Nanjing)

EAVA Organizer濣East Asia Vitiligo Association President濣Cheng-Che E. LAN ( 喴㔦ⓙ ) Secretary-General濣Wei-Tai YU ( ὀ䶔㳗 ) 5

General Information VENUE Kaohsiung Exhibition Center (KEC) is nestled in Kaohsiung, Taiwan. This business exhibition center is open in April 2014. The center has a total floor area of 67,000m2, which can accommodate 1,424 exhibition booths and different meeting room sizes suitable for up to 4,000 people. It provides a place for holding international conferences and trade shows. The exhibition center boasts of its multifunctional and ÀH[LEOH DUHDV DQG RI LWV FDSDELOLW\ WR KRVW GLႇHUHQW NLQGV of events, making it a perfect venue to host the TDA 2020 and the TSID 2020 annual meeting.

2ႈFLDO /DQJXDJHƝEnglish 5HJLVWUDWLRQ 3KRWR LGHQWL¿FDWLRQ ZLOO EH UHTXLUHG IRU UHJLVWUDWLRQ 2. Registration Time for each conference dayƝ Friday, Nov. 13 12:00-17:30 Saturday, Nov. 14 08:00-17:30 Sunday, Nov. 15 08:00-13:30 ˩for attending TDA General Assembly, registration open at 07Ɲ30˪ 7KH RQVLWH UHJLVWUDWLRQ GHVN ORFDWHV RQ WKH WKLUG ÀRRU of Kaohsiung Exhibition Center. (No.39, Chenggong 2nd Road, Qianzhen Dist., Kaohsiung 806, Taiwan, ROC). For details, please refer to the linkƝ httpƝ//www.kecc.com.tw

$FFHVV &RQWURO 1. Please wear your name badge at all timesƞ attendees will need the name badge to gain admission to VFLHQWL¿F VHVVLRQV DQG WKH H[KLELWLRQ DUHD 3OHDVH QRWH WKDW RXU VWDႇ PHPEHUV DUH LQVWUXFWHG QRW to permit entry without a name badge.

2. The Congress does not provide childcare. Children and infants are not permitted in any of the congress session rooms or events. Disruptive behavior will result in the revocation of attendance privileges. Attendees must be 18 years of age or older to attend any social activities.

0HDO ,QIRUPDWLRQ 1. Lunches and coffee breaks are included in the registration fee. 2. Gala dinner is canceled due to the COVID-19 pandemic.

&DQFHOODWLRQ DQG 5HIXQG 3ROLF\ 1. Due to cost considerations, the registration fee is non-refundable if the attendee cannot attend for personal reasons. 2. Should the meetings need to be cancelled or rescheduled for any catastrophic or weather causes, registration fees will be refunded in full by the Taiwanese Dermatological Association (TDA).

&RQIHUHQFH 3ROLF\ The unauthorized use of any form of device to audiotape, photograph, or video-record is prohibited during the lectures

:,), VHUYLFH Kaohsiung Exhibition Center (KEC) provides complimentary wireless internet access service. WiFi for mobile phone, tablets, and laptops will be accessible within the Center. No special registration process or fees are required.

&HUWL¿FDWH RI $WWHQGDQFH The certificate of attendance can be obtained online DIWHU FRQJUHVV HYDOXDWLRQ WKURXJK WKH FRQJUHVV RႈFLDO website.

Registration Fee Category

Before Oct. 15th Pre-Registered Fee

Nov. 13th- 15th Onsite Register Fee NTD 5,500 (approx. 180 USD)

NTD 5,500 (approx. 180 USD)

Asian Society of Dermatopathology (ASD)

Member

NTD 4,500 (approx. 150 USD)

East Asia Vitiligo Association (EAVA)

Member

NTD 4,500 (approx. 150 USD

League of ASEAN Dermatological Societies (LADS)

Member

NTD 4,500 (approx. 150 USD

Physician

NTD12,000 (approx. 400 USD)

Medical Student

NTD 1500 (approx. 50 USD)

Non-member

Medical NTD 3,000 Personnel (approx. 100 USD)

Remark

An ASD member ID or a membership application form required for discounted rates

Member ID required for discounted rates

NTD 5,500 (approx. 180 USD) NTD 15000 (approx. 500 USD) NTD 2,000 (approx. 65 USD)

Student ID is required for registration

NTD 3,500 (approx. 120 USD)

Research Assistant Physician Assistant Registered Nurse

1RWHVĆ? 1. The online registration system for the Pre-Registered Fee will be closed at 24:00 of Oct. 15, 2020 (GMT+8 Taipei Local Time). Only onsite registration is available after Nov. 13, 2020. 2. The registration fee for TDA session included ASD and EAVA session. 3. Register on-line meeting of ASD and EAVA onlyĆ?httpsĆ?//tinyurl.com/y6y5bjlh $FFRPSDQ\LQJ SHUVRQ FDQ DWWHQG WKHWUDGH H[KLELWLRQ EXW QRW WKH VFLHQWLÂżF VHVVLRQV 5. When TDA Member, Associate Member or Non-Member is also a student, you will be charged by your own identify. If you want to register as a student, the continuing education credits will not be obtained. 6. For Luncheon, please pre-register for receiving meal voucher.

Transportation

Kaohsiung Station

High Speed Rail Zuoying Station

KEC

Kaohsiung Light Rail C8

Fuxing 3rd Rd

d dR 2n in Yix

Fuxing 4th Rd

Xinguang Rd.

Sanduo Shopping District R8

Rapid Transit Red Line Zhongshan 2nd Rd

No. 39, Chenggong 2nd Rd., Kaohsiung City 806, Taiwan

Siwei 4th Rd

Zhonghua 5th Rd

Kaohsiung Port

Kaohsiung Exhibition Center (KEC)

Chenggong 2nd Rd

Singuang Ferry Wharf

Zhonghua 4th Rd

Jianguo 3rd Rd

Kaohsiung International Airport

7DR\XDQ ,QWHUQDWLRQDO $LUSRUW 1RUWKHUQ 7DLZDQ The airport is in the top 30 busiest airports in Asia and hosts over 25 million passengers each year. Over 35 airlines serve the airport with flights throughout Asia and Europe and North America. The fastest and easiest way to get to Kaohsiung City from Taoyuan International Airport is by High Speed Rail.

.DRKVLXQJ ,QWHUQDWLRQDO $LUSRUW 6RXWKHUQ 7DLZDQ Kaohsiung International Airport is an air transportation hub in southern Taiwan and located in the down town of Kaoshiung City. Direct flights from over 40 major Asian cities.

7DLZDQ +LJK 6SHHG 5DLO High Speed Rail connects from Taoyuan International Airport (TPE) to Kaohsiung City in 1 hour and 30minutes. Terminal in Kaohsiung is Zuoying StationƝ20 minutes taxi ride to KEC, or take the Kaohsiung Rapid Transit to Sanduo Shopping District which is then a 10 minute walk to KEC. You could also take a taxi from the Sanduo Shopping District to KEC.

.DRKVLXQJ 5DSLG 7UDQVLW Take Kaohsiung Rapid Transit Red Line and get off at Sanduo Shopping District Station which is the closest to KEC. It’s a 10-minute walk from there. Kaohsiung Light Rail Transit (Circular Line) Kaohsiung Light Rail / C8 StationƝKaohsiung Exhibition Center 8

1. Test-ride ScheduleĆ?First train 07:00 am, last train 21:00 pm 2. Every 10 minutes during peak hours. Every 15 minutes during off-peak hours. 3. Test-ride stationĆ?C1 Lizihnei-C8 Kaohsiung Exhibition Center. Passengers must press the â&#x20AC;&#x153;openâ&#x20AC;? button while getting on / off trains. 4. Please visit Kaohsiung Light Rail to learn more updated information. (httpsĆ?//www.krtco.com.tw/en/index.aspx)

+LJKZD\V NorthwardsćżŁ+LJKZD\ 1R WR =KRQJ]KHQJ 5RDG ([LW Äş =KRQJ]KHQJ 5RDG Äş 7XUQ OHIW RQ WR =KRQJKXD 5RDG Äş 7XUQULJKW RQ WR 6LZHL 5RDG Äş 7XUQ OHIW RQ WR &KHQJJRQJ 5RDG Äş $UULYH SouthwardsćżŁ+LJKZD\ 1R WR .DRKVLXQJ (QG =KRQJVKDQ 5RDG ([LW PDNH ULJKW Äş =KRQJVKDQ 5RDG Äş 7XUQ OHIW RQ WR ;LQJXDQJ 5RDG Äş 7XUQ OHIW RQ WR &KHQJJRQJ QG 5RDG Äş $UULYH

.DRKVLXQJ 3XEOLF %XVHV 1. 168 2. Red 16 (Kaohsiung Software Technology Park Sanduo Shopping District Station) 3. 70 (Cianjhen Station Chang Gung Memorial Hospital) (Above information has been partially adapted from the official website of KEC)

3DUNLQJĆ?Parking Lot Opening HoursĆ?8 Am-10 Pm 5DWHVĆ?CarĆ?NT$40 / per hour

MotorbikesĆ?NT$40 / per time

LEVEL 3

Ңᓡୢ

ŕŅł

ŊůŧŰ

ᆩၯൢӪġġġġġġġġġġġġġġġġġ౪ൟൢӪ

ŗŊő

அߜོ

ୢġŅŪůŪůŨġŢųŦŢ

Ⴋυ੕ൢୢġņĮűŰŴŵŦųġŢųŦŢ Ҫጳऋİं‫ـ‬İኅ୦

Pre-conference : Nov. 13, 2020, Friday RM304A (250) Medical dermatology 13:00-14:00

RM304B (250) Subspecialty Society Registration

RM303A (55)

RM302A (55)

ASD

Satellite

Evidence-Based Pediatric Dermatology Dermatopathology selfDermatology ( ⏗䁊ℹ䫌凮朹⯸⹛䚕冁憒⭟㛪 ) assessment part 1 ( ⏗䁊⯍嬰憒⭟⭟㛪⌻徍 ) 15:30-16:00 &RႇHH %UHDN Interactive case discussion 16:00-17:30 Acne and rosacea forum (Dermatopathology Society of the Philippines) 14:00-15:30

Satellite symposium ( 塈⤼ )

Nov 14, 2020, Saturday RM305 (500)

RM301B (500)

Medical Aesthetic dermatology dermatology

RM304A (250)

RM304B (250)

RM303A (55)

RM303B (55)

RM302A (55)

RM302B (55)

TSID

Satellite

ASD

TDA oral

EAVA

Satellite

08:00-08:30

Registration Satellite What's new Skin Symposium Clues to the Free paper EAVA Invited 08:30-10:30 in atopic Cosmeceutical immunity, and diagnosis (1-8) lectures ( 䦕Ὥ ) dermatitis immunotherapy ( 咺湾◰ ) 10:30-11:00 &RႇHH %UHDN Opening of TDA 11:00-12:30 Plenary session Lunch Lunch symposiumƝ Lunch Lunch EAVA business Autoimmune Symposium 12:30-13:30 Symposium Symposium meeting ( 䦸憒ạ ) blistering (Merz) disease Treatments of vitiligo in the Dermatological Satellite ,QÀDPPDWRU\ surgery-The Free paper Best of TSID Symposium What's new in skin Thread lifting 13:30-15:00 experience of (9-14) ( 峤嫥叙 ) 2020 psoriasis disorders the medical ( ヶ檿 ) institutions in Taiwan 15:00-15:30 &RႇHH %UHDN Satellite Hair and stem Collagen Free paper EAVA Free Skin cancer Symposium Infection 15:30-17:00 cells forum VWLPXODWLRQ ¿OOHU (15-20) Communication ( 䙥术὚ )

Lunch Symposium ( ⭰䛆䔆㉧ )

Satellite Symposium ( ⫳䔆 ) ( 䑅例 )

Satellite Symposium ( ⍁俳併 )

Nov. 15, 2020, Sunday RM305 (500)

RM301B (500)

Medical Aesthetic dermatology dermatology

RM304A (250)

RM304B (250)

RM303A (55)

RM303B (55)

RM302A (55)

RM302B (55)

TSID

Satellite

ASD

TDA oral

Business meeting

Satellite

TDA general 08:00-08:30 assembly

TSID business meeting

What's new in autoimmune 08:30-10:30 disease & drug reaction

Microbiota, Skin and Health

10:30-11:00 11:00-12:30

Botulinum toxin

Satellite Symposium ( 檿⾞併 )

Soft tissue and nail tumor

&RႇHH %UHDN Plenary session

Lunch Symposium Lunch Lunch Lunch Pigment Symposium Free paper 12:30-13:30 Symposium Symposium Research ( ⍁俳併 ) ( 㱪憒⭟ ) ( 㮻䉠㧩 ) and phototherapy Update in the Satellite What's new in Energy Based Genetic skin Symposium melanoma and 13:30-15:00 skin tumor Device disease lymphoma ( ⏖勌⤒ ) 15:00-15:30 &RႇHH %UHDN Dermatopathology Injectable self-assessment ㄆ㞺⭟⇭ ¿OOHUVƝbeauty part 2 Free paper 15:30-17:00 Infectious NOT the ASD Closing disease forum beast ceremony Farewell remarks

Medical Satellite education Symposium Case Report Satellite ( ℑ⾾㗡 ) (21-35) Symposium ( 䑅例 ) ( ⫳䔆 )

Lunch Symposium ( ⦕ₙ䵙俇 ) ( 㛃ẅ )

TSDAS general assembly

Lunch Symposium ( ㄂⊂㠠 )

Case report (36-46)

SDRDF

Satellite Symposium ( ㄂⊂㠠 )

Satellite Case report symposium (47-57) ( 㛃ẅ )

Satellite symposium ( ℑ㒵 )

1992 ⹛Ə⏗䁊⋾Ḕ⌾⏫✗⤁ἴ䚕冁䦸∴弐⏳Ẩ䆘⿘㌷䍢Əㇷ䪲㜓⟡憸㛪ⷳ㜂僤䂡⏗䁊䚕冁䦸⭟䔳ⅴ岉䍢㢰啫Ḳ⊂˛㘩ℰ匶効Ə ⋭⋭怵ṭṳ⌨⹥⹛˛ằ⹛㜓㛪ᾄ㓁㔦⺃⅓␱⯍㖤㛧㖗䙫岈⛿㲼ạ䮈䏭徍㲼Ə恟⇡㖗䙫䬓ṄⰭ告Ṳ㛪˛⇭∌䂡Ɲ㤱⛲㜷˚僈ᾱ⻿˚ ␚備⻿˚㤱὚㇦˚ὀ⹟⏟˚Ἴ⮃㉦˚㜵⾾⭶˚愔墼㕮˚䳧䦧取˚晚䦧䐛˚晚⛲䅶˚㛥凯晭˚␚Ẳⱘ˚唈␯劚˚惔䌕㙡˚䳧㙖䐑˚ 揿㕮⭶˚⼜㙖䙺˚⼜曙Ẕ告Ṳ⅘㛰⌨Ṅἴ告ṲƏ乣乳㎏ⰼ㛪⋀˛ ‫⟥‫‬䈌曃 1Ʊ 䲪サ宠Ʊ䴺⸾摉Ṅ ⌀亾∽㐗㉆䮾⺳姙ⵥ Professor Lu Yau-Chin Memorial Lectureship (Since 1992) 娔䪲㖣 1992 ⹛Ə˥␩俧⍦㕀㍯䳧⿜嬂⺎˦Ḫ䂡䳧⿜⏗䁊䚕冁䦸柿⯵ạ␩俧⍦㕀㍯˛㭋嬂⺎恧媲䕝Ị⛲暂䚕冁䦸⭟䔳㳗㕾㖣㮶⹛⏗䁊䚕冁䦸憒⭟㛪⹛㛪㜆敺䙣塏⯯栳㻻嬂˛徫ằⷙ恧媲䳫ᷰ⌨ἴ⛲暂䚕冁䦸⭟䔳柩⯽⭟俬咅⏗Ə✏⏗䁊䚕冁䦸憒⭟㛪 ⹛㛪㻻嬂 ( 媲婚奲ᷲ昫塏 )˛ ␩俧⍦㕀㍯ (1925-1991) 㘖ṳ㈗⽳⏗䁊䚕冁䦸⥇⟡䙣ⰼ柿⯵ạḲᷧ˛䕉㥔凑⛲䪲⏗䁊⤎⭟憒⭟晉Ə1964 ⹛Ọ 39 㭙勘⹛ 㗮Ợ㭊㕀㍯Ə㭞Ợ⏗⤎憒晉䚕冁䦸ḢỢ⤁⹛ (1972-1975, 1982-1989)Əḍ㖣 1966 ⹛嵛併⛲㝃Ⅎ⤎⭟⸒⾅ Conant 㕀㍯䟻῕ 憒䔏䜆厳⭟Ə㋨乳㷘俼Ə㖣 1977 ⹛䍙㗌㜓㝘⋾⤎⭟憒⭟⍁⣒⭟ἴ˛␩㕀㍯㖣⭟堺䟻䩝岉䍢剖⤁ƏˣḔ⛲ạ䚕冁䖬⛽孃ˤ⛂弖 Ḫ憴奨吾ὃ˛1963 ⹛䙣塏⤁⬻『䚕䈮Ḳ媽㕮㖣㗌㜓˥䚕冁䦸Ḳ减⹱˦曃婳Ə廪䏥ằ䆆䟌Ḳ Tanner “mesh graft” Ⰱ㗐ᷧ⹛˛ ␩㕀㍯㛪⏳⤁ἴ䚕冁憒⭟ℯ怙Ə㖣 1975 ⹛≜䪲凡䁊䚕冁䦸憒⭟㛪Əḍ㦕Ợ≜㛪䏭Ṳ敞⛂Ⱝ˛␩俧⍦㕀㍯䕉䔆凛⊂⏗䁊䚕冁䦸䙣ⰼƏ⛲ⅎ岮㠣䚕冁䦸⏳Ẩㇽ㛰⹟⽾妑䂀ℯ峉Ə倭偤⅝㕀䚱Əㇽ᷽Ị䛟ₚƏ䞢ỗ梏䮫˛ằ㗌Ọ˥␩俧⍦㕀㍯䳧⿜嬂⺎˦ ䷓㇞ℯ峉Ə乣⽧敲ὭƏ㔃㈲⥕怙Ə㈺怇㛛⣖斱䙫⏗䁊䚕冁䦸˛ ⌀亾∽㐗㉆䮾⺳姙ⵥ⨶仃 (1993-2020)濣 ⴲⵤ

᳹姙⨶仃

ⴲⵤ

᳹姙⨶仃

1993

Richard L. Dobson 㕀㍯

2007

Yasuo Kitajima 㕀㍯

1994

䟚㨲⺞㭊㕀㍯

2008

Yoshiki Miyachi 㕀㍯

1995

Kowichi Jimbow 㕀㍯

2009

Masutaka Furue 㕀㍯

1996

Hideo Yaoita 㕀㍯

2010

Shinji Shimada 㕀㍯

1997

Eugene A. Bauer 㕀㍯

2011

Jean-Hilaire Saurat 㕀㍯

1998

Georg Stingl 㕀㍯

2012

捥㭊㗵㕀㍯

1999

奦ⷄ㭍ṳ㕀㍯

2013

Jean-Claude Roujeau 㕀㍯

2000

嗮㕮⍁㕀㍯

2014

Peter M. Elias 㕀㍯

2001

Tezuka Tadashi 㕀㍯

2015

Harvey Lui 㕀㍯

2002

Stephen I. Katz 㕀㍯

2016

2003

Kunihiko Tamaki 㕀㍯

2017

Shinichi Sato 㕀㍯

2004

MasakoMizoguchi 㕀㍯

2018

Sybren de Hoog 㕀㍯

2005

Vincent J. Hearing 㕀㍯

2019

Mark Udey 㕀㍯

2006

≰㉝㝘㕀㍯

2020

Jean L. Bolognia 㕀㍯ Yoshiki Tokura 㕀㍯

2Ʊ 䕬偘恩⨶僅⥐榒㭆䠔㘮㐗㉆䈌 Professor Tsu-Chieh Shen Award (Since 2014) 2014 ⹛Ə楽≜ “ 㱯䤽㝗㕀㍯䌵 ”Ə䌵⋜峱⊐ₚ㒔⩹檻㕮⬾⠘⯵ㇽ⽘柚ⅎ⮠Ə㗵桖僤ᾪ怙䤥㛪⤎䜥憴好䚕冁⁌⺞Ə㎷⌮䚕冁䦸⭟䙫⽉屈⑳⽘柦⊂ (Image and Impact)˛㖣㮶⹛⏗䁊䚕冁䦸憒⭟㛪⹛㛪柹䌵˛㮶ờ⽾䌵ὃ⒨䌵憸㖗⏗⹊ṻ吓KƏḍ凛峯䳧⿜䌵⺎凮嬰㛟Ə㮶⹛柷⮁䌵⋜ᷧ凚ᷰờὃ⒨˛㜓䌵柬敲徍ỌὭƏⷙ㛰⅝ẽ⯯䦸憒⭟㛪Ủ㔯˛媲⏫ἴ㛪Ⓢ勌✏⠘䫇曃婳ㇽ䶙巖㖗偅䛲∗ℑ䦧䙫⠘⯵ㇽ娼媽ὃ⒨˛㭈徵⯮姱ざ㎷ᾂ䵍㜓⟡憸㛪˛勌婙ὃ⒨㛧⽳⎾娼⯐朹䝅Ə㦕䍙 “ 㱯䤽㝗㕀㍯䌵 ” 㭱㦕Ə姱ざ㎷ᾂ 俬ẍ⏖䍙峯啫慓˛㜓⟡憸㛪偖䵈 E-mailƝserdf220@gmail.com 㭆䠔㘮㐗㉆䈌㨵⬄⹕᳹ 2014

嗲㞃㗌⠘悘ᾱ⏰姿俬

2015

⏗䁊㖗䔆⠘吓⍁嵬˚僈㮺屑姿俬

2016

偖⏯⠘晚曏摒姿俬

2017

Ḕ⤕态姱䤥晚‰⺔姿俬

2018

偖⏯⠘㜵㨠ạ姿俬

2019

Ḕ⛲㘩⠘䧲䂚䑲姿俬嗲㞃㗌⠘溪ộ䦲姿俬

2020 㱯䤽㝗㕀㍯ẍ䂡⏗䁊䚕冁䦸⭟䙣ⰼ䙫憴奨柿⯵ạƏ⎪凮≜䪲⏗䁊䚕冁䦸憒⭟㛪ḍ㋨乳岉䍢⭟㛪˛㜓⟡憸㛪⾜⽾㱯㕀㍯ ⮝ạ⏳ヶƏỌ⅝⏴嫘䂡㭋䌵柬⑤⏴Ə䳧⿜ẽ⯴⏗䁊䚕冁䦸⭟䙣ⰼ䙫㷘恇⽘柦˛ 㱯䤽㝗㕀㍯ (1923-2001) 婼䔆㖣⏗⌾㖗䇆ⷩƏ1945 ⹛㗌㜓Ⲑ㈲憒⭟⯯敧⭟㠈憒䦸䕉㥔Ə㛴⋀⏗⤎昫娔憒晉䚕冁䦸 (1955-1958) ⽳Əㆰ㝃偗㗵晉敞Ḳ恧⎪凮檿暫憒⭟⤎⭟匰≜ㇷ䪲凮㗐㜆⻡娔˛ᷧ䔆溪憸㭙㛯岉䍢㖣檿暫憒⭟⤎⭟䚕冁䦸Ə ㎏⊼⌾⏗䁊ℑ剖䚕冁憒⭟㛴⋀凮䟻䩝Əὃ備勘㈴Ə敲≜檿暫憒⭟⤎⭟䚕冁䦸ㇷ䂡⏗䁊䚕冁䦸⭟憴掕˛㱯㕀㍯ὃ備勘㈴˚ 㠪㜵㻦敧凮⇡按⇡⊂ᾪ怙⤁ἴ⛲暂䟌⏴⭟俬咅⏗⭟堺ẋ㴨Ə孺⹛廼憒⸒ᷴ䔏⇡⛲⍚僤侹⽾㛧ℯ怙䙫䟌嬿凮㉧堺˛ 3Ʊ ≘㟋㑮䏝ᶡ◉教⨶亐䱑椕 AAD (American Academy of Dermatology) Mentorship Program (Since 2015) 併⛲䚕冁䖬⭟㛪㘖᷽䔳ᷱ㛧⤎䙫䚕冁䦸憒⸒䴫主Ḳᷧ˛䂡㎷⌮ἶ晉憒⸒⎪⊇ American Academy of Dermatology (AAD) ⹛㛪⭟堺㛪字䙫⭟侹ㇷ㔯Ə㜓⟡憸㛪㮶⹛峱⊐ᷧἴ⛲ⅎ岮㷘䚕冁䦸憒⸒⎪凮 AAD ⹛㛪Əḍ㒻Ợἶ晉憒⸒Ḳ mentor˛⸝柿 ἶ晉憒⸒⎪凮 AAD ⹛㛪㜆敺㴢⊼˚⭟侹奶䕒˚䵺樾⇭Ẓ⎱䔆㴢䅎㖀˛ 2022AAD 姩㖣ᷰ㛯 25-29 㗌㖣溢⡅嫟⡅ⷅ Boston ⷩ˛㭈徵⏫ἴ㛪Ⓢ帛年⠘⏴ Mentorship˛Boston 㘖併⛲㭞⏙⏴➵Ə ‣ ⽾怇娑˛2023 AAD 姩㖣 ᷰ 㛯 17-21 㗌㖣巖㗺㖖 ⭰ 悊 ⷅ New Orleans ⷩ˛2024 AAD 姩㖣 ᷰ 㛯 8-12 㗌㖣 San Diego, California 凰堳˛ 㨵ⴲ AADMentorship Program ⹕䈌恩⳩ ⴲⵤ

AAD ◮涜

䈰䈌恩⳩

㗋↗㤝㢉

2015

San Francisco

愔䙥䎱

⤮併憒晉

2016

Washington DC

≰⤵嘔

檿暫敞⺁憒晉

2017

Orlando, Florida

㜵㍞䐍

曀⑳憒晉

2018

San Diego

㖤ᷧ㖗

⏗⋾敞⺁憒晉

2019

Washington DC

⼜㛃⭮

⏗⋾敞⺁憒晉

2020

Denver, Colorado

溪㮺デ

⛇䖒ガ㛪字⎽㵯

2021

San Francisco

⏖僤⛇䖒ガ⎽㵯

4Ʊ淑↳ⴲ巓恩⳩傲⅙㑺⨶圑䛒䤴 Stellar Success Award Young Scientist Award in Psoriasis Research Program 滺⋜⛲ⅎ⹛廼䚕冁䦸憒⸒⯴ṥ䙓䙫㴨堳䖬⭟˚䖬り䔆㴢⒨峑˚减⹱㲢䘩˚⟡䣵䖬䏭䔆䏭䬰⏫㖠杉⤁⁁䟻䩝˛㮶⹛柷姯柹䙣 ᷧ凚⛂⏴ℑ䦧媽㕮⽾䌵俬˛峱⊐憸栴䂡㖗⏗⹊ᷰ凚ᷪ吓K˛峱⊐⹛廼䚕冁䦸憒⸒⤁⾅Ṳ䛟旃䟻䩝凮⭟堺ẋ㴨˛ Ɣ 䔚媲㖠⻶媲₀⦌ῲạ CVƏỊ塏『吾ὃ⅏㕮ƏE-mail ㇽ惜⮫凚㜓⟡憸㛪㛪✧˛媲娢㗵䔚媲⹛⺍Ə㮶ῲ⹛⺍㈑㭉㗌㜆䂡⅒㛯ᷰ⌨ᷧ㗌˛ 㜓⟡憸㛪偖䵈㖠⻶Ɲ 岈⛿㲼ạ䚕冁䦸⭟䙣ⰼ㕮㕀⟡憸㛪怊䵈曢婘Ɲ02-2711-8288 ₚ䜆Ɲ02-2752-3368 E-mailƝri3480dgdavid@gmail.com 㛪✧Ɲ⏗⋾ⷩ⤎⭰⌧⿇⭄㝘巖⛂㮜 333 噆 3 㧺㨵ⴲ Stellar Success Award 妔㑅䈌䈰䈌恩⳩ ⴲⵤ

䈰䈌恩⳩

2017

僈㥁㝥˚溪朽⮳˚㜵⭆䨾˚㝾Ⰱ⭶˚䍲滵刃

2018

㝾Ⰱ⭶˚悘桖掗˚僈㥁㝥˚唈暬䫠

2019

ὀ䶔㳗˚㝾Ⰱ⭶˚悘桖掗˚䍲滵刃

2020

唈暬䫠˚ὀ䶔㳗˚㝾Ⰱ⭶˚㈛勘῕˚佬晤

5Ʊ⋏宅㲯䕬偘䢏恩⳩傲㐪 (Since 2017) ⏗䁊䚕冁䦸憒⭟㛪僤㛰ằ㗌哓⊪䙣ⰼ凮⯯㥔⽉屈⎱䤥㛪✗ἴ˛㘖䔘␩㕀㍯⎱⤁ἴ䚕冁憒⭟ℯ怙䙫徂⋋敲≜⎱ᷴ㖞㛰ℑ䦧㖗堧⊇⅌㈧⅘⏳⭳ㇷ˛㜓⟡憸㛪晋ṭ䵍⹛廼䚕冁䦸憒⸒滺⋜㈺㰊⣽Ə⏳㘩奨⏸娘⤁岮㷘䙫˚‣⽾⽳怙⭟侹˚⯴䤥㛪㛰䨴㥜⤰䍢䙫∴弐憒⸒塏总媇㑖䙫㕓ヶ凮ㄆ嬄˛㜓⟡憸㛪㮶⹛⯮柹䙣㕟⏴ SERDF Lifetime Achievement AwardƏ塏㏁怀Ẃ岮㷘怵⎢⤁⹛ ⯯㥔ᷱ䙫⊑⊂凮㋨乳䙫䤥㛪⤰䍢˛ㇸῸ嬠喰怀ῲ㩆㛪Ə塏总媇㑖䙫ㄆ嬄˚㕓ヶ凮㉦嫥˛㜓⟡憸㛪⯮㛪⊑⊂ₚ㉦Ə忤暏ẽῸ䙫党㭌Ə㋨乳旃㇞˚㛴⋀怀壈䙫ạ㯸Ə孺ㇸῸ⾅Ṳ䙫⯯㥔㛛⎾∗䤥㛪⯱㕓凮傖⮁˛ 㨵ⴲ SERDF Lifetime Achievement Award 䰀嵩⠇䈹䈌䈰䈌恩⳩ ⴲⵤ

䈰䈌恩⳩

2017

惔㉦䵘憒⸒˚⭒╆䒆憒⸒

2018

Ⱐ⛲曽憒⸒˚嶀㦕䙣憒⸒

2019

嗮㕮⍁憒⸒˚㖠䓿㣇憒⸒˚␚Ὲ剖憒⸒

2020

唈㰛岒憒⸒

6Ʊ 淑↳宅㲯恩⳩㖲᳈⬢㣑Ʊ屃屈朙⮮䕂䛒䤴 Outstanding Award in Dermatological Science Programư(Since 2020) 2020 ⹛嵞娔何˧␚⤐峃ℯ䔆㚏␚晚咨咨⥚⣒䚕冁䦸⭟⁸⇡媽㕮䌵˨Ọ䌵⋜⏗䁊䚕冁䦸⭟䔳ℑ䦧ạ㈴㉼⅌⌺嵱⭟堺䟻䩝凮柩⯽媽㕮≜ὃƏ怙俳㎷檿⛲ⅎ憒䘩⒨峑Ə⢅怙⛲㯸⁌⺞䥶䤰凮⏗䁊⛲暂⭟堺✗ἴ˛䌵⋜䮫⛴Ɲ䓫恟Ḳ䚕冁䦸⭟⭟堺媽㕮⏖䂡Ɲ 䚕冁⟡䣵䖬䏭䔆䏭䟻䩝˚䚕冁䖥䖬㴨堳䖬⭟˚䖬り䔆㴢⒨峑˚减⹱㲢䘩䬰䬰䛟旃⯍嬰憒⭟˚ṥ䙓⎱䚕冁怵㔶ℴ䖒䖥り˚ℹ䫌⎱ 俨ạ䚕冁䖥䖬䟻䩝˚䚕冁兒䘋⭟䬰䬰䛟旃䚕冁䦸⭟柿⟆䟻䩝媽㕮˛㮶⹛柷姯柹䙣ᷧ⏴⽾䌵俬˛峱⊐憸栴䂡㖗⏗⹊ᷰ⌨吓K˛ 峱⊐䚕冁䦸憒⸒⾅Ṳ䛟旃䟻䩝凮⭟堺ẋ㴨˛䔚媲㖠⻶媲婚奲憒⭟㛪䶙䫀⅓␱ㇽ凮㜓⟡憸㛪偖䵈˛

Professor Lu Yau-Chin Memorial Lectureship Masayuki Amagai

Masayuki Amagai, M.D., Ph.D. is Professor and Chair, Department of Dermatology, Keio University School of Medicine (2005- ), and Dean, Keio University School of Medicine (2017- ). He is also Team Leader, Laboratory for Skin Homeostasis, RIKEN Center for Integrative Medical Sciences (2013- ). He did a postdoctoral fellowship at Dermatology Branch, NCI, NIH with guidance of Dr. John R. Stanley (1989-1992). Dr. Amagai has served professional societies in leadership positions including as President of Japanese Society for Investigative Dermatology (2012-14), and President of Japanese Dermatological Association (2018- ). He has also been serving a number of international journals, including as Consulting Editor for the Journal of Clinical Investigation (2007- ) and Section Editor for Journal of Investigative Dermatology (2002-2017). He is an International Member of the National Academy of Medicine USA (2016-)and a Council Member of Science Council of Japan (2018-). Dr. Amagai's clinical and research interests center on autoimmune and allergic skin diseases, skin barrier, and skin immunology. Specifically, he has been studying on the pathophysiological mechanisms of pemphigus, peripheral tolerance, the skin barrier homeostasis, and the impact of impaired skin barrier on the onset of atopic dermatitis and other allergic disorders.

Cracking the codes of autoimmune disease, pemphigus SessionĆ?Plenary session

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 11:00 to 11:30

RM 305 â&#x20AC;&#x201C; LEVEL 3 Pemphigus is a group of IgG autoantibody-mediated blistering diseases of the skin and mucous membranes that includes three major formsĆ?pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus. Histologically, there is intraepidermal blister formation due to the loss of cellâ&#x20AC;&#x201C;cell adhesion of keratinocytes. Immunopathologically, in vivo bound and circulating IgG autoantibodies against desmogleins are found. Patients with pemphigus vulgaris and pemphigus foliaceushave IgG autoantibodies against desmoglein 3 and desmoglein 1, respectively, while patients with paraneoplastic pemphigus also have IgG autoantibodies against plakin molecules as well as a T-cell-mediated autoimmune reaction that leads to an interface dermatitis. Our longstanding interests in pemphigus have led to the identification of the autoantigen as Dsg3 for pemphigus vulgaris (1991), the production of recombinant proteins for Dsg1 and Dsg3 (1994, 1995), the development of ELISA as serological diagnostic tools (1997), the proposal of desmoglein compensation theory for logical explanation of sites of blisters (1998), and the generation of an active disease model for pemphigus vulgaris (2000). Last 10 years, we have been more focusing on autoreactive T cells, which help B cells to produce autoantibodies as well as react against self-antigen with resultant tissue injury. Using the mouse model of pemphigus vulgaris, we isolated Dsg3-reacting T cell clones that are responsible for pathogenic anti-Dsg3 IgG production, and generated Dsg3-specific T cell transgenic mice and found WKDW WKRVH 7 FHOOV ZHUH FDSDEOH RI QRW RQO\ LQGXFLQJ DQWLERG\ SURGXFWLRQ EXW DOVR LQWHUIDFH GHUPDWLWLV LQ D 7&5 DYLGLW\ DQG ,)1 Č&#x2013; dependent manner. Paraneoplastic pemphigus shows fatal involvement of lung as a form of bronchiolitis obliterans probably due to T-cell-mediated autoimmune reaction. Intriguingly, Dsg3 is not expressed in lung in normal conditions, while ectopic Dsg3 expression is observed in the lungs with squamous metaplasia which is often found in the lungs of patients with paraneoplastic pemphigus. Dsg3 and other epidermal Ags were ectopically expressed in the lungs after inflammation or pulmonary injuries, which was sufficient for recruitment of Dsg3-specific CD4+ T cells at least in mice. Thus, squamous metaplasia after pulmonary epithelial injury may play a crucial role in redirecting the skin-specific autoimmune reaction to the lungs in PNP. The current major topic in our laboratory is to clarify the mechanisms of peripheral tolerance to Dsg3 for self-reactive T cells. Dsg3deficient thymus was transplanted to athymic mice to produce a unique condition in which Dsg3 was expressed only in peripheral tissue, not in the thymus. Dsg3-specific CD4+ T cells developed in the transplanted thymus but subsequently disappeared in the periphery. Furthermore, Dsg3-specific T cells that developed under Dsg3-deficient conditions disappeared following adoptive transfer into wild-type recipients in an antigen-specific manner. These findings indicate the important role of peripheral tolerance to prevent harmful autoimmune reaction. The strategy of controlling the peripheral tolerance will provide a novel therapeutic approach to develop antigen-specific immune suppression for devastating autoimmune diseases.

Friday, 13 Nov. RM 304A 14:00-15:30

Evidence-Based Dermatology ( ŃŽá˘&#x160;á&#x201E;&#x201A;á&#x153;&#x152;á&#x161;&#x201A;á?°á?°ŕ˝źâ&#x20AC;ŤÚ&#x17E;â&#x20AC;Źá&#x2019;˛ ) ModeratorĆ?Ching-Chi Chi ( äŽžă&#x201D;ä&#x2039;¨ , Taiwan) Ć&#x2018; 14:00-14:50

COVID-19 in dermatology practiceĆ? perspective of three levels of prevention in public health

Tao-Hsin Tung ( ĺ&#x152;Ąĺź&#x2018;ĺ&#x192;&#x2020; , Taiwan)

Ć&#x2018;14:50-15:20

How dangerous is short-term corticosteroid use? Reading the â&#x20AC;&#x2DC;Association between oral corticosteroid bursts and severe adverse eventsĆ?a nationwide population-based cohort studyâ&#x20AC;&#x2122; paper

Ching-Chi Chi ( äŽžă&#x201D;ä&#x2039;¨ , Taiwan)

Ć&#x2018; 15:20-15:30

Q&A

RM 303A 14:00-15:30

Dermatopathology self-assessment part 1 ModeratorĆ?Han-Nan Liu ( â&#x2026;&#x2021;ăˇ â&#x2C6;&#x2022; , Taiwan) Ć&#x2018;14:00-14:30

Case 01-05

Cheng-Hsiang Hsiao ( ĺ?Ťă¨Ąä Ł , Taiwan)

Ć&#x2018; 14:30-15:00

Case 06-10

Wei Zhang ( âˇłć&#x161;&#x; , China)

Ć&#x2018; 15:00-15:30

Case 11-15

Cher-Wei Liang ( ă&#x153;żâ&#x17D;°äąŤ , Taiwan)

16:00-17:30

Interactive case discussion (Dermatopathology Society of the Philippines) ModeratorĆ?*HRUJLQD & 3DVWRUÂżGH 3KLOLSSLQHV

Ć&#x2018; *HRUJLQD & 3DVWRUÂżGH 3KLOLSSLQHV $UQHOID & 3DOL]D 3KLOLSSLQHV (LOHHQ &XELOODQ 3KLOLSSLQHV

Johann Dayrit (Philippines), Daisy King-Ismael (Philippines), Jasmin Jamora (Philippines)

RM 304B 14:00-15:30

Pediatric Dermatology ( ŃŽá˘&#x160;â&#x20AC;Ťŕš&#x2021;Ú&#x2039;â&#x20AC;Źá&#x2021;&#x201E;ß§Đ?Ô&#x2018;ŇŞá&#x152;łá&#x161;&#x201A;á?°ŕ˝ź ) ModeratorĆ?Yang-Shia Dai ( ă&#x192;˛áśŽć&#x2014;&#x153; , Taiwan) Ć&#x2018; 14:00-14:30

Pediatric atopic dermatitisĆ?theory and reality

Ć&#x2018;14:30-15:00

Case Challenge

Ć&#x2018; 15:00-15:30

Common Q&A at Outpatient Clinic

Yang-Shia Dai ( ă&#x192;˛áśŽć&#x2014;&#x153; , Taiwan) I-Hsin Shih ( ă&#x2018;ťá˛žă&#x2018;Ž , Taiwan) Wan-Yi Chou ( â&#x152;ŚâŠ&#x2122;ážž , Taiwan) Yao-Nien Chuang ( ĺ&#x2030;&#x2C6;ä&#x201A;˝â´˛ , Taiwan) Nien-Feng Chang Liao ( âˇłâś&#x201D;â´˛âŽŽ , Taiwan)

16:00-17:30

Acne and rosacea forum ModeratorsĆ?Pa-Fan Hsiao ( ĺ?Ťä&#x201D;źĺ&#x2026;Ş , Taiwan), Yin-Chun Chen ( ć&#x201D;ąä&#x2013;&#x2020;â&#x2039;&#x2122; , Taiwan) Ć&#x2018; 16:00-16:25

Pathogenesis of RosaceaĆ&#x17E; genetic background, innate immunity, and skin barrier

Ć&#x2018;16:25-16:50

The discovery of a new comedolytic addressing the microcomedone

Ć&#x2018; 16:50-17:15

Trifarotene - A novel treatment for acne and rosacea

Ć&#x2018; 17:15-17:30

Q&A

Kenshi Yamasaki (Japan) Jean-Hilaire Saurat (Switzerland) Kai-Che Wei ( ć¨?ă ľâ&#x17D;° , Taiwan)

Saturday, 14 NOV. RM 305 08:30-10:30

What's new in atopic dermatitis ModeratorsƝTom Chan ( 夷㔸὏ , Taiwan), Chih-Hung Lee ( 㘌⺕⩍ , Taiwan) Ƒ 08:30-08:50

Systemic treatment considerationƝwhat’s new for moderate to severe AD

Ƒ08:50-09:10

Atopic dermatitis 2020 update

Ƒ 09:10-09:30

Disease trajectories in childhood ADƝ with a focus on prenatal exposure

Ƒ 09:30-09:50

Environmental factors in the pathogenesis and clinical outcome of atopic dermatitis

Ƒ09:50-10:10

Treatments for Childhood ADƝan update on emerging therapies

Ƒ 10:10-10:30

Is AD a systemic disease?

Jacob Thyssen (Denmark) Po-Ju Lai ( 宲㚍⡀ , Taiwan) Kwei-Lan Liu ( ⅇ⠌哫 , Taiwan) Peter Yu Yu ( ẜḏ , Taiwan) Chia-Yu Chu ( 㗯⩴䌚 , Taiwan) Yung-Tsu Cho ( ∑斋⎰ , Taiwan)

11:00-12:30

Plenary session ModeratorƝHsin-Su Yu ( ḗⴶ⊶ ) Ƒ 11:00-11:30

Cracking the codes of autoimmune disease, pemphigus (Professor Lu Yau-Chin Memorial Lectureship)

Masayuki Amagai (Japan)

ModeratorƝCheng-Che E. Lan ( 咋㏽⎰ ) Ƒ11:30-12:00

Environment and skin

Jean Krutmann (Germany)

ModeratorƝYu-Hung Wu ( ⋱佰ⷖ ) Ƒ12:00-12:30

Emerging trends in non-invasive diagnosis in dermatology and dermatopathology

Manu Jain (USA)

13:30-15:00

What's new in psoriasis ModeratorsƝWei-Tai Yu ( ḗ䱫㮮 , Taiwan), Nan-Lin Wu ( ⋱∕旔 , Taiwan) Ƒ 13:30-13:50

Evolution of pathophysiologic insights in psoriasis

%ULDQ 1LFNRORႇ 86$

Ƒ13:50-14:10

Psoriasis and comorbidity

Ƒ 14:10-14:35

Update on the pathogenesis of psoriasis

Shang-Hung Lin ( 㙕⫘⩍ , Taiwan)

Ƒ 14:35-15:00

What's the future of psoriasis treatment?

Chung-Yee Hui ( 壯ᶰ䌢 , Taiwan)

Akimichi Morita (Japan)

15:30-17:00

Hair and stem cells forum ModeratorsƝChao-Chun Yang ( 㠈㗛惜 , Taiwan), Chih-Chiang Chen ( 攱⺕ⷵ ,Taiwan) Ƒ 15:30-15:50

New stem cell marker of interfollicular epidermal cells and the SRVVLEOH HႇHFWV RI YLVLEOH OLJKW

Ƒ15:50-16:10

Managing patients with male pattern hair lossƝ my clinical experience

Ƒ 16:10-16:20

Break

Ƒ 16:20-16:40

Hair regeneration from radio-/chemo-therapeutic injury

Ƒ16:40-17:00

Female pattern hair loss at a glance

Kyoung-Chan Park (Korea) Ren-Yeu Tsai ( 叟ᵿ斦 , Taiwan)

Sung-Jan Lin ( 㙕曊㿴 , Taiwan) Ching-Ying Wu ( ⋱昐䤌 , Taiwan)

Saturday, 14 NOV. RM 301B 08:30-10:30

Cosmeceutical ModeratorĆ?Pin-Chi Chiu ( ĺ˝Żâ?żć¸&#x2C6; , Taiwan) Ć&#x2018; 08:30-08:50

â&#x2039;˝âŚ&#x201E;â&#x2019;¨âť&#x160;â?ąă˛źĺĽśäŽ&#x2C6;ä?ĺ&#x2021;Žâ&#x2039;˝âŚ&#x201E;â&#x2019;¨ć&#x20AC;źĺĽśâť&#x160;â?ąâ&#x2021;áş&#x2019;

Wen-Horng Lee ( ă&#x2DC;&#x152;ă&#x2018;&#x2026;ćŻš , Taiwan)

Ć&#x2018;08:50-09:10

ć&#x2DC;&#x2122;ă&#x203A;&#x201C;ä&#x201D;&#x2030;â&#x2019;¨ăŞ&#x2030;ă¸&#x201C;á¸˛ĺĽśäŽŤĺ&#x2021;Žä´&#x2014;äŽ§ - áşĄćŞťă¸&#x201C;ĺŠ?

Ching-Gong Lin ( ă&#x2122;&#x2022;ăł&#x192;âŠŹ , Taiwan)

Ć&#x2018; 09:10-09:30

ć&#x2DC;&#x2122;ă&#x203A;&#x201C;ä&#x201D;&#x2030;â&#x2019;¨ăŞ&#x2030;ă¸&#x201C;á¸˛ĺĽśäŽŤĺ&#x2021;Žä´&#x2014;äŽ§ - ćŞťâŁ˝ă¸&#x201C;ĺŠ?

Victor Shan ( â&#x2018;Źă˝¸â&#x20AC;&#x2021; , Taiwan)

Ć&#x2018; 09:30-09:40

Q&A

Ć&#x2018;09:40-10:00

ĺ&#x2014;&#x152;âŚ&#x201E;â&#x2019;¨ä&#x2C6;łâˇŠâ &#x203A;äŤ?ä&#x2C6;&#x201D;á¸˛â&#x201E;&#x2018;â&#x2039;&#x2030;ĺ&#x2021;Žâ&#x160;&#x160;â&#x2039;&#x2030;

Ć&#x2018; 10:00-10:20

7KH ÂżUVW FOLQLFDO VWXG\ RI &\VWHDPLQH YV +\GURTXLQRQH RQ Asian face

Ć&#x2018; 10:20-10:30

Q&A

Mandy Chao ( ĺą&#x2014;ä&#x2030;&#x2021;ä&#x20AC;&#x2026; , Taiwan) Yung-Hsueh Huang ( ćś â&#x2020;&#x2026;â¨ś , Taiwan)

13:30-15:00

Thread lifting ModeratorsĆ?Cheng-Kun Wang ( ä&#x2030;&#x2030;ă¨Ąâ&#x2DC;˘ , Taiwan), Hung-Hsu Yang ( ă &#x2C6;âˇ&#x2013;ă&#x2019;Ť , Taiwan) Ć&#x2018; 13:30-14:00

The complications of thread lifting and the management

Ć&#x2018;14:00-14:30

Nerve injury caused by thread procedure

Ć&#x2018; 14:30-15:00

Material and deep plane thread lift

Chia-Hsien Hsieh ( ĺ§&#x203A;á¸ąă ° , Taiwan) Kuang-Cheng Chang ( âˇłâ&#x20AC;&#x2021;ă¨Ą , Taiwan) Ching-Shung Yang ( ă &#x2C6;ă&#x20AC;´â&#x2C6;&#x2026; , Taiwan)

15:30-17:30

&ROODJHQ VWLPXODWLRQ Ă&#x20AC;OOHU ModeratorsĆ?Nai-Jen Hsu ( ĺŁŻá´ áľż , Taiwan), Chao-Chin Wang ( ä&#x2030;&#x2030;ă&#x201C;Ťă§ť , Taiwan) Ć&#x2018; 15:30-16:00

Crucial injection concepts and literature updates of the SRO\FDSURODFWRQH EDVHG ÂżOOHU

Shang-Li Lin ( ă&#x2122;&#x2022;áł&#x2C6;äŚ&#x2030; , Taiwan)

Ć&#x2018;16:00-16:30

Global consensus guidelines of hyperdiluted RDS for skin WLJKWHQLQJ Há&#x201A;&#x2021;HFWV

Ya-Hui Chen ( ć&#x201D;ąć&#x2013;&#x192;âž&#x17E; , Taiwan)

Ć&#x2018; 16:30-17:00

'Lá&#x201A;&#x2021;HUHQW SUHSDUDWLRQ DQG XVDJH RI 3RO\ / /DFWLF $FLGĆ?concept of bone implant Poly-L,Lactic Acid

Ć&#x2018; 17:00-17:30

Poly-D,L-Lactic Acid Ć?mechanisms and clinical applications

Cheng-Chieh Huang ( ćś ă?˝á˝? , Taiwan) Chuan-Yuan Lin ( ă&#x2122;&#x2022;â˛&#x203A;â&#x20AC; , Taiwan)

Saturday, 14 NOV. RM 303A 08:30-10:30

Clues to the diagnosis ModeratorƝYu-Hung Wu ( ⋱佰ⷖ , Taiwan) Ƒ 08:30-09:00

The apoptotic keratinocyte

Ƒ09:00-09:30

Characteristic histopathology of genodermatoses

Ƒ 09:30-10:00

3ODVPD FHOO LQ¿OWUDWHV LQ GHUPDWRSDWKRORJ\

Ƒ 10:00-10:30

Clues to drug reaction

Rajiv Joshi (India) Choa-Kai Hsu ( 壯悕₯ , Taiwan) Shang Ian Tee (Singapore) Yu-Hung Wu ( ⋱佰ⷖ , Taiwan)

13:30-15:00

,QÁDPPDWRU\ VNLQ GLVRUGHUV ModeratorƝM. Ramam (New Delhi) Ƒ 13:30-14:00

The histopathology of autoimmune bullous diseases

Ƒ14:00-14:30

Unusual clinico-pathological variants of sarcoidosis and diagnostic challenges

Meenakshi Batrani (India)

Ƒ 14:30-15:00

Recent understandings of granulomatous skin diseases

Jun Asai (Japan)

Daisuke Tsuruta (Japan)

15:30-17:00

Infection ModeratorƝJoyce Lee (Singapore) Ƒ 15:30-16:00

Cutaneous infectious diseasesƝAn update

Ƒ16:00-16:30

Monsters in the skin

Ƒ 16:30-17:00

Perianal Tuberculosis and Crohn’s diseaseƝ a diagnostic challenge

Wayne Grayson (South Africa) Panitta Sitthinamsuwan (Thailand) Norain Karim (Malaysia)

Saturday, 14 NOV. RM 302A 08:30-10:30

EAVA Invited lectures ModeratorsƝCheng-Che E. Lan ( 咋㏽⎰ , Taiwan), Feng-Jie Lai ( 宲嬎὏ , Taiwan) Ƒ 08:30-08:50

Holistic management of vitiligoƝMy Journey

Ƒ08:50-09:05

Epidermal endocrine units regulates meIanocyte function in vitiligo

Ƒ 09:05-09:20

The role of home use phototherapy in the treatment of vitiligo

Ƒ 09:20-09:35

$73 3 ; LQGXFHG LQÀDPPDVRPH DFWLYDWLRQ DV D QHZ SOD\HU for vitiligo development

Ƒ09:35-09:50

Melanocyte behaviors during depigmentation and repigmentation processes in a chemical vitiligo mouse model

Tamio Suzuki (Japan)

Ƒ 09:50-10:05

Surgical approaches for vitiligo

Jung-Min Bae (Korea)

Ƒ 10:05-10:20

Use of Janus Kinase Inhibitors in dermatology: Focusing on vitiligo

Ƒ 10:20-10:30

Discussion

Davinder Parsad (India) Ichiro Katayama (Japan) Flora Xiang ( 朷吼䵠 , China) Sang-Ho Oh (Korea)

Cheng-Che E. Lan ( 咋㏽⎰ , Taiwan)

13:30-15:00

Treatments of vitiligo in the Dermatological surgery-The experience of the medical institutions in Taiwan ModeratorƝYu-Pin Cheng ( 快䀚⸪ , Taiwan) Ƒ 13:30-13:45

Quantitative outcome assessment of color match and the extent of repigmentation by image analysis software

Yen-Jen Wang ( 䉉䛒ᵸ , Taiwan)

Ƒ13:45-14:00

Management of vitiligo patients with surgical interventions

Chau Yee (Charlene) Ng ( 涁㓫䌚 , Taiwan)

Ƒ 14:00-14:15

3URFHGXUDO DSSURDFKHV IRU VWDEOH YLWLOLJR RQ GLႈFXOW WR WUHDW VLWHV

Ƒ 14:15-14:30

Review and prospect of surgical treatment of vitiligo patient

Ƒ14:30-14:45

Melanocytes transplantation with simple, available, inexpensible equipment

Ƒ 14:45-15:00

Discussion

Jin-Bon Hong ( 㯨㠦彤 , Taiwan) Chao-Hsing Kao ( 榖䀥㓝 , Taiwan) Yu-Pin Cheng ( 快䀚⸪ , Taiwan)

15:30-17:00

EAVA Free Communication ModeratorsƝCheng-Che E. Lan ( 咋㏽⎰ , Taiwan), Chau Yee Ng ( 涁㓫䌚 , Taiwan) Ƒ 15:30-15:45

Optimal treatment for vitiligo (Invited Lecture)

Atsushi Tanemura (Japan)

Ƒ15:45-16:00

Pathogenesis of vitiligo from the viewpoint of genetics (Invited Lecture)

Masahiro Hayashi (Japan)

Ƒ 16:00-16:10

)XQFWLRQDO JHQRPLF VFUHHQLQJ IRU LGHQWL¿FDWLRQ RI WKHUDSHXWLF targets of vitiligo

Jimyung Seo (Korea)

Ƒ 16:10-16:20

Evaluation of low-dose tofacitinib combining narrowband UVB therapy for treating vitiligo patients who had failed previous therapyƝA pilot study

Wei-Cheng Fang ( 㑷䀐䣉 , Taiwan)

Ƒ16:20-16:30

Feasibility of Oral Tranexamic acid (TA) for vitiligo patients with melisma

Ƒ 16:30-16:40

3URSRVDO RI D 1HZ &ODVVL¿FDWLRQ RI 6HJPHQWDO 9LWLOLJR DQG Evaluation of Its Clinical CoursesƝA Retrospective Review of 956 Patients

Ƒ 16:40-16:50

(ႈFDF\ DQG VDIHW\ RI LQWUDYHQRXV PHWK\OSUHGQLVRORQH SXOVH therapy for progressive vitiligoƝa retrospective study of 33 therapy experiences from a single institute

Ƒ 16:50-17:00

Discussion

Pin-Hsuan Chiang ( 㬝⍿勯 , Taiwan) Jongwook Oh (Korea)

Moyuka Irimada (Japan)

Sunday, 15 NOV. RM 305 08:30-10:30

What's new in autoimmune disease & drug reaction ModeratorsƝWen-Hung Chung ( 拖㑅⩍ , Taiwan), Stephen Chu-Sung Hu ( 侟㠘㘼 , Taiwan) Ƒ 08:30-08:55

Immune mechanism & new therapeutic in cutaneous lupus erythematosus

Ƒ08:55-09:20

Current understanding and therapeutic strategies for pemphigus

Ƒ 09:20-09:45

Pathomechanism and management for Scleroderma

Ƒ 09:45-10:10

Paraneoplastic pemphigus mimicking Stevens-Johnson syndrome/ toxic epidermal necrolysis

Ƒ10:10-10:25

Alopecia areataƝrecent progress

Chun-Bing Chen ( 攱Ẉ宑 , Taiwan) Hua-En Lee ( 㘌劭⼧ , Taiwan) Yukie Yamaguchi (Japan) Wen-Hung Chung ( 拖㑅⩍ , Taiwan) Riichiro Abe (Japan)

11:00-12:30

Plenary session ModeratorƝPui-Yan Kwok ( 徫㭙⼧ , Taiwan) Ƒ 11:00-11:30

From melanocytes to melanoma

Boris Bastian (USA)

ModeratorƝChia-Yu Chu ( 㗯⩴䌚 , Taiwan) Ƒ11:30-12:00

Systemic sclerosis – from pathophysiology to treatment

Thomas Krieg (Germany)

ModeratorƝYun-Ting Chang ( ⷳ新ᵫ , Taiwan) Ƒ12:00-12:30

Skin microbiome and acneƝwhat's the role?

Mauro Picardo (Italy)

13:30-15:00

:KDW V QHZ LQ VNLQ WXPRU ModeratorsƝShih-Tsung Cheng ( 快大⩕ , Taiwan), Yen-Jen Wang ( 䉉䛒ᵸ , Taiwan) Ƒ 13:30-13:50

Current advances in melanoma treatment

Ƒ13:50-14:10

Single cell transcriptome analysis of acral melanoma

Ƒ 14:10-14:30

Diagnosis and management of mosaic disorders

Ƒ 14:30-14:50

The Mechanisms of Photocarcinogenesis -update-

Ƒ14:50-15:00

Q&A

Chiao-En Wu ( ⋱㐗⼧ , Taiwan) Daw-Yang Hwang ( 涁弑㊘ , Taiwan) Akiharu Kubo (Japan) Nishigori Chikako (Japan)

15:30-17:00

Infectious disease forum ( ཐࢗᏰϷ ) ModeratorsƝSheau-Chiou Chao ( 屗㖇䢉 , Taiwan), Pei-Lun Sun ( ⨩⚷ứ , Taiwan) Ƒ 15:30-16:00

⸟奲『䖬䙫䚕冁塏䏥⎱⅝㲢䘩

Ƒ16:00-16:10

䖌䙓㲢䘩䙫㳏ヶṲ柬

Ƒ 16:10-16:40

䚕冁⣽䦸嘼何⎱㲢䘩䛟旃䙫ㄆ㞺

Ƒ 16:40-17:00

减⹱ᷴ⏖⿤䕌䙫⯶㝘奦 - 埙埙⍘㩆

Chia-Wen Lee ( 㘌Ⓡ㑅 , Taiwan) Sheau-Chiou Chao ( 屗㖇䢉 , Taiwan) Chun-Wei Lu ( 䖥Ẉ䌉 , Taiwan) Ming-Tsan Wang ( 䉉慖䂤 , Taiwan)

Sunday, 15 NOV. RM 301B 08:30-10:30

Botulinum toxin ModeratorsƝChrang-Shi Lin ( 㙕搵䁗 , Taiwan), Yi-Hua Liao ( ⶔ⻟劭 , Taiwan) Jeng-Hsien Lin ( 㙕㏽宠 , Taiwan)

Ƒ 08:30-09:00

)DFWRUV LQÀXHQFLQJ WKH GLႇXVLRQ RI ERWXOLQXP WR[LQV

Ƒ09:00-09:30

7KH LQÀXHQFH RI QHXURWR[LQ UHVLVWDQFH LPPXQRJHQLFLW\ RQ LWV aesthetic application

Michael Kao ( 榖Ⓡら , Taiwan)

Ƒ 09:30-10:00

+RZ WR RSWLPL]H WKH HႇHFWV RI LQWUDGHUPDO ERWXOLQXP WR[LQ IRU rosacea-associated erythema

Pin-Chi Chiu ( 彯⍿済 , Taiwan)

Ƒ 10:00-10:30

Botulinum toxin in migraine treatment

Shih-Pin Chen ( 攱᳔⸪ , Taiwan)

13:30-15:00

Energy Based Device ModeratorsƝRen-Yeu Tsai ( 叟ᵿ斦 , Taiwan), Sindy Hu ( 侟ủ⤵ , Taiwan) Ƒ 13:30-14:00

Treatment of keloid, hypertrophic and atrophic scars with energy-based devices

Ƒ14:00-14:30

What's news in high-Intensity focused ultrasound and laser hair removal

Ƒ 14:30-15:00

$ UHDO JDPH FKDQJHU" 7KH FRGH WR DFKLHYH LGHDO HႇHFW RI HIFEM technology from the perspective on mechanism and design of technology and individual discrepancy

Shiou-Han Wang ( 䉉Ậ⋩ , Taiwan) Che-Hao Hsu ( 壯⎰嬨 , Taiwan) Carl Cheng ( 快◉儭 , Taiwan)

15:30-17:00

,QMHFWDEOH ÀOOHUV濣beauty NOT the beast ModeratorsƝChung-Jen Tseng ( 㖼⺞ᵿ , Taiwan), Yau-Li Huang ( 涁亾䦉 , Taiwan) Ƒ 15:30-16:00

$VLDQ OLS HQKDQFHPHQW E\ +$ ¿OOHU LQMHFWLRQ FODVVL¿FDWLRQV DQG injection techniques

Ƒ16:00-16:30

The checklist implementation for the worst-case scenario in ¿OOHUV LQMHFWLRQ

Ƒ 16:30-17:00

⥩Ἴ嶏⏰恦⇝ - 併⮠憒⭟䙫䲥䥅娼἗

Peter Hsien-Li Peng ( ⸫宠䡬 , Taiwan) Yau-Li Huang ( 涁亾䦉 , Taiwan) ( 㘌⻟〥 , Taiwan)

Sunday, 15 NOV. RM 302A 08:30-10:00

Medical education ModeratorsƝChia-Yu Chu ( 㗯⩴䌚 , Taiwan), Wei-Ming Wang ( 䉉ἇ慖 , Taiwan) Ƒ 08:30-08:55

僤⊂⯵⏸㕀備 (CBME) 凮䚕冁⯯䦸憒⸒姺䷛

Jen-Hung Yang ( 㠈ᵿ⩍ , Taiwan)

Ƒ08:55-09:20

憳䧲䡸媙䧲 (milestone) 䙫奶≪凮⯍巷

Yu-Che Chang ( ⷳ䉇⑄ , Taiwan)

Ƒ 09:20-09:45

Challenges in using the ACGME milestone for the dermatology resident assessments

Yi-Chien Yang ( 㠈⩚ủ , Taiwan)

Ƒ 09:45-10:00

Q&A

Jen-Hung Yang ( 㠈ᵿ⩍ , Taiwan)

13:30-15:00

SDRDF ModeratorƝJi-Chen Ho ( ḓ⩚ㄽ , Taiwan) Ƒ 13:30-13:50

Psoriasis and PsA 2019

Shang-Hung Lin ( 㙕⫘⩍ , Taiwan) Wei-Tai Yu ( ḗ䱫㮮 , Taiwan) Hsien-Yi Chiu ( 彯札扮 , Taiwan) Ting-Shun Wang ( 䉉淌僚 , Taiwan)

Ƒ13:50-14:30

Psoriasis and PsA 2020

Ya-Chu Tsai ( 叟斃䦷 , Taiwan) Wei-Tai Yu ( ḗ䱫㮮 , Taiwan) Shang-Hung Lin ( 㙕⫘⩍ , Taiwan) Ying-Xiu Dai ( ヲ冯Ậ , Taiwan) Yang Lo ( 乃攻 , Taiwan)

Ƒ 14:30-15:00

SERDF Board Meeting

Sunday, 15 NOV. RM 303A 08:30-10:30

Update in soft tissue tumor and nail tumor ModeratorĆ?Thuy Phung (US) Ć&#x2018; 08:30-09:15

Update in cutaneous soft tissue tumours

Ć&#x2018;09:15-09:40

Vascular tumors & vascular malformations reviewed from .18+ YDVFXODU DQRPDOLHV ÂżOHV

Ć&#x2018; 09:40-10:05

Genetic characterization of cutaneous mesenchymal neoplasm

Ć&#x2018; 10:05-10:30

Malignant and benign nail tumor

Eduardo Calonje (UK) Seok-Jong Lee (Korea) Ikmal Hisyam Bakrin (Malaysia) Dong-Youn Lee (Korea)

12:30-13:30

Free paper ModeratorĆ?Bai-Yao Wu ( â&#x2039;ąä&#x201D;źâ&#x203A; , Taiwan) Ć&#x2018; 12:30-12:40

Azacytidine-induced localized Sweets Syndrome in Myelodysplastic Syndrome

Pankhuri Dudani

Ć&#x2018;12:40-12:50

A Case of Neutrophil-rich, Anaplastic Large Cell Lymphoma (ALCL) Showing Relapsing Course

Seong Min Hong

Ć&#x2018; 12:50-13:00

A study of the clinico-histopathological features of panniculitis presenting to a tertiary care centre in India

Narayanan A

Ć&#x2018; 13:00-13:10

Primary Cutaneous Extranodal NK-/T-Cell Lymphoma, Nasal TypeĆ?A Rare Case Report

Huy Nguyen

Ć&#x2018;13:10-13:20

Primary anetoderma and acquired cutis laxa associated with glomerulonephritis in a 37-year old Filipino maleĆ?a case report

Ć&#x2018; 13:20-13:30

Generalized purpuric lichen nitidus in a 32-year old Filipino maleĆ?a case report

Val Constantine Cua Soraya Elisse Escandor

13:30-15:00

Update in the melanoma and lymphoma ModeratorĆ?Tan Suat Hoon (Singapore) Ć&#x2018; 13:30-14:10

7KH :+2 &ODVVLÂżFDWLRQ RI 0HODQRPDV DQG 1HYL

David Elder (US)

Ć&#x2018;14:10-14:35

Malignant Melanoma and its Simulators from shanghai

Ye-Qiang Liu (China)

Ć&#x2018; 14:35-15:00

Cutaneous lymphoma update

Jisun Cha (US)

15:30-17:00

Self-assessment discussion part 2 ModeratorĆ?Julia Yu-Yun Lee ( ă&#x2DC;&#x152;ä&#x2030;&#x2021;ć&#x2013;° , Taiwan) Ć&#x2018; 15:30-16:00

Case 16-20

Chi-Shun Yang ( ă &#x2C6;â??ć&#x203A;&#x201E; , Taiwan)

Ć&#x2018;16:00-16:30

Case 21-25

Panitta Sitthinamsuwan (Thailand)

ModeratorĆ?Yu-Hung Wu ( â&#x2039;ąä˝°âˇ&#x2013; , Taiwan) Ć&#x2018; 16:30-17:00

ASD Closing ceremony

Speakers & Abstracts Plenary session

Jean Krutmann

Jean Krutmann obtained his MD from the University of Münster, Münster, Germany in 1986. After several stays abroad (including a post doctorate at Case Western Reserve University in Cleveland, Ohio, USA and a DFG stipend at the University Hospital for Dermatology in Vienna, Austria), he became resident Assistant/Associate Professor at the University Hospital for Dermatology of Freiburg, Germany. From 1994 until 2001 he was full Professor/Deputy Director of the University Hospital for Dermatology Düsseldorf, Düsseldorf, Germany. In 2001 he was appointed Chair of Environmental Medicine at the Medical Faculty of Heinrich Heine University Düsseldorf, thereby becoming Director of IUF in the process. Under his directorship in 2011 the institute became a member of the Leibniz Association and was renamed IUF – Leibniz Research Institute for Environmental Medicine. Dr. Krutmann’s research focuses on dermatoxicology, immunodermatology, and photodermatology, with a special emphasis on environmentally induced skin diseases and skin aging. Aside from several national and international prizes, including the Arnold Rikli Award, Albrecht Fleckenstein Award, Paul Gerson Unna Award, Oscar Gans Award, CE.R.I.E.S. Research Support Award, Dermopharmacy Innovation Award, and the TaniokuKihei Memorial Award, since 2010 Dr. Krutmann has been a member of the Leopoldina, the German National Academy of Science. He has also been a speaker of the Leibniz Research Alliance “Healthy Ageing” since 2012, and an honorary member of the Society for Investigative Dermatology and the Japanese Society for Investigative Dermatology since 2019. Within the scope of the cooperation with Fudan University in Shanghai, China, he is Distinguished Adjunct Professor as well as Senior Visiting Professor of the Human Phenome Institute at the School of Life Sciences, and Associate Chair of the Strategic Steering Committee of the International Human Phenome Project. The author/co-author of more than 450 contributions to scientific journals and books, he has also served as the editor of nine textbooks.

Environment and skin SessionƝPlenary session

Saturday, Nov. 14, 2020 – from 11:30 to 12:00

RM 305 – LEVEL 3 Skin health is affected by intrinsic (e.g. genetic) and extrinsic factors. This interplay is well illustrated at the level of skin aging. In recent years it has been appreciated that extrinsic skin aging is not merely due to chronic exposure of human skin to ultraviolet (UVB and A) radiation, but that wavelengths beyond UV, e.g. in the visible and near infrared range contribute as well. In addition, population-based cohort studies have shown that chronic exposure to selected air pollutants such as traffic-related particulate matter, soot, nitrogen oxide and ozone is associated with an increased manifestation of skin aging traits, e.g. pigment spots or wrinkles. In this presentation I will review (i) the epidemiological evidence supporting these conclusions, (ii) mechanistic studies employing ex vivo and in vivo human skin models to study the potential cause/effect relationship between air pollution and skin aging, (iii) and how such models can be used to identify cosmetic actives to effectively shield human skin against such threats. I will also discuss very recent studies which suggest that different environmental factors including distinct wavelengths present in solar radiation as well as defined air pollutants can influence each other and that this interaction is relevant for skin health.

Manu Jain

I am an Assistant Attending (optical imaging specialist) in the Department of Dermatology at Memorial Sloan Kettering Cancer Center (MSKCC) and Weill Cornell Medicine (WCM). I have over 10 years of experience working in the field of in vivo/ex vivo microscopy including reflectance confocal microscopy (RCM), fluorescence confocal microscopy (FCM), multiphoton microscopy (MPM), and optical coherence tomography (OCT). I am leading the clinical, research, and teaching program for RCM in dermatology. I am the Director of CME annual confocal course at MSKCC. I hold leadership roles as Vice President of American Confocal Group (ACG), Secretary of the International Tele-Dermatology Society (ITDS). Currently, I am actively involved with reflectance confocal microscopy (RCM), an optical imaging tool that is now being used in dermatology clinics to guide the diagnosis of melanocytic and non-melanocytic skin lesions, especially basal cell carcinoma (BCC) and melanoma. I have imaged over 600 patients in past 5 years and made bedside diagnosis. I am exploring the potential of new non-invasive approaches such as combined RCM-OCT devices, high-resolution OCT, and fluorescent dyes for topical application for diagnosis of skin lesions. I am also testing ex vivo devices such as OCT and FCM in freshly excised tissue as a means for guiding Mohs surgery. I work with a group of computer scientists and biomedical engineers to develop automated algorithms for diagnosing skin lesions. I have published extensively in many peer-reviewed reputed journals and co-authored several book chapters in the field of in vivo and ex vivo microscopy. I have been an invited guest speaker in multiple national and international meetings.

Emerging trends in non-invasive diagnosis in dermatology and dermatopathology SessionƝPlenary session

Saturday, Nov. 14, 2020 – from 12:00 to 12:30 RM 305 – LEVEL 3

Traditionally, diagnosis of skin cancer and other non-neoplastic lesions rely on histopathological evaluation. Although, histopathology is the gold standard it requires time-consuming tissue processing, which often delays the diagnosis and management of the patients. Currently, frozen section is the only modality for rapid histopathological evaluation, however, it still requires tissue sectioning and freezing which may disrupt the pathology. To overcome the limitations related to tissue processing and provide rapid histopathological evaluation several optical imagingbased ex vivo and in vivo microscopes are build including confocal microscope (CM), multiphoton microscope (MPM), and optical coherence tomography (OCT) microscopes. In vivo microscopes are used to make diagnoses in patients without removing the lesions - noninvasive no biopsy approach.One such microscope is the in vivo reflectance confocal microscope (RCM), which is being currently used in dermatology to evaluate neoplastic and non-neoplastic mucocutaneous lesions. RCM generates “quasi-histopathology” images in real-time. It has dramatically reduced the rate of benign biopsies. Additionally, some of the early skin cancers, when diagnosed with RCM, can proceed directly to non-invasive treatment such as topical treatment or photodynamic therapy. Besides diagnosis, RCMis also used for non-invasive treatment monitoring and guide scouting biopsies. RCM has acquired billing codes in the USA and is used by dermatologists, dermato-pathologists, and Mohs surgeons in their routine workflow. Despite its advantages, RCM can only image tissues up to a depth of 200 microns in the skin and cannot image deeper lesions. OCT, another in vivo microscope can overcome this limitation and has been combined with RCM as an RCM-OCT device for imaging lesions at cellular-level and for depth assessment simultaneously, improving diagnosis and management of keratinocytic carcinomas such as basal cell carcinoma. 29

Ex vivo microscopes, including CM and OCT, are mostly compact bench-top systems that can be placed in the grossing room or in the surgical suite for rapid evaluation of freshly excised tissue at histopathological levelÄ&#x192;without the need of tissue processing and cutting. They have the potential to be used as an adjunct or alternative for frozen section analysis during Mohs surgery and for selection of tissue for biobanking. Furthermore, as there is no tissue cutting involved, the entire tissue can be preserved for ancillary studies such as IHC and molecular analysis.

Boris Bastian

Dr. Boris Bastian received his MD degree and Dr. med degree from the Ludwig-Maximilian University of Munich. After completing a residency in dermatology at the University of WĂźrzburg, he received additional training in dermatopathology and completed a postdoctoral fellowship at the University of California, San Francisco before joining the institution's faculty and starting his research laboratory at UCSFâ&#x20AC;&#x2122;s Helen Diller Family Comprehensive Cancer Center in 1999. In 2010 he moved to the Memorial Sloan-Kettering Cancer Center to become Chairman of the Department of Pathology. In 2011 he returned to UCSF, where he now holds the title of Gerson and Barbara Bakar Distinguished Professor of Cancer Biology and Professor of Dermatology and Pathology. He founded the Clinical Cancer Genomics Laboratory at UCSF, which performs molecular diagnostics for patients of the Helen Diller Family Comprehensive Cancer Center. He has clinical responsibilities in the Dermatopathology Section of the Departments of Dermatology and Pathology, where he also oversees the molecular diagnostic laboratory. Dr. Bastianâ&#x20AC;&#x2122;s research focuses on the molecular genetics of cutaneous neoplasms, with a particular emphasis on the discovery of genetic alterations useful for diagnosis, classification, and therapy. His laboratory has contributed to the discovery of several genetic alterations in melanocytic neoplasia that are relevant for therapeutic and diagnostic purposes and his proposed integrated taxonomy provided the framework for the recently revised WHO classification of melanocytic neoplasms. He served as the President of the Society of Melanoma Research from 2010 to 2013 and has received numerous awards for his work including the election to the German National Academy of Sciences, the Lila Gruber Award for Cancer Research of the American Academy of Dermatology, and an Outstanding Investigator Award of the National Cancer Institute.

From melanocytes to melanoma SessionĆ?Plenary session

Sunday Nov. 15, 2020 â&#x20AC;&#x201C; from 11:00 to 11:30

RM 305 â&#x20AC;&#x201C; LEVEL 3 Melanomas harbor recurrent genetic alterations that vary strikingly in pattern depending on anatomic site and other features such as anatomic VLWH GHJUHH RI FXPXODWLYH 89 H[SRVXUH DQG DJH RI RQVHW FRQÂżUPLQJ SULRU QRWLRQV DERXW WKH H[LVWHQFH RI GLVWLQFW PHODQRPD VXEW\SHV 7KHVH VXEW\SHV GLá&#x201A;&#x2021;HU LQ WKHLU HYROXWLRQ IURP SUH QHRSODVWLF OHVLRQV 6RPH KDYH D EHQLJQ SUHFXUVRU QHYXV ZKLOH RWKHUV DULVH IURP PHODQRPD LQ situ or seemingly de novo. Transition from one progression stage to the next requires the acquisition of additional genetic alterations. All fully established melanomas harbor multiple genetic alterations, which disrupt a set of key homeostatic pathways. While present simultaneously LQ WKH PHODQRPD FHOOV WKH PXWDWLRQV DURVH LQGLYLGXDOO\ DV VHSDUDWH HYHQWV WKDW DOWHUHG WKH JHQHWLF LQIRUPDWLRQ DW GLá&#x201A;&#x2021;HUHQW ORFL DW WKH JHQRPH DW GLá&#x201A;&#x2021;HUHQW SRLQWV LQ WLPH GXULQJ WKHLU HYROXWLRQ 0HODQRPDV RQ VXQ H[SRVHG VNLQ KDYH KLJK EXUGHQV RI PXWDWLRQV ZLWK PXWDWLRQDO VLJQDWXUHV of UV radiation as the predominant carcinogen. Similar mutation burdens can be found in the non-cancerous melanocytes adjacent to these melanomas or in skin without melanomas, indicating that it is the types of mutations not their number that dictate whether a melanocyte becomes neoplastic. 7KH HYROXWLRQDU\ WUDMHFWRULHV OHDGLQJ WR PHODQRPD IDYRU D VXFFHVVLRQ RI DOWHUDWLRQV LQ ZKLFK DFWLYDWHG RQFRJHQHV DULVH HDUO\ DQG DUH VXá&#x201A;&#x2C6;FLHQW to form a pre-neoplasticlesions. These precursor lesions are kept in check by various tumor suppressor mechanism that select for the types of secondary and tertiary genetic alterations that advance the evolution to the next progression stage and ultimately to melanoma. The pattern in which oncogene activation arises early in the evolution is particularly common, because the activating mutations in oncogenes drive cell SUROLIHUDWLRQ DQG H[SDQG WKH QXPEHU RI FHOOV DQG WKHUHE\ LQFUHDVH WKH SUREDELOLW\ WKDW RQH RI WKH FORQDO GHVFHQWV RI WKH ÂżUVW PXWDWHG FHOO DFTXLUHV one of the subsequent mutations that override the tumor suppressive mechanisms maintaining the preneoplastic state. Genetic alterations that are required for progression include loss of function mutations in tumor suppressor genes such as CDKN2A, but TERT promoter mutations arise earlier in most progression cascades. Melanomas originating from melanocytes not residing within epithelial structures such as the epidermis or mucosal membranes include uveal melanoma and blue nevus-like melanoma. This neoplasms are not caused by UV radiation and arise WKURXJK DFWLYDWLQJ PXWDWLRQV RI WKH *ÄŽT VLJQDOLQJ SDWKZD\ 7KH\ OLNHO\ DULVH IURP D GLá&#x201A;&#x2021;HUHQW VXEOLQHDJH RI PHODQRF\WHV DQG KDYH D SURSHQVLW\ WR metastasize to the liver. Benign neoplasms can progress to melanoma through clinically andhistopathologically well characterized intermediate states, in which an additional mutation to e.g. BRAF V600E mutation allows a secondary clonal expansion of morphologically distinct cells that is not considered malignant. Examples include the BAP1-inactivated Spitzoid tumor (BAP1 bi-allelic inactivation), pigmented epithelioid melanocytoma (PRKAR1A EL DOOHOLF LQDFWLYDWLRQ DQG GHHS SHQHWUDWLQJ QHYXV Č&#x2022; FDWHQLQ SDWKZD\ DFWLYDWLQJ PXWDWLRQ In summary different melanoma subtypes can be distinguished that vary in their cell of origin, relationship to UV radiation as the primary FDUFLQRJHQ SDWWHUQ RI VRPDWLF PXWDWLRQV FOLQLFDO DQG KLVWRSDWKRORJLFDO DSSHDUDQFH DQG PHWDVWDWLF EHKDYLRU 7KH\ DULVH IURP GLá&#x201A;&#x2021;HUHQW SUHFXUVRU lesions, sometimes through distinct intermediate lesions. The types of melanomas and their individual evolutionary trajectories with precursor OHVLRQV FDQ EH RUJDQL]HG LQ D WZR GLPHQVLRQDO PDWUL[ DV LQ WKH XSGDWHG PHODQRPD FODVVLÂżFDWLRQ LQ WKH FXUUHQW :+2 VHULHV RQ VNLQ WXPRUV

Thomas Krieg

I am a clinical dermatologist with a strong background in Extracellular matrix and cell biology. In the clinic we concentrate on severe skin disease with a particular focus on scleroderma and wound healing. We participate national and international clinical studies and have founded a nationwide network for scleroderma patients. The main interest of our basic research is to analyze the role of interactions between extracellular matrix and cells for the function of skin and its diseases. We particularly concentrate on the molecular and cellular basis of fibrosis and atrophy in connective tissue diseases and dissect the role of the extracellular matrix and its degrading enzymes in the growth and metastasis of invading tumors. A third focus is on the role of epithelial - mesenchymal interactions and defined extracellular matrixcomponents for wound repair and chronic healing disorders occurring in the elderly population.

Systemic sclerosis â&#x20AC;&#x201C; from pathophysiology to treatment SessionĆ?Plenary session

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 11:30 to 12:00

RM 305 â&#x20AC;&#x201C; LEVEL 3 Systemic sclerosis (scleroderma) is an autoimmune mediated fibrotic disease, which is involving the skin and many other organs. Although the initial trigger is still unknown the current understanding of the pathophysiology involves an early damage of the endothelial cells followed by an inflammatory infiltrate. The inflammatory cells, including T-cells, B-cells and macrophages are releasing fibrogenic cytokines (TGF-Ă&#x;, PDGF,CTGF), which activate fibroblasts. The resulting myofibroblasts are then responsible for the excessive deposition of extracellular matrix in the involved tissue. Clinically, the disease is characterized by a RaynaudÂ´s syndrome, which can precede the first cutaneaous involvement for several years, by altered capillary loops and later by an acrosclerosis and digital ulcerations. The disease has a broad clinical heterogeneity and several subsets can be differentiated. These are characterized by the clinical course, the involvement of internal organs and by the presence of specific circulating autoantibodies. Dependent on the subsets involvement of internal organs includes e.g. the lung, the heart, the kidney and the GI tract. There are already many therapies available, which allow to manage these organ complications. Unfortunately there is still no effective therapy to modify the course of the disease completely. However, based on a better understanding of the underlying molecular and cellular processes during the last few years several new targets have been identified and specific inhibitors were developed, which will be soon available for therapeutic trials.

Mauro Picardo, is Director of the Clinical and Experimental Department and of Cutaneous Physiopathology and

Metabolomic Center at the San Gallicano Dermatological Institute in Rome, Italy. He worked in the field of acne and sebogenesis for a long period with specificinterest in lipidomic analysis and their modifications in acne. He was trained at the Rome University â&#x20AC;&#x153;La Sapienzaâ&#x20AC;?. His main topics of interest are skinbiochemistry, free radicals mediated damage of the skin, mechanism of control of skinpigmentation, and pigmentary disorders. As chairperson of the Integrated Center ofMetabolomic Research (CIRM) at the San Gallicano Institute, coordinate lipidomic studies onacne and related disorders (seborrheic dermatitis, rosacea) in sebum and blood samples. Hisgroup has defined several collaborations with national and international research groups. Hehas served in the Board and President of national (SIDEMAST) and International (EIS, ESDR,ESPCR, IFPCS) scientific societies. In collaboration with Alain Taieb chair the Vitiligo EuropeanTask Force and the Pigmentary disorders group of the EADV. Professor Picardo was the organizer of several national and international conferences (like the successful Acne Rosaceaand related disease held in Rome in Dec 2009) and he is member of the Editorial Board ofsome dermatological and biochemical journals including Pigment Cell and melanomaResearch and Experimental Dermatology. He is author of more than 300 publications in peerreviewed journals (H index 60) and of more than 30 chapters in different books.

Skin microbiome and acnećżŁwhat's the role? SessionĆ?Plenary session

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 12:00 to 12:30

RM 305 â&#x20AC;&#x201C; LEVEL 3 Acne is a common chronic inflammatory condition affecting the pilosebaceous unit. Itâ&#x20AC;&#x2122;pathogenesis is multifactorial and has classically been attributed to altered sebaceous glandactivity with associated hyperseborrhoea, alterations in fatty acid composition, hormonalalterations, follicular hyperkeratinization and immune system activation. It is increasinglybelieved that the interaction between skin microbes and host immunity plays an importantrole in this disease related to the perturbed microbial composition and activity. There hasbeen a recent shift in the interpretation of the role of C. acnes (formerly P.acnes) in thepathogenesis of the diseaseĆ?rather than C. acnes hyperproliferation, the loss of balancebetween the different phylotypes, together with a dysbiosis of the skin microbiome, isassociated with acne development. Infact in acne patients a predominance of C. acnesphylotype IA has been observed, with a more virulent profile his detectable the loss ofdiversity of C. acnes phylotypes acts as a trigger for innate immune system activation,leading to cutaneous infammation. Recent studies showed that the gut microbiome is alsoinvolved in acne, through interactions with the skin microbiome. Moreover it has beendefined that sebum has a relevant role in controlling skin microbiome growth. We haverecently described the qualitative and quantitative alterations of sebum components in acne patients. With abnormalities in free fatty acids composition and of diacylglycerols , and increase of lipoperoxides which have been shown to be pro-inflammatory and to influence keratinocyte proliferation. Recently published data by our group indicated that the alteration of sebum composition could be dependent on an inadequate sebocyte differentiation process. In vitro, low differentiated sebocytes in vitro expressed a higher level of the insulin receptors resulting in a higher susceptibility to insulin stimulus, and after insulin stimulation upregulate the mTOR downstream proteins and lipogenic genes expression, and secretion of inflammatory mediators producing an â&#x20AC;&#x153;acne-likeâ&#x20AC;? VHEXP 7KH WUHDWPHQWV ZLWK VSHFLILF 33$5Č&#x2013; DFWLYDWRU OHDGV WR VHERF\WH GLIIHUHQWLDWLRQ DVVRFLDWHG ZLWK D decrease in the insulin sensitivity and consequently to a modification of lipid metabolism-related gene expression and a decrease of inflammatory mediators production. The topical treatment with the compound (2 and 5%) (phase 1 and 2 studies) resulted in a significant improvement of moderate to severe acne associated with an Improvement of sebum composition with no need for antibiotic therapy. Our data indicated that the microbiomal alterations is secondary to the sebaceous alteration and that normalization of its secretion leads to re-establishment of a physiologic skin microbial.. As commonly used topical and systemic antibiotics induce cutaneousdysbiosis, our new understanding of acne pathophysiology has prompted a change in direction for acne treatment.

Speakers & Abstracts TDA

Riichiro Abe

Riichiro Abe received an MD degree in 1994 and a Ph.D. degree in 2001 from HokkaidoUniversity, Sapporo, Japan. He was a postdoctoral fellow at the Picower Institute for Medical Research, New York, from 1998 to 2000. Since September 2015, he has been a Professor at Niigata University. His interests are in adverse drug reactions, skin regenerative medicineand skin oncology. 1994-1998 Hokkaido University Graduate School of Medicine 1998-2000 Research fellow, Picower Institute for Medical Research, NY 2000-2002 Staff dermatologist, Hokkaido University Graduate School of Medicine 2002-2007 Instructor, Hokkaido University Graduate School of Medicine 2007-2010 Assistant Professor, Hokkaido University Graduate School of Medicine 2010-2015 Associate Professor, Hokkaido University Graduate School of Medicine 2015-present Professor and Chair, Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences 2018-present Editor-in-Chief, Journal of Dermatological Science

Alopecia areata濣recent progress

SessionƝ(Medical) What's new in autoimmune disease & drug reaction

Sunday, Nov. 15, 2020 – from 10:10 to 10:25

RM 305– LEVEL 3 Alopecia areata is a disorder that results in nonscarring hair loss. The psychological impact can be significant, leading to feelings of depression and social isolation. The treatment of alopecia areata is a challenge for all dermatologists. New medications are needed due to lack of efficacy of many treatments or their side-effect profile. Available treatment options at best are beneficial for milder cases, and the rate of relapse is high. Understanding the exact mechanisms of hair loss in alopecia areata is therefore of utmost importance to help identify potential therapeutic targets. I will discuss the most recent treatment including JAK inhibitors, and show our recent data to reveal pathogenesis of alopecia areata.

Nishigori Chikako is Professor and Chairman of Department of Dermatology at Kobe University. She was trained as

a dermatologist at Kyoto University and received her Ph.D. there. She joined Prof. Kripke’s laboratory at MD Anderson Cancer Center. Her major topics of interest are photodermatolog, genodermatoses, skin cancers, and pigment cell disorders. She served as president of Japanese Society for Photomedicine and Photobiology (2013-2018) and now she serves as president of Japanese Photodermatology Society and board of Japanese Dermatological Association. She has received “Edna Roe Lectureship 2014” from the International Union of Photobiology for her achievements on photobiology.

Mechanismsof photocarcinogenesis -updateSessionƝ(Medical) What's new in skin tumor

Sunday, Nov. 15, 2020 – 14:30 to 14:50

RM 305 – LEVEL 3 Photocarcinogenesis is multistage process that involves initiat ion, promotion and progression. In addition UV induced immunesuppression is closely involved in photocarcinogenesis. UV directly and indirectly induces DNA lesions, which cause genetic mutations.Accumulation of DNA lesions caused by UV in several cancer related genes plays a crucial role in carcinogenesis. Indeed even in actinic keratosis, percancerous lesions, genetic alterations can be obsered. A conventional knowledge demonstrated that UVB indued DNA lesion causes genetic mutation (initiation) and UVB-inflammation (sunburn) induces promotion. However recent findings revealed that photocarcinogenesis pathway is more complex consequences where each of these process, mediated by various cellular, biochemical, and molecular changes, are closely related to eah other. Pyrimidine photoproducts that result from direct DNA lesions induced by UV and involved in developing skin cancer through mutations that lead to the upregulation or downregulation of signal transduction pathways, cell cylce dysregulation, and depletion of antioxidant defenese. In addition pyrimidine dimers have been shown to trigger UV induced immunesuppression, which also plays an important role in phtocarcinogenesis, partly by upregulation of IL-10, an immunosuppresive cytokine. UVB (and UVA) also produces oxidative stress and oxidative DNA damage in skin cells, which causes alteration of the genesinvolved in cell cycle, apoptosis and modification of cell signaling by redox regulation, resulting in inflammation. It has been shown that in Ogg1 knockout mice, which are deficient in reparing 8-oxo-7,8-dihydroguanine (8-oxoG), UV irradiation up-regulates the inflammatory gene, implyaing that 8-oxoG is involved in triggering inflammation. Sunburn is elicited by oxidative stress caused by UV at or near the membrane. We found that anti-inflammatory dietary food, Spirulina platensis (Sp) can reduce the development of UVB-induced skin tumors in mice. The inhibitory effect of Sp on acute UV response, “sunburn”,was confirmed macroscopically DQG PLFURVFRSLFDOO\DORQJ ZLWK D VLJQLILFDQW GHFUHDVH LQ WKH SUR LQIODPPDWRU\ F\WRNLQHV H[SUHVVLRQV VXFK DV ,/ ȕ DQG &[FO in mice irradiated with UVB. Sp has an antioxidant effect as it had reduced the formation of 8-oxoG, whereas it had little effect on the amount of pyrimidine photoproducts. These results indicated not only cumulative dose but intensity of UV is considered for skin cancer prevention.People who takes immune suppressant and some kinds of medicine, including voriconazole and hydrochlorothiazide should be cautious to carry out sunprotections.

Akiharu Kubo

Akiharu Kubo received his MD from Osaka University in 1994, followed by dermatology residency training at Osaka University and cell biologist training at Kyoto University. He received his PhD from Osaka University in 2000. In 2006, he moved to Keio University School of Medicine, where he has made seminal discoveries on the roles of tight junctions in the skin barrier and homeostasis. He is the head physician of the outpatient clinic of Dermatology in Keio University Hospital since 2013, leads genetic analyses and counseling of genodermatoses in Japan, and has determined several disease-causative genes for genodermatoses, including Nagashima-type palmoplantar keratosis. He is a board member of JSID from 2015 and has contributed to the JSID Young Academician-Fostering Seminars (KisaragiJuku) and the JSID Summer School (Aoba Juku) to recruit and encourage young physicians/researchers. He has received several awards to his research contribution including Seigo Minami Memorial Award from the Japanese Dermatological Association and JSID award from the Japanese Society for Investigative Dermatology.

Diagnosis and management of mosaic disorders SessionƝ(Medical) What's new in skin tumor

Sunday, Nov. 15, 2020 – 14:10 to 14:30

RM 305 – LEVEL 3 Various congenital nevi, including epidermal nevus, sebaceous nevus, nevus comedonicus, melanocytic nevus, and etc., are caused by postzygotic genetic changes that occurred during the prenatal period. The presence of genetically different cells in one identical body is called mosaicism,and the diseases caused by mosaicism is called mosaic disorders. The genetic alterations that cause mosaic disorders are classified into two categories, (1) genetic alterations that cause both systemic and mosaic disorders, such as NF1 mutations in neurofibromatosis type 1 and segmental neurofibromatosisƞ (2) genetic changes that cause only mosaic disorders, such as BRAF mutation causing giant congenital melanocytic nevus but becoming embryonic lethal if all cells have the genetic change. If the patient’s mosaic disorder is caused by a genetic alteration in the former category, genetic counseling is necessary to assess the risk of transmitting the genetic alteration to the next generation and developing a systemic disease. Genetic diagnosis of the mosaic disorders and evaluation of the germline mosaicism is a key point for the genetic counseling.

Akimichi Morita

Professor Akimichi Morita is currently serving as the Department Chair of Dermatology and Vice Director of Nagoya City University Hospital. He was the Editor-in-Chief of the Journal of Dermatological Science from 2008 to 2013, and is currently the Editor-in-Chief for Photodermatology, Photomedicine, Photoimmunology. He also the current President of the Japanese Society of Investigative Dermatology (JSID) and the President of the Japanese Society for Photomedicine and Photobiology. His research interests include phototherapy, cutaneous immunology, regulatory T cells, skin aging, and psoriasis. Professor Morita has authored more than 200 publications in peer-reviewed journals (Total Impact FactorƝ1047.5, h-indexƝ41).

Psoriasis and comorbidity

SessionƝ(Medical) What's new in psoriasis

Saturday, Nov. 14, 2020 – from 13:50 to 14:10

RM 305 – LEVEL 3 The medical treatment for psoriasis has changed drastically during the last few decades with a significant improvement in treatment outcomedue to the introduction of biologic drugs in 2010. Currently in Japan, eight different biologic drugs are available that allow for maintaining tight control of psoriasisskin symptoms (Psoriasis Area Severity Index score of 90/100). Psoriasis as a systemic inflammatory disease has recently attracted increased attention, and theinfluence of comorbid psoriasis on the long-term prognosis of arthritis, arteriosclerosis, diabetes, cardiovascular disease, and liver disease has gained great interest. Therefore, dermatologists today should treat psoriasis not only from a dermatologic perspective, but also from a systemic, long-term perspective. In addition, it is more important than ever before to collaborate with other departments, including rheumatology, to manage the needs of patients with psoriasis and make decisions regarding treatment policy. Disease-modifying therapies, which can treat disease directly, are anticipated to play an important role. Patients with psoriasis, a chronic immunologic skin inflammation, often develop diabetes. At present, it is not clear how psoriasis leads to or correlates with glucose intolerance. We investigated whether psoriasis itself correlates with hyperglycemia in humans and mice. In patients, psoriasis severity correlated with high blood glucose levels, and treatment of psoriasis with phototherapy improved insulin secretion. Imiquimod (IMQ) administration in mice with features of human psoriasis induced systemic and cutaneous inflammation, and resulted in hyperglycemia. Although it should be determined if psoriasis-like cutaneous inflammation alone can induce hyperglycemia, the IMQ-treated mice showed impaired insulin secretion without significant islet inflammation. Notably, administration of anti-interleukin-17A monoclonal antibodies improved hyperglycemia in psoriatic patients and IMQ-treated mice with psoriasiform features. These findings suggest that hyperglycemia is highly associated with psoriasis, mainly through interleukin-17.

Brian Nickoloff

Dr. Nickoloff received his MD and PhD (Biochemistry) from Wayne State University and completed an internship in Internal Medicine at Harbor General – UCLA Hospital in 1980. Following completion of his Pathology residency at Brigham and Women’s Hospital at Harvard Medical School in 1983, he began a Dermatopathology Fellowship in the Department of Dermatology at Stanford University Medical Center. In 1984 he was appointed as the Director of Dermatopathology and Assistant Professor of Dermatology at Stanford while working with Dr. Eugene Farber. In 1987, he relocated his practice and laboratory to the University of Michigan and became an Associate Professor (with Tenure) of Pathology and Dermatology in 1990. Dr. Nickoloff was named as Director of the Skin Disease Research Laboratory at Loyola University of Chicago Medical Center in 1996, and is a Professor of Pathology, Microbiology and Immunology at Loyola. In 2003, he became Director of the Oncology Institute, and Deputy Director of the Cardinal Bernardin Cancer Center. In 2011 he relocated to Grand Rapids to become Professor and Division Director of Dermatology at the College of Human Medicine, Michigan State University. In 2003 he received an Achievement Award from the American Skin Association, and in 2007 he delivered the Eugene M Farber Translational Research Award lecture to the Society of Investigative Dermatology (SID)ƞ the Rene Touraine Lecture to the European Society for Dermatology Researchƞ and was elected to the SID Board of Directors .Dr. Nickoloff authored of over 375 publications, 40 book chapters, and served as Editor for 3 books. He has been an invited speaker around the world. In August 2014 he relocated to Indianapolis, Indiana and joined Eli Lilly as a Senior Medical Fellow.

Evolution of pathophysiologic insights in psoriasis SessionƝ(Medical) What's new in psoriasis

Saturday, Nov. 14, 2020 – from 13:30 to 13:50

RM 305 – LEVEL 3 Psoriasis was historically viewed as a skin disease, but now is considered a disease of the immune system. The crosstalk between keratinocytes and immunocytes mediated by cytokines was originally captured in the theory of the cytokine network in psoriasis in 1991. This presentation will review the evolution in concepts and progress in deciphering the immunopathogenesis of psoriasis spanning the 20th and 21 st century.

Kyoung-Chan Park

Emeritus professor of Seoul National University College of Medicine. Research focus are melanocyte biology, artificial skin and skin stem cells and cosmetics. Actively involved in various societies, credentialising his role as a dermatological expert. From “2008 to 2011” and “2014 to 2017”, served as president of Asian Society for Pigment Cell Research and president of International Federation of Pigment Cell Societies, respectively. Education and training 1974-1980 M.D. Seoul National University, College of Medicine 1987-1990 Ph.D. Seoul National University, College of Medicine Career 2000-2020 Professor, Seoul National University, College of Medicine 2003-2016 Chairman of Department of Dermatology, SNU Bundang Hospital 2012President of Korean Society for Cosmetic Dermatology 2011-2018 President of Korean Society for Pigment Cell Research 2008-2011 President of Asian Society for Pigment Cell Research 2014-2017 President of International Federation of Pigment Cell Society Major interests and publications Melanocyte biology, skin stem cells, and cosmetic science Over 300 SCI(E) publications

New stem cell marker of interfollicularepidermal cells and the possible effects of visible light SessionƝ(Medical) Hair and stem cells forum

Saturday, Nov. 14, 2020 – from 15:30 to 15:50 RM 305 – LEVEL 3

The epidermis is a stratified epithelium, differentiating from keratinocyte stem cells (KSCs) which are contained in the basal layer and in the bulge of hair follicles. KSCs produce transit-amplifying (TA) progenitors that generate differentiated keratinocytes and other epithelial skin components. Compared to hair follicle stem cells, much less is known about human interfollicular epidermal stem cells (IFESCs), which lack robust markers for prospective isolation. Previously, we developed a method for the isolation of IFESCs by using type IV collagen adhesion assay. Proliferative potential of isolated IFESCs was tested by using 3 dimensional skin equivalent models. In order to identify IFESCs, various molecular markers have been investigated and few molecular markers are known for KSCs or TA progenitors. In particular, p63 is considered to be a master regulator of morphogenesis, identity, and regenerative capacity of stratified epithelia. However, p63 is not specific as a molecular marker of IFESCs when considering the expression of p63 in the epidermis. Because expression of p63 is found to be distributed even up to granular layer, more specific molecular markersare necessary for localization of IFESCs. Even though molecular markers of IFESCs are not clear yet, little is known about the chromatin dynamics of these cells. There are some reports of histone modifications which are used to define chromatic regions with different regulatory functions. In this presentation, we are going to present the new stem cell marker combined with p63 and HDAC. In addition, microRNAs are tiny noncoding RNAs, which negatively regulate gene expression by binding to the 3’ untranslated region (UTR) of target messenger RNAs (mRNAs). A number of microRNAs have been reported which seemed to be related with regenerative potential of KSCs. In addition, visible light has beneficial effects on skin wound healing. However, the effect of visible light on skin stem cells has not been studied. The effects of visible light in the skin will be discussed in terms of small wavelength difference.

Jean-Hilaire Saurat

Jean-Hilaire Saurat, MD, is professor emeritus at Geneva University where he chaired the department of Dermatology for 28 years. He had studied Dermatology at the Hopital Saint-Louis, and Experimental Pathology at the Faculte Necker Enfants Malades, both in Paris. Prof. Saurat has been President of the International League of Dermatological Societies (ILDS), President of the European Society for Dermatological Research (ESDR), and the European Academy of Dermatology and Venereology (EADV). Jean-HilaireSaurat, MD, is professor emeritus at Geneva University where he chaired the department of Dermatology for 28 years. He had studied Dermatology at the Hopital Saint-Louis, and Experimental Pathology at the Faculte Necker Enfants Malades, both in Paris. Prof. Saurat has been President of the International League of Dermatological Societies (ILDS), President of the European Society for Dermatological Research (ESDR), and the European Academy of Dermatology and Venereology (EADV). Prof. Saurat has been chief editor of Dermatology 1986-2015, and has been section editor of the Journalof Investigative Dermatology 1987-1997. He is the leading editor for editions 1st through 6th of the French Textbook of Dermatology Elsevier-Masson pub. Prof. Saurat’ current research includesƝsebaceous glands pathophysiology, skin aging/dermatoporosis, dermatotoxicology, and retinoids. His past research interests have included inflammatory skin diseases, graft-versushost reaction, severe drug reactions, and pediatric dermatology. Prof.Saurat currently has a selected private practice in Geneva. Prof. Saurat citations report indicates his 1.019 publications were cited 19.245 times, with an h-index of 66. Prof. Saurat is “Chevalier de la Legion d’Honneur” France.

The discovery of a new comedolytic addressing the microcomedone SessionƝ(Subspecialty) Acne and rosacea forum

Friday, Nov. 13, 2020 – 16:25 to 16:50

RM 304B – LEVEL 3 Although the different steps of the acne cycle have beenwell described, the pathophysiological mechanisms and thesequence of events of comedogenesis were not clearly defineduntil recent years. Professor Jean-Hilaire SAURAT (Geneva), aworld leader in dermatology, explains how his research ledto proposing a new paradigm for the development of thecomedones and how SilybumMarianum Fruit Extract (SMFE) wasdiscovered and translated into the clinic with the developmentof Cleanance Comedomed TM , a new comedolytic product foracne prone skin. By preventing the transformation of lesions thatare still invisible (microcomedones), the new comedolytic active i ngredient Comedoclastin TM helps to limit the appearance ofnew lesions and contributes to long-term benefit.

Jacob Thyssen

Dr. Thyssen has been associated with the University of Copenhagen since 2000, receiving his education there and serving on the academic faculty as a Professor since 2017. He has been a consultant dermatologist at Herlev-Gentofte Hospital for the past 5 years. Earlier in his career, Dr. Thyssen studied under research sabbaticals at Harvard Medical School and at the University of California–San Francisco, where he focused on atopic dermatitis and the complexity of the skin barrier. Dr Thyssen is a member of several societies and working groups, including the International Eczema Council (IEC), the European Task Force of Atopic Dermatitis (ETFAD), and the European Dermato-Epidemiology Network (EDEN). He a frequent speaker at international meetings. Dr Thyssen has published >480 articles, edited 3 text books and written 17 book chapters. He is a section editor at Contact Dermatitis and an associate editor at Dermatitis and a former associate editor of the British Journal of Dermatology.

Systemic treatment consideration濣 what’s new for moderate to severe AD

SessionƝ(Medical) What's new in atopic dermatitis

Saturday, Nov. 14, 2020 – from 08:30 to 08:50 RM 305 – LEVEL 3

This presentation provides a clinical overview of current and future treatment options in moderate to severe atopic dermatitis. Treatment mechanisms, key outcome and safety data from clinical trials are discussed regarding biologics and JAK inhibitors that are in late clinical development stage or that have already been approved.

Kenshi Yamasaki

PositionƝ Vice-chair, Associate Professor, Department of Dermatology, Tohoku UniversityGraduate School of Medicine Vice chair, Dermatology Clinic, Tohoku University Hospital Current interest in dermatologyƞ Clinicsƞ rosacea, acne, hidradenitis suppurative, vitiligo, autoimmune diseases, skin surgery Clinical trialsƞ psoriasis, palmoplantar pustulosis, hidradenitis suppurative, atopic dermatitis, prurigo, vitiligo Basic researchesƞinnate immunity, antimicrobial peptides, melanosome, melanocyte biology, vitiligo pathogenesis, allergy, genome-wide association study (GWAS), artificial intelligence (AI)

Pathogenesis of rosaceaćż¤ genetic background, innate immunity, and skin barrier SessionĆ?(Subspecialty) Acne and rosacea forum

Friday, Nov. 13, 2020 â&#x20AC;&#x201C; from 16:00 to 16:25 RM 304B â&#x20AC;&#x201C; LEVEL 3

5RVDFHD LV D FRPPRQ DQG FKURQLF LQĂ&#x20AC;DPPDWRU\ VNLQ GLVHDVH SUHVHQWLQJIDFLDO HU\WKHPD WHODQJLHFWDVLD SDSXOHV DQG SXVWXOHV 7KH FOLQLFDO DQG etiological observations and molecular studies suggested that individuals with rosacea have certain genetic background and that an altered innate LPPXQH UHVSRQVH LV LQYROYHG LQ WKH SDWKRJHQHVLV RI WKH YDVFXODU DQG LQĂ&#x20AC;DPPDWRU\ GLVHDVH VHHQ LQ SDWLHQWV ZLWK URVDFHD $PRQJ LQQDWH LPPXQH system, Toll-like receptors (TLRs), TLR2 is abundantly expressed in the skin of rosacea individuals. TLR2 expression is also co-localized with the distribution of kallikrein 5 in epidermis of rosacea. Accompanying with kallikrein 5 expression, rosacea skin has high protease activity, which would lead PAR-2 (protease activating receptor-2) activation to increase signals relating to itchiness. Individuals with rosacea also express abnormally high levels of cathelicidinantimicrobial peptides in epidermis. The abnormal cathelicidin can enhance neovascularization, recruit neutrophils and PDVW FHOOV DQG FDXVH LQĂ&#x20AC;DPPDWLRQV LQ URVDFHD VNLQ $OWHUHG PLWH DQG PLFUREH KDELWDW DUH DOVR REVHUYHG LQ URVDFHD VNLQ 7KHVH ÂżQGLQJV PD\ KHOS H[SODLQ WKH EHQHÂżWV RI FXUUHQW WUHDWPHQWV DQG VXJJHVW QHZ WKHUDSHXWLF VWUDWHJLHV KHOSIXO IRU DOOHYLDWLQJ WKLV GLVHDVH 7KLV SUHVHQWDWLRQ GLVFXVVHV WKH possible molecular mechanisms for the pathogenesis of rosacea from current clinical observations and laboratory research.

Yukie Yamaguchi

I am Yukie Yamaguchi MD, PhD, currently working at Yokohama City University Graduate School of Medicine as an associate professor in dermatology department. I received my MD degree from Hamamatsu University School of Medicine, Japan in 2000. After my residency and fellowship in Dermatology at Yokohama City University, I enrolled in the graduate program and received PhD degree from the same university in 2007. During PhD training, I was led by Prof.KuwanaMasataka MD, PhD in Rheumatology at Keio University, Tokyo Japan. Then, I went abroad U.S. as a post doctorate under Prof. Carol Feghali-Bostwick PhD at the University of Pittsburgh, PA in 2008. During my post doctorate studies, I mainly studied the pathogenesis of scleroderma, in particular the mechanisms of fibrosis, focusing on several proteins, e.g. Endostatin, Caveolin-1, and IGFBP5, which exert important roles on fibrosis. Upon returning to Japan in 2010, I started faculty carrier at the Department ofEnvironmental Immuno-Dermatology in Yokohama City University Graduate School of Medicine. My specialty areas are connective tissue diseases (scleroderma, dermatomyositis, lupus, vasculitis) and psoriasis, and performs several clinical and basic studies related to those diseases. My current research topics are extracellular matrix on their biological activities, wound healing, monocytes/macrophages on fibrosis, membrane protein modulating cellular signaling, aggravating factors of psoriasis.

Focusing on extracellular matrix in Scleroderma pathology and clinical practice SessionĆ?(Medical) What's new in autoimmune disease & drug reaction

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 09:20 to 09:45

RM 305 â&#x20AC;&#x201C; LEVEL 3 Topic 1.Clinical features and pathogenesis of scleroderma. Scleroderma is an autoimmune, connective tissue disease characterized by organ ÂżEURVLV DXWRDQWLERG\ SURGXFWLRQ DQG YDVFXODU DEQRUPDOLWLHV 7KH SDWKRJHQHVLV RI VFOHURGHUPD LV QRW HQWLUHO\ FOHDU DQG LV YHU\ FRPSOH[ 7KLV talk will focus on the pathogenesis of scleroderma, important clinical perspectives in early diagnosis and recent therapeutic candidates. Topic 2.Matricellular proteins that play an important role in remodeling. Remodeling is an important perspective in the pathogenesis of the disease leading to excessive organ fibrosis. The extracellular matrix is not just as a deposited protein, but also has biological activity to regulate cellular activity. Focusing on the matricellular protein, periostin, we discuss its contribution to the pathogenesis of fibrosis and its potential as a fibrosis biomarker. Topic 3.Development of fibrosis inhibiting peptides. It is interesting aspect that peptides derived from the extracellular matrix may inhibit fibrosis. I will introduce our study as a candidate for anti-fibrotic protein.

Kuang-Cheng Chang âˇłâ&#x20AC;&#x2021;ă¨Ą

â?&#x2014;ä &#x160;âž&#x2022;ă&#x2022;&#x203A;â˝&#x2030;ć&#x2020;&#x2019;â&#x;ă&#x203A;Şä?Ľáť˘â&#x2030;&#x2013;ä?áš˛ć&#x2022;&#x17E; â?&#x2014;ä &#x160;â˝&#x2030;ćŞťä˝ľâŽ ă&#x2022;&#x203A;â?Żć&#x2020;&#x2019;â&#x;ă&#x203A;Şâ&#x2030;&#x153;ă&#x203A;Şä?áš˛ á¸&#x201D;ĺ?&#x2013;ăŻ¸â&#x203A;˛â?&#x160;ĺ&#x201E;ťă&#x161;?ć ść?&#x2030;ä˝ľâ&#x;ć&#x2020;´âťĄć&#x2020;&#x2019;â&#x;ă&#x203A;ŞćĄ&#x17D;â&#x201D;ść&#x2020;&#x2019;â¸&#x2019; ćŞżâž&#x17E;ä˝ľ Scalptra ( äŤ&#x152;ć ść&#x2021;&#x201E; ) â?&#x2014;ä &#x160;â&#x152;§ă&#x2022;&#x20AC;â&#x;ĺŹ&#x201A;â¸&#x2019; âž&#x17E;â&#x203A;˛ MERZ âž&#x2022;ă&#x2122;?ä&#x201C;&#x17E; &Xeromin ĺ °ăŽšâ?&#x2014;ä &#x160;â&#x152;§ă&#x2022;&#x20AC;â&#x;ĺŹ&#x201A;â¸&#x2019; âž&#x2022;ă&#x2022;&#x203A;ĺ&#x20AC;˝äľşáˇ§ă&#x203A;&#x;á˝&#x192;äżŹ The art and scincence of face lift á¸&#x201D;ă&#x2022;Žä&#x2C6;Żá¸˘ĺ&#x2013; Structral fat grafting á¸&#x201D;ă&#x2022;Žä&#x2C6;Żâ&#x2030;&#x2013;á¸˘ĺ&#x2013; Facial volumization an anatomic approach á¸&#x201D;ă&#x2022;Žä&#x2C6;Żâ&#x2030;&#x2013;á¸˘ĺ&#x2013;

Nerve injury caused by thread procedure SessionĆ?(Aesthetic) Thread lifting

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 14:00 to14:30

RM 301B â&#x20AC;&#x201C; LEVEL 3 Dr. KC Chang collect the symptom of facial nerve injury after injection. THe location and depth of frontal branch,zygomatic branch,buccal branch and marginal mandibular brandh will explain based on anatomic study.

Nien-Feng Chang Liao âˇłâś&#x201D;â´˛âŽŽ

EducationĆ? M.D. China Medical University Postgraduate TrainingĆ? Resident, Division of Dermatology, China Medical University Hospital Fellowship, Department of Dermatology, National Taiwan University Hospital Professional MembershipsĆ? Taiwanese Dermatological Association Taiwanese Society for Dermatological and Aesthetic Surgery Taiwanese Association for Psoriasis and Skin Immunology Major Research FieldĆ? Psoriasis Vitiligo Atopic dermatitis

Clinical dilemma â&#x20AC;&#x201C; childhood vitiligo

SessionĆ?(Subspecialty) Pediatric Dermatology

Friday, Nov. 13, 2020 â&#x20AC;&#x201C; from 15:00 to 15:30

RM 304B â&#x20AC;&#x201C; LEVEL 3 Vitiligo is a chronic disabling disease. Estimated prevalence rates range from 0â&#x20AC;&#x201C;2.16% in children and adolescents. It has a profound impact on the quality of life of patients, especially in children and their family. In clinical practice, physicians usually have some difficulties in management of childhood vitiligo. In general, we must explain the available therapeutic options, and establish realistic expectations. The lack of a universally effective treatment must be clearly explained. The therapy is usually long-lasting and requires their adherence, whose response is often delayed, and repigmentation may not always occur despite intensive treatment. We list the most clinical relevant questions and myths as belowĆ? Is vitiligo curable? Systemic immunosuppressants in children? Is the phototherapy safe in children? Is long-term usage of topical calcineurin inhibitors safe in children?

Sheau-Chiou Chao ĺą&#x2014;ă&#x2013;&#x2021;ä˘&#x2030; Education 1985-1990 Career 1990-1994 1999-2000 2002-

M.D. College of Medicine, National Cheng Kung University

Resident, Department of Dermatology, National Cheng Kung University Hospital Researcher, Department of Dermatology, Thomas-Jefferson University Associate Professor, Department of Dermatology, College of Medicine, National Cheng Kung University 2005-2009Ć&#x17E; 2015-2020 Chief, Department of Dermatology, College of Medicine, National Cheng Kung University Professional interests Pediatric Dermatology Cosmetic Dermatology Molecular Biology

ä&#x2018;Łä&#x201D;Şăšä&#x201D;&#x20AC;ä&#x2022;&#x201A;ăŽŚâż?áľ&#x2030;ć&#x203A;&#x192;

SessionĆ?Infectious disease forum

Sunday, Nov. 14, 2020 â&#x20AC;&#x201C; from 16:00 to 16:10

RM 305 â&#x20AC;&#x201C; LEVEL 3 Scabies is a contagious skin infestation by the mite Sarcoptesscabiei. The most common symptoms of scabies are intense itching and a pimplelike skin rash. The scabies mite usually is spread by direct, prolonged, skin-to-skin contact with a person who has scabies. In developed, highincome settings, health institution and residential home outbreaks challenge health and social care services. Diagnosis is challenging and often delayed, and management of outbreaks is costly. DiagnosisĆ?1. KOH 2. Dermoscope 3.Epiluminescence microscopy 4. â&#x20AC;&#x2DC;burrow ink testâ&#x20AC;&#x2122; (BIT) 5. Molecular diagnostic tests Treament 1. 1% gamma benzene hexachloride 2. Benzyl benzotelotion(BBL) 3. Crotamiton(Ulex) 4. Sulfur 5.Permethrin 5% dermal cream 6.Ivermectin

Mandy Chao ĺą&#x2014;ä&#x2030;&#x2021;ä&#x20AC;&#x2026;

EducationĆ?School of Pharmacy, Taipei Medical University Work ExperienceĆ? Country Manager, Ego Pharmaceuticals (Current) Head of Consumer, Galderma Taiwan Marketing Manager/Active Cosmetics Division, Lâ&#x20AC;&#x2122;Oreal 3URGXFW 0DQDJHU &RQVXPHU +HDOWK 3URGXFW 'LY 3DUNH 'DYLV 3Âż]HU Mandy is an experienced country manager with a demonstrated career path in the cosmetic and pharmaceuticals industry for many years. She is also professional in marketing management, pharmaceutics, sales management, market analysis, and cosmeceuticals sales.

ĺ&#x2019;ŁâĄ&#x203A;â?żä&#x201E;&#x160;âł&#x20AC;â&#x203A;˛äŚ´ä&#x192;Ťá´&#x2030;áż¨â&#x2020; ĺ&#x192;&#x2026;â&#x2026;Ąâ&#x2020;

SessionĆ?(Aesthetic) Cosmeceutical

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 09:40 to 10:00

RM 301B â&#x20AC;&#x201C; LEVEL 3 The competition in the cosmeceutical market has become increasingly fierce. In this speech, I will not only analyze the competitive advantages and underlying disadvantages of the overall Taiwan cosmeceutical market based on years of relevant work experience, but also analyze the potential opportunities and threats in the post-COVID-19 period. This speech will cover the following topicsĆ? 1. Legal and regulatory aspects 2. Industry- government-university-medical profession cooperation 3. Business diversification 4. Expertise development 5. Case sharing We (Ego Pharmaceuticals) hope to attract more experts and talents to join the cosmeceutical market and improve peopleâ&#x20AC;&#x2122;s lives through the science of healthy skin.

Shih-Pin Chen ć&#x201D;ąáł&#x201D;â¸Ş

Dr. Shih-Pin Chen graduated from Faculty of Medicine and Institute of Clinical Medicine, National Yang-Ming University, Taiwan. He received his resident training at Department of Neurology, Taipei Veterans General Hospital and post-doctoral fellowship training at Neurovascular Research Lab, Massachusetts General Hospital, Harvard Medical School. He is currently an attending physician of Department of Medical Research, Taipei Veterans General Hospital and Professor of Institute of Clinical Medicine, National Yang-Ming University. He has published numerous research articles in renowned journals such as JAMA Neurology, Brain, Annals of Neurology, Neurology, Pain, and Cephalalgia. He has served as the Associate Editor of Cephalalgia (The Official Journal of International Headache Society).

Botulinum toxin in migraine treatment SessionĆ?(Aesthetic) Botulinum toxin

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 10:00 to 10:30

RM 301B â&#x20AC;&#x201C; LEVEL 3 Botulinum neurotoxin is well known to disrupt transmission at the neuromuscular junction by inhibiting the vesicular release of acetylcholine at cholinergic nerve terminals. In recent years, the potential effects of botulinum toxin in blocking nociceptive neurotransmission are being explored. It is presumed that its mechanism for headache prophylaxis is blockade of peripheral, and subsequently central, sensitization. Initial retrospective trials were promisingĆ&#x17E; however, subsequent studies employing botulinum toxin in preventing migraine or tension type headaches turned out to be unsatisfactory. Nonetheless, the â&#x20AC;&#x153;Phase III REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT)â&#x20AC;? trial revived the KRSH ,Q WKLV VSHHFK , ZLOO EULHĂ&#x20AC;\ LQWURGXFH WKH FXUUHQW HYLGHQFH DQG WUHDWPHQW SDUDGLJP RI ERWXOLQXP WR[LQ LQ WKH WUHDWPHQW RI PLJUDLQH

Ya-Hui Chen ć&#x201D;ąć&#x2013;&#x192;âž&#x17E;

Dr. Ya-Hui Chen is the president of YaSkin Dermatology Clinic in Kaoshiung, Taiwan. She was graduated from Kaohsiung Medical University and obtained master degree from Graduate Institute of National Cheng-Kung University. She was the attending physician and instructor at the department of dermatology, Veterans General Hospital, Kaohsiung after her residency training at National Cheng-Kung University Hospital. She was also a fellow at Boston University, USA and Hokkaido University, Japan. Dr. Chen is not only specialized at dermatology, and also known for her extinguished aesthetic injection technique. Her research work had been published in many international journals, and she had ever received many outstanding teaching/research awards in Taiwan and from abroad.

Global consensus guidelines of hyperdiluted RDS for skin tightening effects SessionĆ? $HVWKHWLF &ROODJHQ VWLPXODWLRQ ÂżOOHU

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 16:00 to 16:30

RM 301B â&#x20AC;&#x201C; LEVEL 3 RadiesseÂŽ (Calcium Hydroxylapatite) has been used in hyperdiluted form as a biostimulator to improve skin texture and firmness. When mixed with lidocaine and saline, RadiesseÂŽ is usually injected superficially and it will provide long lasting skin rejuvenating effects. Dr.Chen has ten-year experience in Radiesse injection and is the coauthor of Pan-Asian Consensus. In this section, she will share her personal experiences and two published papers will be discussed simultaneously which will coincide the current global consensus and recommendations for the hyperdiluted applications of RadiesseÂŽ in face as well as in non-facial areas.

Chun-Bing Chen ć&#x201D;ąáş&#x2C6;ĺŽ&#x2018;

Doctor Chun-Bing Chen received his medical degree from the Chang Gung Memorial Hospital. He received one year residency training in the Department of Medicine in Taipei Veterans General Hospital. He subsequently completed his residency and fellowship training in the Department of Dermatology in Chang Gung Memorial Hospital. He went on to obtain his PhD in Graduate Institute of Clinical Medical Sciences in Chang Gung University. Doctor Chen is an active physician of dermatology and deputy director of Drug Hypersensitivity Clinical and Research Center. He also worked as Lecturer of the department Dermatology at Chang Gung Memorial Hospital. His research interests focus on cutaneous immunological disorders, cutaneous adverse reactions, and pharmacogenomics.

Immune mechanism & new therapeutic in cutaneous lupus erythematosus SessionĆ?(Medical) What's new in autoimmune disease & drug reaction

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 08:30 to 08:55

RM 305 â&#x20AC;&#x201C; LEVEL 3 Cutaneous lupus erythematosus (CLE) is an autoimmune inflammatory skin disease that can present with a variety of cutaneous manifestations. Histologically, skin lesions present as interface dermatitis, which is orchestrated by type I and III interferon regulated cytokines and chemokines. Both innate and adaptive immune pathways are strongly activated in the CLE owing to continuous reactivation of innate pathways via PRRs. These insights into the molecular pathogenesis of CLE have triggered the development of targeted treatment strategies that focus on immune cells (for example, B cells, T cells or plasmacytoid dendritic cells), as well DV LPPXQH UHVSRQVH SDWKZD\V IRU H[DPSOH 355 VLJQDOLQJ -$.ÂąVLJQDO WUDQVGXFHU DQG 67$7 VLJQDOLQJ DQG QXFOHDU IDFWRU Č&#x203A;% signaling) and their cytokines and chemokines (for example, type I interferons, CXCL10, IL-6 and IL-12). New treatment strategies are being developed that mainly target type I interferon producing cells and their pathways.

Kuo-Liang Cheng ĺżŤâ&#x2014;&#x2030;ĺ&#x201E;

Dr. Carl K. L. Cheng is a board certified dermatologist in Taiwan and founded Haute Beaute Skin & Vein Clinic in 2006 and The Bundles Skin Clinic in 2014 in Taipei. He was interested in energy based devices such as laser, RF and ultrasound technology and various injectables such as toxin, fillers, PLC and PLLA and even cosmetic surgery including liposuction, fat transfer and endovenous laser procedure in varicose vein. He also gave lectures in international congress such as ASLMS, IMCAS, AMWC, DASIL, World Congress of Dermatology and had trained many physicians in energy based devices and injectables in Asia. He was also a speaker, advisory board and medical consultant for many companies such as Cynosure, Syneron-Candela, Merz, Lumenis, Solta, Viora, Energist, Allergan, Galderma , etc.

A real game changer? The code to achieve ideal effect of HIFEM technology from the perspective on mechanism and design of technology and individual discrepancy

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 14:30 to 15:00 RM 301B â&#x20AC;&#x201C; LEVEL 3

SessionĆ?(Aesthetic) Energy Based Device

HIFEM technology has been launched in the market in recent years. It provides a new noninvansive approach in improving body contouring for physicians. We will present how to maximize the clinical effects based on individualized variation.

Ching-Chi Chi äŽžă&#x201D;ä&#x2039;¨

Professor Ching-Chi Chi graduated from the School of Medicine, Taipei Medical University. He further completed a Master of Medical Science at Chung Shan Medical University in Taiwan followed by a DPhil in Clinical Medicine at the prestigious University of Oxford in the United Kingdom. Currently a Professor of Dermatology at Chang Gung Memorial Hospital, Linkou and Chang Gung University, he is passionate about the application of evidence-based medicine. His research interest includes evidence-based health care, clinical epidemiology, and medical education. Prof Chi is the President of the Taiwan Evidence Based Medicine Association. He serves as an Editor for the Cochrane Skin Group and Associate Editor for the British Journal of Dermatology and Dermatologica Sinica.

How dangerous is short-term corticosteroid use? Reading the ‘Association between oral corticosteroid bursts and severe adverse events濣a nationwide population-based cohort study’ paper

Friday, Nov. 13, 2020 – from 14:50 to 15:20 RM 304A – LEVEL 3

SessionƝ(Medical) Evidence-Based Dermatology ( ⯍嬰憒⭟㛪⌻徍 )

A recent published Taiwanese study entitled ‘Association between oral corticosteroid bursts and severe adverse eventsƝ a nationwide population-based cohort study’ has caused turmoil among dermatologists. This study reported a twofold risk for gastrointestinal bleeding, sepsis, and heart failure following short-term use of systemic steroids. In this talk, I will go thru this paper and discuss the strengths and limitations.

Hsien-Yi Chiu 彯札扮

Dr. Hsien-Yi Chiu is a broad-certified dermatologist in Taiwan (2012). He received his medical degree from National Taiwan University College of Medicine (2004) and trained in dermatology department in National Taiwan University Hospital (2008~2012). He graduated with honors from the Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University in Taiwan with a PhD degree (2017). At present, he is an attending physician of dermatology in National Taiwan University Hospital, Hsin-Chu Branch and runs a psoriasis special clinic there. He demonstrates a level of interest in dermatology research, particularly for psoriasis research and has authored or co-authored over 70 peer-reviewed scientific articles.

Predictors of time to relapse following ustekinumab withdrawal in patients withpsoriasis who had responded to therapy SessionƝ(SDRDF) Psoriasis and PsA

Sunday, Nov. 15, 2020 – from 13:30 to 13:50 RM 302A – LEVEL 3

Our research screened 500 psoriasis patients who received ustekinumab (669 treatment episodes (TEs)) between 2011 and 2018. Overall, 202 patients (304 TEs), who had responded to therapy and were withdrawn from ustekinumab treatment, were included. The cumulative probabilities of relapse-free at 6 months, 12 months, 18 months, 24 months and 36 months of withdrawal from ustekinumab treatment was 49.3%, 12.6%, 5.3%, 4.7% and 1.6%, respectively. Multivariate regression analyses with a generalized estimating equation showed that after adjustments, biologics-naive, the maximum PASI improvement on ustekinumab, time to achieve PASI-50 after initiation of ustekinumab, family history of psoriasis, chronic kidney disease, and immunosuppressants use while off ustekinumab were significant predictors of time to relapse following ustekinumab discontinuation.

Pin-Chi Chiu 彯⍿済

2018/Nov ~ ƝChief Director of Aletheia Holistic Dermatology Center 2014/Sep ~ 2018/Jan ƝChairman, International Aesthetic Medical Center, China Medical University Hospital Dr. Chiu is a recognized expert on cosmeceuticals, cosmetic dermatology and acne/rosacea/melasma/sensitive skin management. He is appointed to give special lectures about cosmeceuticals and medical dermatology at annual meetings of TDA for many years. Also, he has been frequently invited to speak at national and international conferences about many aesthetic and medical related topics. He also first setup renowned cosmetic and skin-care social media fan group in Taiwan for public education. His work is dedicated to cosmeceuticals in the dermatological science and cosmetic industry.

How to optimize the effects of intradermal botulinum toxin for rosacea-associated erythema SessionƝ(Aesthetic) Botulinum toxin

Sunday, Nov. 15, 2020 – from 09:30 to 10:00 RM 301B – LEVEL 3

(1) 䜆䚕偰㮹㡦厳䴇㳏⯫㲼䙫憒䘩ㆰ䔏 (2) 愹䳆ㅉ『㳂䳬䙫䛟旃㲢䘩 (3) ⥩Ἴ⯵⅌䜆䚕偰㮹㡦厳䴇㖣愹䳆ㅉ『㳂䳬㲢䘩 (4) ⥩Ἴ⟞堳䜆䚕偰㮹㡦厳䴇㖣愹䳆ㅉ『㳂䳬㲢䘩 (5) ⥩Ἴ㐔愴䜆䚕偰㮹㡦厳䴇㳏⯫怙堳⌻⏳㲢䘩

Yung-Tsu Cho â&#x2C6;&#x2018;ć&#x2013;&#x2039;â&#x17D;°

Dr. Choâ&#x20AC;&#x2122;s main field of interest is primarily focused on immunologic skin diseases, including autoimmune bullous diseases, atopic dermatitis, urticaria, cutaneous lupus erythematosus, dermatomyositis, severe cutaneous adverse reactions, and skin toxicities due to oncological treatments. His researches aim to further characterize the clinical presentations, to explore the pathomechanisms, and to find better treatment modalities for these diseases.

Is AD a systemic disease?

SessionĆ?(Medical) What's new in atopic dermatitis

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 10:10 to 10:30

RM 305 â&#x20AC;&#x201C; LEVEL 3 $WRSLF GHUPDWLWLV LV DQ LQĂ&#x20AC;DPPDWRU\ VNLQ GLVHDVH ZKLFK PD\ FDXVH GLVFRPIRUW DQG LPSDLUPHQW OHDGLQJ WR GLVDELOLW\ LQ GDLO\ DFWLYLWLHV UHGXFHG SHUIRUPDQFH LQ OHDUQLQJ GHFUHDVHG SURGXFWLYLW\ LQ ZRUN DQG ZRUVHQHG ÂżQDQFLDO EXUGHQV ERWK IRU LQGLYLGXDO SDWLHQWV DQG HQWLUH KHDOWK FDUH systems. In addition, recent studies have shown that atopic dermatitis may be associated with many other diseases, such as allergic diseases, autoimmune disorders, ocular abnormalities, psychiatric problems, and cardiovascular and cerebrovascular diseases. As a result, such DVVRFLDWLRQV KDYH HYHQ OHG VRPH WR FDWHJRUL]H DWRSLF GHUPDWLWLV DV D V\VWHPLF LQĂ&#x20AC;DPPDWRU\ GLVRUGHU ,Q WKLV WDON , ZLOO VKDUH ZLWK \RX DERXW WKH associated diseases of atopic dermatitis in Taiwan. I will also compare our own data with those data from other countries in the literature and try WR ÂżJXUH RXW WKH V\VWHPLF QDWXUH RI DWRSLF GHUPDWLWLV

Wan-Yi Chou â&#x152;ŚâŠ&#x2122;ážž

Dr. Wan-Yi Chou was trained in departments of both pathology and dermatology at China Medical University Hospital, and received fellowship training at National Taiwan University Hospital. The main fields include nail diseases, nail braces, acne, rosacea, cosmeceuticals, pediatric dermatology and cutaneous side effects of target therapy and chemotherapy. She spent lots of time for educational speech and writing educational articles in dermatologic fields, trying to make some changes in spreading the correct information. Many of the articles were listed in top 3 search results in Google search. She also runs the FB fan page (https://m.facebook.com/wanyichoumd/) and a blog (http://wanyichoumd.blogspot.com)."

Chia-Yu Chu ă&#x2014;ŻâŠ´ä&#x152;&#x161;

Dr. Chia-Yu CHU is currently Professor of Dermatology at National Taiwan University College of Medicine, Taipei, Taiwan and also the President of Taiwanese Dermatological Association (TDA). His main research interests include atopic dermatitis, drug eruptions, urticaria, and autoimmune blistering diseases. In the past 15 years, he has been involved in many clinical trials including novel treatments for atopic dermatitis, urticaria, pemphigus and pemphigoid. As a dermatologist specialized in immunology and allergy, he has published more than 19 book/chapters and 180 articles about atopic dermatitis, drug eruption, urticaria, autoimmune blistering diseases, chemokines/cytokines and cancer progression, and contact dermatitis.

Treatments for Childhood AD: an update on emerging therapies SessionĆ?(Medical) What's new in atopic dermatitis

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 09:50 to 10:10

RM 305 â&#x20AC;&#x201C; LEVEL 3 Atopic dermatitis (AD) is generally considered a T helper type 2-dominated disease. Pediatric AD is usually less severe than adult AD, but it may present as moderate to severe lesions that are inadequately managed by current modalities including emollients/ moisturizers, topical corticosteroids (TCSs), topical calcineurin inhibitors (TCIs), and even systemic immunosuppressants. Therefore, there is still an unmet need for a safe and effective long-term therapy for pediatric AD patients whose disease is inadequately controlled or who are intolerant to current treatments. The emerging therapeutics for AD focus on intervening in the inflammatory pathway by targeting specific cytokines/chemokines or their receptors. Accompanied by thorough characterization of different phenotype and endotype subsets, the application of precision medicine could provide new prospects for the optimal treatment of AD.

Yao-Nien Chuang 剈䂽ⴲ

⏗䁊⤎⭟憒⭟䳢䕉㥔 Ẩ㄂憒䘩岈⛿㲼ạ䚕冁䦸ḢỢ ⽗⋽⟡䝊㕀憒晉䚕冁䦸ἶ晉憒⸒ ṳ㝾⟡䝊㕀憒晉䚕冁䦸ḢỢ ⏗䁊䚕冁䦸憒⭟㛪㛪Ⓢ

Wen-Hung Chung 拖㑅⩍

Dr. Chung is a dermatologist and a specialist of the field in severe cutaneous adverse drug reactions (SCARs) and cutaneous immunologic disorders. He currently serves as director of department of dermatology and drug hypersensitivity clinical and research center at Taipei & Linkou Chang Gung Memorial Hospital. Dr. Chung and his team has identified genetic and bio-markers for SCARs. He identified strong genetic association of HLA-B*1502 with carbamazepine-Stevens-Johnson syndrome(SJS) and toxic epidermal necrolysis (TEN) and HLA-B*5801 with allopurinol-SCARs. In addition, he discovered granulysin as the major mediator for keratinocyte death in SJS/TEN. These markers have been used in clinic before prescription of carbamazepine and allopurinol to prevent SCARs in many countries.

Paraneoplastic pemphigus mimicking Stevens-Johnson syndrome/ toxic epidermal necrolysis SessionƝ(Medical) What's new in autoimmune disease & drug reaction

Sunday, Nov. 15, 2020 – from 09:45 to 10:10 RM 305 – LEVEL 3

Paraneoplastic pemphigus (PNP) is an autoimmune blistering disorder, caused by humoral and cell-mediated autoimmune reactions. PNP is typically presented with painful mucositis, a polymorphic skin eruption, interface dermatitis with or without acantholysis, immunopathology involving plakin family proteins, and an underlying neoplasm. The histology of PNP is usually lichenoid and acantholytic. Keratinocyte necrosis could be one of the manifestations and associated with a poorer prognosis. There is increasing recognition of PNP simulating Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which are majorly druginduced T-cell-mediated cytotoxicity. PNP mimicking SJS/TEN is challenging to distinguish from SJS/TEN. Severe mucositis with skin necrosis are common to both entities. There are shared features including interface dermatitis and keratinocyte necrosis on histopathology. Further investigation are needed to identify the pathomechanisms of these patients

Yang-Shia Dai ヲᶮ旜

Current PracticeƝ Staff, Department of Dermatology, National Taiwan University Hospital (NTUH)ƋSince Jul, 2001ƌ Chairman, Department of Pediatric Dermatology, National Taiwan University Children’s HospitalƋSince Aug, 2014ƌ EducationƝ MD, College of Medicine, National Taiwan University, Taiwan Master degree, Graduate School of Clinical Medicine, Medical College, National Taiwan University PHD candidate, Graduate School of Pharmacy, Medical College, National Taiwan University

Pediatric atopic dermatitis濣theory and reality SessionƝ(Subspecialty) Pediatric Dermatology

Friday, Nov. 13, 2020 – from 14:00 to 14:30

RM 304B – LEVEL 3 There are a lot of guidelines for clinical practice in atopic dermatitis, however, some obstacles are obviously noted. These difficulties in practice are not shown in general guidelines, which needs expertise to make a solution. In this lecture, some practical idea will be presented and open to further discussion.

Ying-Xiu Dai ヲ冯Ậ

Ying-Xiu Dai graduated with a medical degree at National Yang-Ming University. He completed his clinical training in psychiatry and family medicine before starting a dermatology residency at Taipei Veterans General Hospital. His work focuses specifically on psychodermatology and dermatoepidemiology. His recent publication can be found in the Journal of the American Academy of Dermatology, Journal of the European Academy of Dermatology and Venereology, American Journal of Clinical Dermatology, Dermatology, Journal of Dermatology, Archives of Dermatological Research, and Lasers in Surgery and Medicine.

Increased risk of major depressive disorder among probands with psoriasis and unaffected siblings SessionƝ(SDRDF) Psoriasis and PsA

Sunday, Nov. 15, 2020 – from 13:50 to 14:30 RM 302A – LEVEL 3

Research has shown a high familial recurrence risk of psoriasis, suggesting genetic or environmental components in the susceptibility of psoriasis. Siblings of psoriasis probands may share some risk factors with the probands, making them more susceptible to other physical and mental disorders. Previous studies have shown that patients with psoriasis had higher risk for depression. This study included 1,094 probands with psoriasis,1,202 unaffected siblings, and 4,808 matched controls to evaluate the risk of major depressive disorder (MDD) among probands with psoriasis and unaffected siblings. Compared with controls, probands with psoriasis and unaffected siblings had relative risk (RR) of 10.6 (95% confidence interval [CI]Ɲ7.73–14.52), and 2.17 (95% CIƝ 1.44–3.28), respectively, for MDD. In conclusion, probands with psoriasis and unaffected siblings have an increased risk of MDD.

Che-Hao Hsu 壯⎰嬨

Dr. Hsu is the director of Hao Skin Dermatology Clinic located in New Taipei City, Taiwan. He is a board certificated dermatologist and dermatologic surgeon. He is the director of Laser and Photonics Medicine Society of the ROC, deputy secretary-general of Chinese Society of Cosmetic Surgery and Anti-aging Medicine and the reviewer for Journal of Cosmetic Dermatology. Dr.Hsu is fully accredited in aesthetic procedure such as skin rejuvenation, neurotoxin, filler injection, thread lift and lasers. Dr. Hsu had been invited to share his experience in many international meetings.

What's news in high-Intensity focused ultrasound and laser hair removal SessionƝ(Aesthetic) Energy Based Device

Sunday, Nov. 15, 2020 – from 14:00 to 14:30 RM 301B – LEVEL 3

HIFUƝ Liner cartridges vs Dot cartridges HIFU for fat reduction Laser Hair RemovalƝ Pneumatic skin flattening (PSF) Combination of wavelength

Cheng-Chieh Huang 涁㏽὏

Board-certified dermatologist based in Taipei, director of L'excellence aesthetic clinic. Field of interestƝenergy-based devices, injectables, and liposuction

A different preparation and usage of PLLA濣concept of bone implant SessionƝ(Aesthetic) Collagen stimulation filler

Saturday, Nov. 14, 2020 – from 16:30 to 17:00

RM 301B – LEVEL 3 The reconstitution method of PLLA (Scultpra®) has been evolving for years since it was first introduced in 2004. The volume of reconstitution was increased from 3ml to 8ml, and the time needed was reduced from 2 days to immediate before use. I’d like to try a new preparation method – 2ml of distilled water, then mixed with 1ml of hyaluronic acid. The mixture is a very homogenous, soft-gel-like material. I’m injecting this material on bone, such as mandible or canine fossa, much as bone implant.

Daw-Yang Hwang 涁弑㊘

RESEARCH INTERESTS Our lab is interested in the genomics changes in human disease, including cancer and other hereditary diseases. We applied high throughput genomic technologies to discover the disease-causing genes of human disease and driver genes of cancer. Translational researches, in vitro and in vivo, are used to validate their functional contributions to the disease development, progression, along with the development of cancer treatments. EDUCATION PhD Case Western Reserve University, MD Kaohsiung Medical College PROFESSIONAL EXPERIENCES 2019~present Assistant investigator and attending physician, National Institute of Cancer Research, National Health Research Institute 2015/08~present Assistant professor, Medicine, Kaohsiung Medical University

Single cell transcriptome analysis of acralmelanoma SessionƝ(Medical) What's new in skin tumor

Sunday, Nov. 15, 2020 – from 13:50 to 14:10

RM 305 – LEVEL 3 Although acral melanoma (AM) is the most common subtype in people with darker skins, such as Asian. Acral melanoma usually has a poorer prognosis compared to cutaneous melanoma. The differences in the etiology of AM and immune system between Caucasian and Asian that may influence the efficacy of IO therapy remained to be answered. Traditionally, methods such as microarrays and bulk RNA-seq analysis analyze the expression of RNAs from large populations of cells. Recently single cell sequencing technologies collect information from individual cells providing a higher resolution of cellular differences and a better understanding of the function of an individual cell and its microenvironment. The presentation introduces the sc RNA-seq technology and result of single cell transcriptome analysis of AM in Taiwan. Immune cells infiltration of AM were different in cell and gene expression, combined with phenotype or IO response may determine the values of sc RNA-seq in clinical applications.

Chung-Yee Hui 壯ᶰ䌢

Dr Rosaline Chung-yee Hui is a Dermatologist at Chang Gung Memorial Hospital at Linkou, Taipei, and Keelung. Her special interest in Psoriasis makes her one of the opinion leaders in Taiwan.

What’s the Future of Psoriasis Treatment? SessionƝ(Medical) What's new in psoriasis

Saturday, Nov. 14, 2020 – from 14:35 to 15:00

RM 305 – LEVEL 3 In the era of biologics, treatment goal of PASI 100 is possible in 60% patients. We will highlight potential new topical and systemic drugs in development, as well as new treatment goal with holistic approach.

Michael Kao 榖Ⓡら

Dr. Michael Kao is not only a Taiwanese board-certified cosmetic dermatologist, but also one of the founding members of Taiwanese Society for Dermatological and Aesthetic Surgery. He has been practicing aesthetic medicine for 13+ years, specializing in non- to minimally invasive procedures of facial rejuvenation & body shaping. As a frequently invited speaker at international conferences, and a designated trainer by worldwide renowned pharmaceuticals such as Galderma, Merz, and Sinclairüetc. for 8+ years, he focuses not merely on the trend of Asian beauty, moreover pays much attention to the safety issues of filler injections. He has run his own private practice @ Keyway Aesthetic Clinic for 8+ years.

The influence of neurotoxin resistance &immunogenicity on its aesthetic application SessionƝ(Aesthetic) Botulinum toxin

Sunday, Nov. 15, 2020 – from 09:00 to 09:30 RM 301B – LEVEL 3

The occurrence of immuno-resistance of neurotoxin (NT) used in neurologic disorders has been clearly established for many years, yet the situation applied in aesthetic indications has not yet been studied well due to lower dose exposure in every single treatment. However, it is definitely an emerging issue when it comes to gradually increasing NT usage in aesthetic applications nowadays. I would focus on the relationship of NT immunogenicity and its clinical relevance based on the studies that have been published in the 1st part, as well as present some secondary non-responsive (SNR) cases in aesthetic medicine and the results of their neutralizing antibody tests in the 2nd part of this talk.

Po-Ju Lai 宲㚍⡀

Dr. Lai obtained his medical degree in 2007 form Chung-Shan Medical University, Taiwan. Now, he is the director of dermatology at Chung-Shan Medical University Hospital. Besides his medical background and clinical experience, his strong interest in the treatment of atopic dermatitis, pediatric dermatology and psoriasis has inspired him to set up his personal website (httpsƝ//pojulai.blogspot.tw/) for patient education in these fields in 2016. The number of the page views of this website has reached to 1,000,000. The main purpose of creating this website is to share correct and practical information for patients suffering from atopic dermatitis and psoriasis. Dr. Lai firmly believes that patient education is the most important part in treating dermatologic disorders.

Atopic dermatitis 2020 update

SessionƝ(Medical) What's new in atopic dermatitis

Saturday, Nov. 14, 2020 – from 08:50 to 09:10

RM 305 – LEVEL 3 Atopic dermatitis (AD) is a heterogeneous disease that manifests a wide variety of clinical symptoms and signs. In the past few years, extensive research shedlight on the pathogenesis of the disease, allowing for better understanding of immune dysregulations causing the clinical outcome of AD. It is difficult to give a lecture on “what’s new in AD” within short time because this field is so large and rapidly evolving. Many newly proposed concepts and results of randomized control trials are published this year. During this lecture, the main focus involves four aspectsƝnew diagnostic criteria for Chinese population, the findings of primary prevention of atopic dermatitis with emollient, Skin bacterial transplant and emerging treatment.

Chia-Wen Lee 㘌Ⓡ㑅

Ḕⱘ憒⭟晉憒⭟䳢䕉㥔 (1992-1999) 䵺㭞Ɲ檿暫㦕㯸两憒晉㲳Ⱖ⣽䦸ἶ晉憒⸒⎱两憒⸒ ⏗㝘㦕㯸憒晉˚䍰憳㦕㯸憒晉㲳Ⱖ䦸Ḣ㲢憒⸒ 檿暫ⷩ䪲㯸䔆憒晉㲳Ⱖ䦸Ḣ㲢憒⸒ Ⲉⱘ≰ℰ暫憒晉㲳Ⱖ䦸Ḣ㲢憒⸒ 檿併㲳Ⱖ䦸娡㈧Ḣ㲢憒⸒ 泚ⱘ檿併㲳Ⱖ䦸娡㈧∴Ợ晉敞䏥ỢƝ泚ⱘ㜵◰㕮㲳Ⱖ䦸娡㈧晉敞 (2018- ) 㲳Ⱖ䦸憒⭟㛪『䖬⎱⟡ⱋ⦻Ⓢ㛪⦻Ⓢ (2016- ) 䔞『憒⭟㛪『䖬⦻Ⓢ㛪Ḣ⦻ (2020- ) 㲳Ⱖ䦸˚䔞『⭟˚⮝憒䦸憒⭟㛪⯯Ợ嬂⸒ 檿暫上憒⸒⅓㛪䏭Ṳ (2018- ) ⯯敞Ɲ『䖬娡㖞⎱柷昙˚䔞『⭟˚HIV 娡㖞凮柷昙『㉼嗌 2018 䖥䮈余昙䖒䌵⽾Ḣ

âłśĺĄ&#x2030;âťĽä&#x2019;&#x192;ä&#x2022;&#x201A;ä&#x2022;Źĺ &#x2DC;ĺ&#x153;Śä&#x160;źâ&#x160;&#x2C6;â&#x20AC;´ăšä&#x201D;&#x20AC;

SessionĆ?Infectious disease forum

Sunday, Nov. 15. 2020 â&#x20AC;&#x201C; from 15:30 to 16:00

RM 305 â&#x20AC;&#x201C; LEVEL 3 ă&#x20AC;&#x17D;ä&#x2013;Źâ°&#x2DC;ă&#x2DC;&#x2013;ă&#x2039;Žäľşä&#x201D;&#x2DC;ă&#x20AC;&#x17D;ă&#x17D;&#x152;ĺ§&#x;ă&#x2C6;§â&#x201A;&#x161;ă&#x2019;&#x201D;ä&#x2122;Ťä&#x2013;Ľä&#x2013;ŹĆ?äľşä&#x201D;&#x2DC;ă&#x20AC;&#x17D;áş&#x2039;ă&#x17D;&#x152;ĺ§&#x;â&#x2C6;&#x2014;ă&#x17E;ˇáş&#x201A;ä&#x2030; âŽ ä&#x2122;Ťä´&#x2014;ĺ&#x17D;łă&#x2021;˝ä&#x2013;ŹăŽšâťźĺľ&#x17E;ä&#x201D;&#x17E;âĽ&#x161;ă&#x20AC;&#x17D;ä&#x201D;&#x2020;ă˝â&#x17D;ąă˛łâ°Ść&#x20AC;şä&#x2122;Ťä&#x2013;Ľä&#x2013;ŹĆ?á˝˛âĽŠăĄŹăŽšĆ?ăś˛ä&#x2013;ŹĆ?ĺť&#x2020;ă&#x20AC;&#x17D;áˇ˛ä&#x2013;&#x161;Ć? ĺ&#x2026; ĺ&#x201A;&#x2C6;ăş&#x201E;ĺ °ĺ&#x160;¤ĺ&#x2026;&#x2019;Ć?ĺ&#x160;&#x2DC;ă&#x;&#x161;ă&#x20AC;&#x17D;ăś˛ä&#x2013;Źâˇ&#x203A;ĺ °ĺ&#x160;¤ĺ&#x2026;&#x2019;äŹ°Ë&#x203A;â?&#x161;â?&#x2013;ĺ&#x192;¤äľşä&#x201D;&#x2DC;â&#x2026;?áş˝ĺżťâ˝¸ă&#x201E;&#x2020;ă&#x17E;şĆ?ä&#x2022;?ä&#x201E;?âŻ´ĺş&#x2019;ćŞťä&#x2122;Ťâ˝&#x2DC;ć&#x;Śáš&#x2020;áˇ´â&#x201A;Źă&#x2030;ă&#x2013;Łä&#x201D;&#x2020;ă˝Ć?ă˛łâ°Śäł˘äľ&#x2DC;Ć?âĽŠ B â?˛ĺ&#x201A;&#x201E;ä ľË&#x161;ă&#x201E;&#x201A;ăş˛ä&#x2013;ŹË&#x161; ä&#x2013;&#x2DC;ä&#x2013; äŹ°äŹ°Ë&#x203A; ă&#x20AC;&#x17D;ä&#x2013;Źä&#x2122;Ťĺ&#x2021;&#x203A;ä&#x2013;Źâ&#x17D;&#x2020;â&#x2039;Źă&#x2039;&#x201C;Ć?ăĄŹăŽšĺ&#x17E;Ąă&#x2013;˛ćŞťâŻľĺ&#x2021;&#x203A;ä&#x2122;ŤăĄŹăŽšĆ?ăś˛ä&#x2013;Źć&#x203A;&#x20AC;ä?Şĺ&#x17D;łâťźĺľ&#x17E;ä&#x2122;Ťăś˛ä&#x2013;ŹĆ?ä&#x2122;¤ĺ&#x2030;&#x2122;âż&#x153;ä?&#x2021;ĺ&#x17D;łâťźĺľ&#x17E;ä&#x2122;Ťć&#x2122;&#x2014;ć&#x20AC;şâ°Ść&#x20AC;şä ľĆ?âŽŤä&#x201D;&#x2020;ĺ&#x;&#x2122;ćĄ&#x2026;ä&#x2122;Ťć&#x2122;&#x2014;ć&#x20AC;şăť&#x203A;ĺ&#x;&#x2122;âŻľĺ&#x2021;&#x203A;ć&#x2122;&#x2014;ć&#x20AC;şä ľË&#x161;â°Ś ć&#x20AC;şä ľĆ?áşĄćĄ&#x2026;áš&#x161;äŠ¨ä&#x2013;ŹăŽšă&#x201E;&#x2020;ă&#x17E;şä&#x2122;ŤâŻ˝â˝&#x2030;ăžźä&#x2013;&#x160;Ć&#x2039;ĺ?&#x192;ĺ&#x160;&#x2DC;Ć&#x152;Ë&#x161;ĺť&#x2020;ä&#x2013;&#x160;ä&#x2013;ŹăŽšă&#x201E;&#x2020;ă&#x17E;şć&#x2022;&#x17E;â&#x2021;Ąä&#x2122;Ťâ&#x201A;&#x161;ă&#x17E;şă&#x20AC;&#x17D;ĺť&#x2020;ä&#x2013;&#x160;Ć?ä&#x161;&#x2014;ä&#x2013; ä&#x2013;ŹăŽšâťźĺľ&#x17E;ä&#x2122;Ťâ&#x2013;&#x2022;äłťä&#x2013;&#x2DC;ä&#x2013; â&#x17D;ąă&#x203A;§â?&#x2013;âżźä&#x2122;ŤáşĄćĄ&#x2026;â&#x201E;´ä&#x2013;&#x2019;áˇ´â&#x2026;?ä&#x2013;ŹăŽšĺ&#x192;¤ âŻľĺ&#x2021;&#x203A;ă&#x201E;&#x201A;ăş˛ä&#x2013;ŹË&#x203A; ä&#x201D;&#x2DC;ă&#x2013;Łâťźä&#x2122;Łă&#x20AC;&#x17D;ä&#x2013;Źä&#x2122;Ťĺ&#x2021;&#x203A;ä&#x2013;Źâ&#x17D;&#x2020;áˇ´â?łĆ?ĺ&#x2021;?âšąä&#x2122;Ťä&#x2013;Žä&#x160;§Ë&#x161;ä&#x161;&#x2022;ĺ&#x2020; ĺĄ?ä?Ľáš&#x2020;â?Ťä&#x2022;&#x2014;Ć?á˝˛âĽŠĆ?ć&#x2122;&#x2014;ć&#x20AC;şË&#x161;â°Ść&#x20AC;şä&#x2013;Łä&#x2014;&#x201A;ă&#x2021;˝ă&#x203A;°â&#x2021;ă˛łä&#x2030;?ă&#x203A;°â?&#x2013;ĺ&#x192;¤ă&#x2DC;&#x2013;ăś˛ä&#x2013;ŹĆ?ä&#x201D;&#x2020;ă˝â&#x2122;?ă˝&#x2014;ä&#x2014;´Ë&#x161;áˇ˛ä&#x2013;&#x161;ăś˛âˇ&#x203A;ĺ&#x2026;Ąĺ&#x2026;&#x2019; â¤&#x17D;ă&#x203A;°â?&#x2013;ĺ&#x192;¤ă&#x2DC;&#x2013;ăĄŹăŽšĆ?ă˛łâ°Śâ&#x2122;?âżă°&#x203A;ăł&#x2C6;ă&#x203A;°â?&#x2013;ĺ&#x192;¤ă&#x2DC;&#x2013;ä&#x161;&#x2014;ä&#x2013; Ć?äżłă˛łâ°Ść&#x20AC;şĺ?&#x192;ĺ&#x160;&#x2DC;ä&#x160;§ä&#x2013;&#x160;ä&#x160;§ä&#x2030;?â&#x2C6;Žă&#x203A;°â?&#x2013;ĺ&#x192;¤ă&#x2DC;&#x2013;âŻ˝â˝&#x2030;ăžźä&#x2013;&#x160;ă&#x2021;˝â&#x201A;&#x161;ă&#x17E;şă&#x20AC;&#x17D;ĺť&#x2020;ä&#x2013;&#x160;Ë&#x203A;ă&#x20AC;&#x17D;ä&#x2013;Źă&#x153;&#x2018;äľşć ?ä&#x2022;?á¸˛ĺ¨Ąă&#x2013;&#x17E;ă˛˘ä&#x2DC;ŠĆ?â˝łć Ą ä&#x2013;Žâ?&#x2013;ĺ&#x192;¤ă&#x203A;°â°Ść&#x20AC;şä&#x2039; äŠŤË&#x161;áˇ´âŹźË&#x161;ć&#x2122;¤ĺ?ľË&#x161;ă&#x20AC;&#x17D;â&#x160;&#x2020;ĺ&#x192;¤ć&#x161;&#x192;ä¤&#x20AC;Ë&#x161;âžŞĺ&#x2021;&#x2020;Ë&#x161;ĺ §äŽ&#x2C6;ä ľË&#x161;ć&#x2014;&#x192;äŽ§ä ľË&#x161;â˝&#x2DC;ć&#x;Śĺ&#x201A;ľâ&#x201E;šć&#x20AC;&#x2021;ă&#x2021;ˇâ&#x201E;Żâ¤?ă&#x20AC;&#x17D;ăĄŹăŽšË&#x161;ăś˛ĺ&#x17D;łă&#x20AC;&#x17D;ä´ˇĺ&#x2020;&#x192;ä ľË&#x161;ĺ&#x2026;&#x2019;ä&#x2DC;&#x2039;Ë&#x161;ć°žä&#x160;§áˇąä&#x161;&#x2022;ä´&#x2014;ĺ&#x192;&#x2026;ä&#x2DC;ł â&#x17D;ąâĽ&#x161;ă&#x20AC;&#x17D;âŹˇâŽ&#x2022;ć &#x;ä&#x2DC;łË&#x161;âŁ˝ć&#x2122;&#x2014;ä&#x2DC;łË&#x203A; ă&#x20AC;&#x17D;ä&#x2013;Źä&#x2122;Ťć&#x;ˇć&#x2DC;&#x2122;á¸˛ć&#x20AC;şâ&#x2039;Źă&#x2039;&#x201C;â&#x203A;ĄâŽ ă&#x20AC;&#x17D;áź&#x203A;áž?Ë&#x161;â°â&#x2026;?ă&#x20AC;&#x17D;ĺ łä&#x201A;ĄË&#x161;ä&#x2013;&#x2019;ĺ&#x160;žă&#x2013;¤ă&#x2C6;şË&#x161;ă&#x161;&#x203A;ć&#x153;&#x2122;â&#x2C6;´ć&#x;ˇć&#x2DC;&#x2122;ă&#x20AC;&#x17D;ă&#x2030;źĺ&#x2014;&#x152;Ë&#x161;âŽ ă&#x153;&#x2020;äŻ?ăŞ&#x2030;áˇťă&#x203A;°ă&#x201D;Żä&#x2122;Ťă˛˘ä&#x2DC;Šă&#x17E;şä&#x2013;Źä&#x2122;Ťă&#x201A;&#x160;äżŹĆ?ć Śâ&#x201E;´â&#x201A;&#x161;ă&#x2019;&#x201D;Ë&#x203A;

Wen-Horng Lee ă&#x2DC;&#x152;ă&#x2018;&#x2026;ćŻš

My name is Wen-Horng Lee. I am an assistant professor of Department of Applied Cosmetology at Lee-Ming Institution of Technology and an adjunct assistant professor of Chemical Engineering at Ming-Hsin University of Science and Technology. My research interest is Functionalization of nanomaterials, Flavor and Fragrance Compoundings, Essential oil and Herbal Cosmeceutics.

â&#x2021;&#x201D;âĄ&#x203A;â?żâśĄâ&#x152;&#x2C6;ăŽ&#x201C;ĺĄ?äŠ&#x;ä&#x2039;&#x201E;ĺ&#x192;&#x2026;â&#x2021;&#x201D;âĄ&#x203A;â?żĺź&#x201C;ĺĄ?âśĄâ&#x152;&#x2C6;â&#x192;&#x201E;áľŠ SessionĆ?(Aesthetic) Cosmeceutical

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 08:30 to 08:50

RM 301B â&#x20AC;&#x201C; LEVEL 3 âť&#x160;â?ąâŽ äž? , âŽ&#x160;â&#x201A;&#x161;ă&#x2021;˝âť&#x160;â?ąăľ°â&#x17D;ąĺ&#x2122;&#x201A;â ¤Ë&#x161;ĺŠŽâ¤&#x17D;Ć?ă&#x2021;˝ć&#x2020;&#x2019;ä&#x2DC;Šă&#x201D;Żĺ&#x192;¤á¸˛ĺŠ´âŽ , áť&#x152;â&#x17D;ąâ&#x2039;˝âŚ&#x201E;â&#x2019;¨ć&#x20AC;źĺĽśâť&#x160;â?ąâ&#x2021;áş&#x2019; 'HÂżQLWLRQ RI $GYHUWLVLQJ 7KH GHWHUPLQLQJ VWDQGDUGV RI WKH IDOVH H[DJJHUDWHG ODEHOLQJ DQG PHGLFDO Há&#x201A;&#x2C6;FDF\ UHIHUUHG WR WKH $FW DQG 6KDULQJ RI FRVPHWLF YLRODWLRQ DGYHUWLVHPHQWV

Sharon Hua-En Lee ă&#x2DC;&#x152;ĺ&#x160;âź§

Dr. Hua-En, Sharon Lee is a board-certificated dermatologist in Taiwan. She received her medical degree from National Taiwan University. After completing her residency, she went to University of North Carolina at Chapel Hill for the research fellowship in autoimmune bullous diseases. Dr. Lee currently serves as a faculty member in Chang Gung Memorial Hospital, and specializes in the field of immunological skin diseases, including autoimmune bullous diseases, psoriasis, alopecia areata, atopic dermatitis, and vasculitis. Continuing her work at UNC-Chapel Hill, Dr. Lee keeps devoting herself to the research about pathogenesis of pemphigus. She also wishes to optimize the treatment and care for patients with autoimmune bullous diseases.

Current understanding and therapeutic strategies for pemphigus SessionĆ?(Medical) What's new in autoimmune disease & drug reaction

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 08:55 to 09:20

RM 305 â&#x20AC;&#x201C; LEVEL 3 Pemphigus is an autoimmune bullous disease presenting circulating autoantibodies against desmoglein (Dsg) 1 and Dsg 3, resulting in intra-epidermal blistering. Nowadays, the prognosis of pemphigus has improved but patients still suffer from the side effects of steroid and immunosuppressant used to treat the disease. Recently, B cell depletion by rituximab (RTX) has shown a higher remission rate and faster prednisolone tapering, leading to its approval as a first line therapy for pemphigus. However, relapse following RTX occurs in about 40-80% of the patients. Therefore, more effective and less toxic targeted approaches are under development. Other anti-B cell therapies targeting B cell receptor or downstream molecules are being tested in clinical trials. In a mouse model, CAAR-T-cell engineered using Dsg domain to selectively target autoreactive B-cells indicated future therapeutic application. Targeting T-B cell cross talk and local targeted therapy are also under investigation.

Ching-Gong Lin ă&#x2122;&#x2022;ăł&#x192;âŠŹ

â&#x;ă&#x17E;Ć?â&#x203A;˛äŞ˛ć&#x2122;¤ă&#x2014;ľâ¤&#x17D;â&#x;âž&#x2022;ä&#x201D;&#x2020;ä&#x2030;?â&#x17D;ąâ&#x201E;´ä&#x2013;&#x2019;ä&#x;ťäŠ?ă&#x2C6;§â? âŁ&#x2019;â&#x203A;˛äŞ˛â?&#x2014;ä &#x160;â¤&#x17D;â&#x;ä?&#x;ć&#x2020;&#x2019;â&#x;äł˘â&#x;âŁ&#x2019; ä?Ľĺ &#x17E;Ć?â&#x2014;°â&#x152;žĺ&#x2014;&#x152;ä?â¤&#x17D;â&#x;â&#x2039;˝ä˛&#x17D;â&#x2019;¨ă&#x2020;°ä&#x201D;?ĺ&#x2021;ŽäŽ&#x2C6;ä?äł˘ / ĺ&#x2014;&#x152;ä˛&#x17D;ä&#x201D;&#x2020;ă&#x2030;§ä&#x201D;&#x2030;ăĽ&#x201D;â&#x;âŁ&#x2019;â&#x;áź´â&#x;ä§˛â&#x2030;&#x2013;ă&#x2022;&#x20AC;ă?Ż á¸&#x201D;ĺ&#x152;°ĺ&#x2014;&#x152;â &#x152;âş&#x17E;ážŞć&#x20AC;&#x2122;ä&#x201D;&#x2030;â&#x;á¸&#x201D;âžŞá¸˘áť˘ ĺĄ&#x201A;äĽść&#x192;?â&#x2039;˝ä˛&#x17D;â&#x2019;¨ĺĄ&#x201A;ä&#x201D;&#x2020;äŽ&#x2C6;ä?ĺŤ&#x2022;ĺ&#x2014;âŚťâ&#x201C;&#x2C6; äľşă&#x17E;Ć?â&#x2014;°â&#x152;žĺ&#x2014;&#x152;ä?â¤&#x17D;â&#x;ĺ&#x2014;&#x152;ä˛&#x17D;ä&#x201D;&#x2020;ă&#x2030;§ä&#x201D;&#x2030;ăĽ&#x201D;â&#x;âŁ&#x2019;â&#x;áź´â&#x;ä§˛á¸˘áť˘ â&#x2039;˝ä˛&#x17D;â&#x2019;¨ă&#x2020;°ä&#x201D;?ĺ&#x2021;ŽäŽ&#x2C6;ä?äł˘äł˘á¸˘áť˘ â&#x2039;˝ä˛&#x17D;â&#x2019;¨äŚ¸ă&#x2030;§ä&#x;ťäŠ?ă&#x2C6;§ă&#x2C6;§ć&#x2022;&#x17E; ăŻ¸ä&#x201D;&#x2020;áż&#x201E;â &#x152;ă&#x161;?â &#x152;âş&#x17E;ážŞć&#x20AC;&#x2122;á¸&#x201D;âžŞá¸˘áť˘ â?&#x2014;â&#x152;žâˇŠ SBIR âŻ?ă&#x;&#x152;âŚťâ&#x201C;&#x2C6; ă&#x2030;§âŻŻć&#x2122;&#x2030;ă &#x2C6;äľ&#x2DC;áˇ§â&#x2026;&#x152;â&#x;ă¸&#x201C;ć¨žá¸&#x201D;âžŞäżŞäŚ¸â?&#x201C;ć&#x161;áşĄ / â&#x2018;¤ć łâŚťâ&#x201C;&#x2C6; äŚ¸ă&#x2030;§ć&#x192;?âŻ?ă&#x;&#x152;âŚťâ&#x201C;&#x2C6; âŻŻć&#x2022;&#x17E;Ć?â&#x2039;˝ä˛&#x17D;â&#x2019;¨ć&#x201E;´ă&#x2013; ć&#x2022;˛ä&#x2122;Ł â&#x2039;˝ä˛&#x17D;â&#x2019;¨â&#x160;&#x2020;ĺ&#x192;¤ă&#x20AC;&#x17D;ĺ¨źáź&#x2014; â&#x2039;˝ä˛&#x17D;â&#x2019;¨ GMP ä&#x201D;&#x2020;ä&#x2030;?äŚ¸ă&#x2030;§Ë&#x161;á¸&#x201D;ĺ&#x152;°ĺ&#x2014;&#x152;â&#x2039;˝âŚ&#x201E;â&#x2019;¨Ë&#x161;ä&#x201D;&#x2020;ă&#x2030;§â&#x2039;˝ä˛&#x17D;â&#x2019;¨â&#x17D;ąâž&#x2022;ä&#x201D;&#x2020;ä&#x2030;?ă&#x2020;°ä&#x201D;? ĺŹ°ä&#x2026;&#x17D;Ć?ä?&#x;ć&#x2020;&#x2019;â¸&#x2019;Ë&#x161;â&#x2039;˝ä˛&#x17D;â&#x2019;¨ GMP Ë&#x161;â&#x2039;˝ä˛&#x17D;â&#x2019;¨ĺŞŚĺŁ¤âˇ&#x152;ä§˛â¸&#x2019;

ć&#x201C;°ă&#x2013;Şä? â?żăĽ ăłŞá´&#x2030;ĺĄ?äŞ&#x201A;ĺ&#x192;&#x2026;äŻŽäŠž - áľ¸ćŚ&#x2019;ăłŞĺ¤¤ SessionĆ?(Aesthetic) Cosmeceutical

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 08:50 to 09:10

RM 301B â&#x20AC;&#x201C; LEVEL 3 âˇ&#x2122;ä&#x;&#x152;ä´&#x2019;âŁ˝äˇ (UV) ĺź˘âŻŤâŻ´áşĄćŞťă&#x203A;°âŽ&#x161;Ć?ă&#x161;&#x203A;ć&#x153;&#x2122;ă&#x2013;Łä´&#x2019;âŁ˝äˇ ĺź˘âŻŤáˇ´â&#x201A;ŹâŻľĺ&#x2021;&#x203A;ä&#x161;&#x2022;ĺ&#x2020; ă&#x203A;&#x201C;â&#x201A;&#x17E;Ë&#x161;â&#x201E;°äż¨â&#x2039;˝Ć?áźă&#x203A;&#x203A;â&#x161;&#x203A;ć&#x2020;´ä&#x2122;ŤâĽŠâ&#x201E;´ä&#x2013;&#x2019;ă&#x2030;¸â&#x2C6;?â&#x2018;łä&#x161;&#x2022;ĺ&#x2020; ä&#x2DC;łË&#x161;ć°žä&#x160;§ä´&#x2014;ĺ&#x192;&#x2026;ä&#x2DC;łĆ?â&#x;Ąâšźä´&#x2014;ĺ&#x192;&#x2026;ä&#x2DC;łĆ? ćş¸ĺ&#x2030;&#x2122;ä´&#x2021;ä&#x2DC;&#x2039;äŹ°Ë&#x203A;ä&#x201A;Ąášă¸&#x201A;âŻ¸ä´&#x2019;âŁ˝äˇ ä&#x203A;&#x;ć&#x2014;&#x192;ä&#x161;&#x2022;ĺ&#x2020; ä&#x2013;Ľä&#x2013;Źä&#x2122;Ťä&#x2122;Łä&#x201D;&#x2020;Ć?â&#x153;?âž&#x2026;áš˛ă&#x2C6;?âŁ˝ă´˘â&#x160;źâ&#x2C6;´Ć?ă&#x2020;°ĺŠ&#x2122;â žă&#x160; ć ?ä&#x2022;?áż&#x201E;ĺ&#x17E;â&#x160;&#x201A;ä&#x2122;Ťć&#x2DC;&#x2122;ă&#x203A;&#x201C;ä&#x201D;&#x2030;â&#x2019;¨Ë&#x203A;ă&#x153;&#x201C;ăŹ&#x2C6;á¸˘ć łă&#x201C;&#x201C;ă&#x17D;&#x2030;ĺ§ľć&#x2DC;&#x2122;ă&#x203A;&#x201C;ä&#x201D;&#x2030;â&#x2019;¨á¸˛ăŞ&#x2030;ă¸&#x201C;ĺĽśäŽŤ â&#x17D;ąáşĄćŞťć&#x2DC;&#x2122;ă&#x203A;&#x201C;ă&#x201D;Żĺ&#x192;¤ĺ¨źáź&#x2014;ă&#x2013; ă˛źĆ?â&#x2039;Źâ?&#x2019;áşĄćŞť (in vivo) SPF â&#x20AC;Łâ&#x17D;ą (in vivo) UVA áż&#x201E;ĺ&#x17E;ă&#x201D;Żĺ&#x192;¤ (PFA) äŹ°Ć?â&#x2026;?á¸&#x201D;áşĄćŞť SPF â&#x20AC;ŁážŠă&#x17D;&#x2C6;ä&#x201D;? ISO24444Ć?2010 ă&#x2013; ă˛ź (In vivo determination of sun protection factor)Ć?UVA áż&#x201E;ĺ&#x17E;ă&#x201D;Żĺ&#x192;¤ă&#x17D;&#x2C6;ä&#x201D;? ISO24442Ć?2011 ă&#x2013; ă˛ź (In vivo determination of sunscreen UVA protection)Ë&#x203A;

Shang-Li Lin ă&#x2122;&#x2022;áł&#x2C6;äŚ&#x2030;

Dr. Lin is a board-certified dermatologist and one of the most renowned speakers in the field of aesthetic medicine in Taiwan. He founded Shangli Dermatologic & Aesthetic Clinic in Taipei 10 years ago and has been giving lectures and training sessions in numerous global conferences and workshops for years. He has won the best case in non-surgical facial rejuvenation in 2015 at AMEC for his insightful treatment plans and unique injection techniques, and because of his passion and tremendous experience in the fields of injectables, laser and energy-based devices, he is one of the mostly requested and invited speakers worldwide.

Crucial injection concepts and literature updates of the polycaprolactone-based filler SessionĆ? $HVWKHWLF &ROODJHQ VWLPXODWLRQ ÂżOOHU

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 15:30 to 16:00 RM 301B â&#x20AC;&#x201C; LEVEL 3

3&/ EDVHG ÂżOOHUV DUH FRPSRVHG RI &0& JHO DQG SRO\FDSURODFWRQH PLFURVSKHUHV :KLOH WKH IRUPHU DFWV DV D FDUULHU DQG SURYLGHV DQ LPPHGLDWH FRUUHFWLRQ Há&#x201A;&#x2021;HFW WKH ODWWHU VWLPXODWHV FROODJHQ JURZWK DQG IDFLOLWDWHV WKH ORQJ ODVWLQJ UHVXOW RI WKH SURGXFW 7R GHOLYHU RSWLPDO results, product placement in the correct plane with proper amounts and by proper injection techniques, according to the sites of volume loss, is imperative. In this presentation, I will share the up-to-date information about the product and the crucial anatomical points that are indispensable for the optimal clinical results.

Sung-Jan Lin ă&#x2122;&#x2022;ć&#x203A;&#x160;ăż´

Dr. Sung-Jan Lin is the Taiwan Bio-development Foundation Chair in Biotechnology and Professor of Institute of Biomedical Engineering at National Taiwan University. He takes hair follicles as a model to understand how stem cells interact with the environment and respond to various insults to decipher the principles of tissue regeneration. His lab employs a multidisciplinary approach to mitigate organ damage and to enhance tissue regeneration. He has published ~140 journal papers in associated journals, including Cell, Science, PNAS, Nature Communications, Biomaterials, etc. His work has been recognized by Award for Junior Research Investigators of Academia Sinica and Distinguished Research Award of Taiwan Ministry of Science and Technology.

Hair regeneration from radio-/chemo-therapeutic injury SessionĆ?(Medical) Hair and stem cells forum

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 16:20 to 16:40

RM 305 â&#x20AC;&#x201C; LEVEL 3 Anagen hair follicle repair is the regenerative scheme activated to restore the structure following injuries. Germinative/matrix cells within hair bulbs are highly susceptible to injuries, such as chemotherapy and radiotherapy. Mechanistically, extra-bulge epithelial cells in the outer root sheath and the lower proximal cup are quickly mobilized for regeneration. They acquire stem celllike properties, breaking lineage restriction to regenerate all cell types in the lower segment. Facilitating extra-bulge epithelial cellsâ&#x20AC;&#x2122; mobilization ameliorates hair loss from chemo- and radio-therapy. Quiescent bulge stem cells can also be activated, but only after more severe injuries and with slower activation dynamics. They show limited plasticity and regenerate part of the outer root sheath only. The dysrhythmic activation might render bulge stem cells susceptible to concomitant injuries due to their exit from quiescence.

Shang-Hung Lin ă&#x2122;&#x2022;âŤ&#x2DC;âŠ?

Ever since the completion of my dermatological residence and fellowship training. I have worked as a dermatologist in Kaohsiung Chang Gung Memorial Hospital. My areas of specialty include skin cancers, Mohs micrographic surgery, hair transplantation and psoriasis. My research interest is the role of macrophage and its epigenetic regulation in psoriasis and psoriatic arthritis.

Update on the pathogenesis of psoriasis SessionĆ?(Medical) What's new in psoriasis

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 14:10 to 14:35

RM 305 â&#x20AC;&#x201C; LEVEL 3 Psoriasis is a common systemic inflammatory disease that affects several organ systems, including skin, nails, and joints. The innate immunity is important since skin confers the first immunological defense and pivotally regulates subsequent adaptive immune responses. LL37, the antimicrobial peptide, in complex with DNA and RNA is thought to initiate disease exacerbation via plasmacytoid dendritic cells and myeloid dendritic cells. The myeloid dendritic cells subsequently secrete IL-12 and IL-23 to initiate the adaptive immunity. IL-23â&#x20AC;&#x201C;mediated activation of the TH17 pathway is thought to be predominant. IL-23 signaling is mediated intracellularly via Tyk2-Jak2 and STAT3, which leads to transcription of key inflammatory mediators. These cytokines lead to downstream keratinocyte proliferation and infiltration of immune cells into lesional skin.

Upregulation of miR-941 in Circulating CD14+Monocytes Enhances Osteoclast Activation via WNT16 Inhibition in Patients with Psoriatic Arthritis SessionĆ?(SDRDF) Psoriasis and PsA

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 13:30 to 13:50 RM 302A â&#x20AC;&#x201C; LEVEL 3

Psoriatic arthritis (PsA) is a destructive joint disease mediated by osteoclasts. MicroRNAs (miRNAs) regulate several important pathways in osteoclastogenesis. We profiled the expression of miRNAs in CD14+ monocytes from PsA patients and investigated how candidate microRNAs regulate the pathophysiology in osteoclastogenesis. The microRNA-941 was selectively upregulated in CD14+ monocytes from PsA patients by NGS study. Inhibition of miR-941 abrogated the osteoclast development and function while increased the expression of WNT16. After successful treatment, the increased miR-941 expression in CD14+ monocytes from PsA patients was revoked. The expression of miR-941 in CD14+ monocytes is associated with PsA disease activity. MiR-941 enhances osteoclastogenesis in PsA via WNT16 repression. The miR-941 could be a potential biomarker and treatment target for PsA.

Jeng-Hsien Lin ă&#x2122;&#x2022;ă?˝ĺŽ

'U /LQ LV D ERDUG FHUWLÂżHG GHUPDWRORJLVW LQ 7DLZDQ +H JUDGXDWHG IURP 1DWLRQDO 7DLZDQ 8QLYHUVLW\ DQG ÂżQLVKHG KLV dermatology training in National Cheng-Kung University Hospital. He is interested in aesthetic medicine, especially ODVHUV HQHUJ\ EDVHG GHYLFHV DQG WKH LQMHFWDEOH +H LV D WUDLQHU RI PDQ\ GLá&#x201A;&#x2021;HUHQW ÂżOOHUV DQG ERWXOLQXP WR[LQV DQG KDV D lot of international and domestic lectures in aesthetic medicine. He is now the director of Dr. LINâ&#x20AC;&#x2122;s Dermatological Clinic in Kaohsiung.

Factors contributing to the diffusion of botulinum toxins SessionƝ(Aesthetic) Botulinum toxin

Sunday Nov. 15, 2020 – from 08:30 to 09:00

RM 301B – LEVEL 3 Botulinum toxin injection is one of the most popular procedures in aesthetic medicine. There are more and more brands of botulinum toxin in the market. While they are similar in mechanism of action, each of them may differ in molecular compositions, and may contribute to different clinical parameters such as efficacy, duration, or immunogenicity. Diffusion is one of the debated parameters that different brands usually claim for safety. By reviewing the literature, several factors such as different brands, the molecular weight of the toxins, injection volume and reconstituted concentration have been discussed. I will summarize the results, and comment on the design of these studies. I will also present an experimental test of different toxins in Taiwan. Finally, I will conclude these evidences for clinical application.

Kwei-Lan Liu ⅇ⠌哫

Dr. Kwei-Lan Liu is an attending physician of dermatology and aesthetic center at Kaohsiung Chang Gung Memorial Hospital. She is a Doctor of Medicine of National Taiwan University and a Master of Laws of Soochow University, Taipei, Taiwan. She dedicates her daily work to medical dermatology and aesthetic dermatology. She has clinical and research interests in various dermatologic disorders and laser therapy. She also completed an observation fellowship at Department of Dermatology at Samsung Medical Center, Seoul, South Korea, in 2019

Disease trajectories in childhood atopic dermatitis, focusing on prenatal exposure SessionƝ(Medical) What's new in atopic dermatitis

Saturday, Nov. 14, 2020 – from 09:10 to 09:30 RM 305 – LEVEL 3

Atopic dermatitis is the most common childhood skin disease and the first step of atopic march. The etiology of atopic dermatitis is multifactorial with interaction among genetics, immune and environmental factors. There is a complex interaction between different environmental factors, including heavy metals, pollution, and other exogenous factors. Understanding these factors is crucial to providing guidance for primary prevention. We reviewed prenatal exposures and presented a prospective birth cohort study in Taiwan. This study also investigated the change of serum total immunoglobulin E levels and atopic status in the Taiwanese birth cohort over 15 years.

Yang Lo 乃攻

Dr. Yang Lo graduated from Kaohsiung Medical University, College of Medicine in 2014. He performed Post-graduate year resident training in National Taiwan University Hospital from 2015 to 2016. He performed residency training and served as chief resident in Department of Dermatology at Cathay General Hospital from 2016 to 2020. He is now an attending physician in Department of Dermatology at Cathay General Hospital with a special interest in immune diseases and psoriasis.

Clinical features and genetic polymorphism in Chinese patients with erythrodermic psoriasis SessionƝ(SDRDF) Psoriasis and PsA

Sunday, Nov. 15, 2020 – from 13:50 to 14:30 RM 302A – LEVEL 3

Erythrodermic psoriasis (EP) is a rare variant of psoriasis with more complication and poorer biologic drug survival compared to plaque type psoriasis vulgaris (PV). No prior study has explored the human leukocyte antigen (HLA) or other genetic polymorphism in patients with EP. This study is aim to describe the clinical features, comorbidities and HLA polymorphism among Chinese patients with EP.

Chun-Wei Lu ä&#x2013;Ľáş&#x2C6;ä&#x152;&#x2030;

'U /X &KXQ :HL LV D ERDUG FHUWLÂżHG GHUPDWRORJLVW DQG D OHFWXUHU DWWHQGLQJ SK\VLFLDQ RI &KDQJ *XQJ 0HPRULDO +RVSLWDO DermatologyĆ&#x17E; Ph.D candidate, Institute of Clinical Medicine, Chang Gung University. His main research interests are DGYHUVH GUXJ UHDFWLRQ FXWDQHRXV DGYHUVH Há&#x201A;&#x2021;HFW RI DQWL FDQFHU PHGLFDWLRQ ZRXQG KHDOLQJ DQG VNLQ LQIHFWLRXV GLVHDVH He is actively involving in the clinical patient care, patient education and research on SCARs and dermatologic adverse events associated with cancer treatments at Drug Hypersensitivity Clinical and Research Center and Immune-Oncology Center of Excellence at Chang Gung Memorial Hospital.

Medical procedure and treatment-related infections SessionĆ?Infectious disease forum

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 16:10 to 16:40

RM 305 â&#x20AC;&#x201C; LEVEL 3 With the evolution of personalized medicine, the use of various new surgical procedures, and the development of various new drugs, such as target therapy for different kinds of cancers, biologics for different kinds of autoimmune diseases. The effect and quality of life have brought great progress. However, these new medical treatments may be accompanied by the risk of certain infections. Atypical wound infections after surgery, skin infections after the use of target therapy, and even internal organ infections have all been common problems in recent years. A clear understanding of the risks associated with possible infections, related treatment and prevention when using related drugs is an important part in clinical practice.

Peter Hsien-Li Peng â¸ŤĺŽ äĄŹ

Dr. Peter Peng is a board certificated dermatologist and dermatologic surgeon in Taiwan. He is the Founder & Director of Dr. Pengâ&#x20AC;&#x2122;s Dermatological, Cosmetic and Laser Clinic (P-Skin professional Clinic) in Kaohsiung, Taiwan. In 2017, he opened the second clinic -international dermatological clinic in Kaohsiung, Taiwan. With two decades of experience, Dr. Peng is a world-renowned expert in many of the aesthetic fields such as lasers and EBD, injectable,thread lifting and body contouring, and has been invited to share his innovative aesthetic approach in over 200 events across Europe, Asia, Africa, Australia, North and South Americas. Dr. Peng published more than 20 SDSHUV LQ DHVWKHWLF ÂżHOG LQ UHFHQW \HDUV

Asian lip enhancement by HA filler injectionclassifications and injection techniques

SessionĆ? $HVWKHWLF ,QMHFWDEOH ÂżOOHUVĆ?beauty NOT the beast

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 15:30 to 16:00 RM 301B â&#x20AC;&#x201C; LEVEL 3

Injectables, especially HA fillers, are increasing in popularity and setting a global trend for minimal invasive treatments. In the past decade, the global aesthetics community has become more focused on midface treatments. Lips are important markers for feminization and beautification of the female. The Asian lips are generally fuller than Caucasian lips. The way to inject Asian lips may a little bit different from inject Caucasian ones with more on reshaping the lips than augmenting the lips. In this talk, I will present my classifications systems and injection strategies for Asian lip reshaping by using HA filler injections.

Victor Shan ⑬㽸

⭟˙˙㭞Ɲ⏗⋾憒⭟⤎⭟ῄ⁌䇆棱⭟䳢䕉㥔䏥˙˙ỢƝSGS ⏗䁊㪉樾䦸㉧傈Ụ㛰昷⅓⏟⁌⺞䔉㥔㛴⋀㛴⋀惏䵺䏭䵺˙˙㭞ƝSGS ⏗䁊㪉樾䦸㉧傈Ụ㛰昷⅓⏟⁌⺞䔉㥔㛴⋀堳択䵺䏭 SGS ⏗䁊㪉樾䦸㉧傈Ụ㛰昷⅓⏟⁌⺞䔉㥔㛴⋀㛴⋀⯯㠯䵺䏭 SGS ⏗䁊㪉樾䦸㉧傈Ụ㛰昷⅓⏟䔆⑤䦸⭟㛴⋀堳択ḢỢ SGS ⏗䁊㪉樾䦸㉧傈Ụ㛰昷⅓⏟䔆⑤䦸⭟㛴⋀堳択⯯Ⓢ 憒䘩♏㜷怙⏊┭㥔⋀ḢỢ 䵘ᷧ㘆ⷛℲ敧ⷩ䵺䏭䛟旃䵺㭞ƝSGS 樾嬰⎱Ứ㥔ℑ⋽Ṳ㥔例㛴⋀⒨峑䳢䵘岮㷘娑Ⓢ SGS ⁌⺞䔉㥔⯯㠯⮉㈝䮈䏭 SGS ⁌⺞棆⒨䔚媲⯯㠯䵺䏭 2017~2019 ⹛⎾恧㒻Ợ⏗⋾憒⭟⤎⭟棆⒨⭰⅏䳢㥔䔳嬂⸒ 2013˚2014 ⹛⎾恧㒻ỢḔ凯⤎⭟䔆㉧䔉㥔凮⁌⺞棆⒨䙣ⰼ媙䧲嬂⸒ 岈⛿㲼ạự䔟䤥㛪䥶∐⟡憸㛪㴢⊼姺䷛嬂⸒ ⯯敞柿⟆Ɲ⋽䲎⒨˚ῄ⁌棆⒨⎱Ḕ匰嗌塂䔆⭰⅏䮈䏭 ⊆㔯娼἗婍樾奶≪ ⁌⺞䔉㥔ⷩ⠛奶≪ ⮉㈝䮈䏭⎱㛴⋀㺄态 ⯯㠯㴢⊼䬽䕒

擰㖪䏠⍿㥠㳪ᴉ塍䪂僅䯮䩾 - 榒⟔㳪夤 SessionƝ(Aesthetic) Cosmeceutical

Saturday, Nov. 14, 2020 – from 09:10 to 09:30 RM 301B – LEVEL 3

⋽䲎⒨昙㛓䛟旃㸓婍Ẳ䴠Ọ⎱䵺樾⇭Ẓ娔₀⎱⎪俪㖠㲼䰈Ẳ˚⤁䨕㸓婍㢄ờ媑㗵

I-Hsin Shih 㑻Ჾ㑮

Graduated from School of medicine, College of medicine, Taipei Medical University Department of Dermatology, Chang Gung Memorial Hospital Visiting scholar, Stanford University Medical Center Associate Professor of Chang Gung Memorial Hospital Director of Pediatric Dermatology, Chang Gung Memorial Hospital Member of Taiwan Dermatological Association Supervisor, Taiwan Dermatological Association Member of American Academy of Pediatric

Ren-Yeu Tsai 叟ᵿ斦

Dr. Tsai is a dermatologist and dermatologic surgeon in Taiwan. He is the founding president of the Taiwan Society for Dermatological and Aesthetic Surgery and board director of Taiwan Dermatological Association. Now, he is the president of Tsai's Hair & Skin clinic and associate professor of dermatology in Taipei medical university. He also served as associate editor of Jounal of Cosmetic Dermatology, contributing editor of Dermatologic Surgery, consulting editor of Dermatologica Sinica and editor of Chinese Journal of Dermatology.

Managing patients with male pattern hair loss濣myclinical experience SessionƝ(Medical) Hair and stem cells forum

Saturday, Nov. 14, 2020 – from 15:50 to 16:10

RM 305 – LEVEL 3 Patients with male pattern hair loss are commonly encountered in dermatological clinical practice, and formulating individualized management strategies for patients with hair loss is very important. After the first step of making a correct diagnosis of male pattern hair loss (androgenetic alopecia), planning of treatment occurs through discussions with the patient. Since treatment of androgenetic alopecia should continue life-long in theory, patient compliance is paramount for successful treatment. My lecture will summarize my clinical experience from working with patients with male pattern hair loss for more than 25 years.

Ya-Chu Tsai ĺ?&#x;ć&#x2013;&#x192;äŚˇ

'U <& 7VDL LV D FHUWLÂżFDWHG GHUPDWRORJLVW FXUUHQWO\ SUDFWLFLQJ LQ )DU (DVWHUQ 0HPRULDO +RVSLWDO DQG DV D GLUHFWRU RI Taiwanese Association for Psoriasis and Skin Immunology. She had received scholarship and research awards in the ÂżHOG RI SVRULDVLV +HU LQWHUHVWV PDLQO\ IRFXV RQ LPPXQRGHUPDWRORJ\ LQFOXGLQJ SVRULDVLV DWRSLF GHUPDWLWLV XUWLFDULD DQG hair loss therapies.

Oral disease-modifying antirheumatic drugs with antiviral potential SessionĆ?(SDRDF) Psoriasis and PsA

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 13:50 to 14:30

RM 302A â&#x20AC;&#x201C; LEVEL 3 Immunosuppressants often raise the concern of infection risks, especially for patients with underlying immune disorders. However, some disease-modifying antirheumatic drugs (DMARDs) with inherent antiviral activity would be a reasonable choice in the situation of concomitant viral infections and flare up of autoimmune diseases. This topic covers DMARDs with antiviral mechanisms plus trial evidence for viruses including SARS-CoV-2.

Tao-Hsin Tung ĺ&#x152;Ąĺź&#x2018;ĺ&#x192;&#x2020;

Tao-Hsin Tung received the Ph.D. degree in Public Health, National Yang-Ming University, Taipei, Taiwan, in 1996 and 2005, and SJD degree in Department of Crime Prevention and Correction, Central Police University, Taoyuan, Taiwan, in 2011 and 2018. In 2004, he joined the Department of Medical Research and Education, Cheng-Hsin General Hospital, as an Associated Researcher, and in 2008 became a Researcher. His current research interests include clinical epidemiology, biostatistics, evidence-based medicine, disease screening, medical law, and criminology.

COVID-19 (coronavirus) in dermatology practicećżŁ Perspective of three levels of prevention on public health

SessionĆ?(Medical) Evidence-Based Dermatology ( âŻ?ĺŹ°ć&#x2020;&#x2019;â&#x;ă&#x203A;Şâ&#x152;ťĺž? )

Friday, Nov. 13, 2020 â&#x20AC;&#x201C; from 14:00 to 14:50 RM 304A â&#x20AC;&#x201C; LEVEL 3

The scientists in China endeavored to find out appropriate vaccines and drugs due to the COVID-19 virus is spreading rapidly. The spread of the virus is rapid as the transmission capability of COVID-19 is much higher than SARS due to the binding affinity of COVID-19 to human ACE2. Multiple transmission ways also contribute to the wide spread of this virus. From the public health viewpoint, the categories of prevention included primary, secondary and tertiary stages. Primary prevention aims to prevent disease before it may occur. Secondary prevention aims to decrease the influence of a disease that has already happened. Tertiary prevention aims to relief the impact of an ongoing situation that has lasting clinical effects. In this talk, we could expect to achieve the following goalsĆ?1. Public health strategies of COVID-19 in dermatology practice 2. Explain the importance of COVID-19 in dermatology practice 3. Integrated model for surveillance of COVID-19 in dermatology practice

Ting-Shun Wang ä&#x2030;&#x2030;ćˇ&#x152;ĺ&#x192;&#x161;

Dr. Wang got his M.D from National Yang-Ming University in 2009. Then he entered Department of Dermatology, National Taiwan University Hospital to be a resident of dermatology for 4 years from 2009. He became a dermatologist (specialist) in 2013 and he had been in charge of special clinic of psoriasis at NTUH for 6 years. In 2015, he got an oversea scholarship and went to Department of Dermatology, Tokyo University Hospital as a visiting scholar for 2 months. In 2019, he got another oversea scholarship and went to Department of Dermatology, Jikei University Hospital as a visiting scholar for 2 months. His interest is mainly in psoriasis and other immunologic diseases and he had published 26 SCI articles.

Biologics switch in psoriasis

SessionĆ?(SDRDF) Psoriasis and PsA

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 13:30 to 13:50

RM 302A â&#x20AC;&#x201C; LEVEL 3 Biologic switch in psoriasis is frequent in clinical practice, thus evidence-based recommendations on the subsequent treatment FKRLFH DUH KLJKO\ QHHGHG $OWKRXJK VZLWFKLQJ EHWZHHQ 71) ÄŽ DQWDJRQLVWV KDV EHHQ UHYLHZHG LQIRUPDWLRQ UHJDUGLQJ VZLWFKLQJ between newer non-TNF-based biologics is lacking. Thus, we reviewed the current literature to provide more comprehensive information about new biologics such as IL-12/IL-23, IL-17 andIL-23 antagonists. In addition, we wanted to provide new evidence to guide clinicians to choose biologics among treatment choices

Shiou-Han Wang ä&#x2030;&#x2030;áşŹâ&#x2039;Š

ä?Ľáť˘Ć?ä?˛áż&#x2022;â?&#x2019;ä&#x161;&#x2022;ĺ&#x2020; äŚ¸ĺ¨Ąă&#x2C6;§ć&#x2122;&#x2030;ć&#x2022;&#x17E; â?&#x2014;â¤&#x17D;ć&#x2020;&#x2019;ć&#x2122;&#x2030;ä&#x161;&#x2022;ĺ&#x2020; ć&#x192;?â&#x2026;Łáť˘á¸˘ă˛˘ć&#x2020;&#x2019;â¸&#x2019; ć&#x2020;&#x2019;äżŹĺ¨Ąă&#x2C6;§âŻŻâŽ?ć&#x2022;§ĺ¨Ąć&#x2020;&#x2019;â¸&#x2019; â&#x;ă&#x17E;Ć?â?&#x2014;ä &#x160;â¤&#x17D;â&#x;ć&#x2020;&#x2019;â&#x;äł˘ć&#x2020;&#x2019;â&#x;âŁ&#x2019; â?&#x2014;ä &#x160;â¤&#x17D;â&#x;ć&#x203A;˘ăŠ&#x2020;ĺ˛Žĺ§ąâ&#x;ć&#x2122;&#x2030;ä&#x201D;&#x2020;ć&#x2020;&#x2019;ć&#x203A;˘âŹˇä˘?âŁ&#x2019; â?&#x2014;ä &#x160;â¤&#x17D;â&#x;âˇ&#x152;â&#x;ć&#x2122;&#x2030;ăŠ&#x2020;ă˘&#x2014;âˇ&#x152;ä§˛â&#x;âŁ&#x2019; ä&#x152;ľć&#x;ŹĆ?Elsevier â ¸â&#x2021;ĄâŻ?ä¨Śĺ˛&#x2030;ä?˘ä&#x152;ľ (Certificate of Outstanding Contribution in Reviewing) á¸&#x201D;ĺ?&#x2013;ăŻ¸â&#x203A;˛ä&#x201D;&#x2020;ä&#x2030;?ć&#x2020;&#x2019;â&#x;âˇ&#x152;ä§˛â&#x;ă&#x203A;Şâš&#x203A;âş?ă&#x203A;§á˝&#x161;ä&#x;ťäŠ?ĺŞ˝ă&#x2022;Žä&#x152;ľ (Best Annual Paper Award) á¸&#x201D;â&#x203A;˛âˇ&#x152;ä§˛â¸&#x2019;â&#x;ă&#x203A;Şâˇ&#x152;ä§˛ĺŞ˝ă&#x2022;Žä&#x152;ľ (Engineering Paper Award) â?&#x2014;ä &#x160;â¤&#x17D;â&#x;ć&#x2020;&#x2019;â&#x;äł˘ă&#x203A;&#x;â?&#x17E;ä&#x152;ľ â?&#x2014;ä &#x160;â¤&#x17D;â&#x;ăŠ&#x2020;ă˘&#x2014;âˇ&#x152;ä§˛â&#x;äł˘ă&#x203A;&#x;â?&#x17E;ä&#x152;ľ äľşă&#x17E;Ć?ĺĄ&#x201A;ä&#x201D;&#x2020;äĽśâ&#x2C6;?ć&#x192;?ćŁ&#x2020;â&#x2019;¨ĺ&#x2014;&#x152;ä&#x2030;?äŽ&#x2C6;ä?ä˝&#x2122;ć&#x2020;&#x2019;ä&#x2DC;Šâ&#x2122;?ă&#x153;ˇâŻ?ă&#x;&#x152;âŚťâ&#x201C;&#x2C6; ĺ˛&#x2C6;â&#x203A;żă˛źáşĄĺ&#x2014;&#x152;âŽ&#x161;ă&#x201D;¸ăż&#x2020;â&#x;Ąć&#x2020;¸ă&#x203A;ŞćŁ&#x2020;ĺ&#x2014;&#x152;ä˝&#x2122;âŚťĺž?ć&#x2020;&#x2019;ä&#x2DC;Šâ&#x2122;?ă&#x153;ˇáˇąâˇŠâ˝łâ°â&#x2026;?ĺ¨źáź&#x2014;âŻ?ĺ&#x2014;âŚťâ&#x201C;&#x2C6; ĺ˛&#x2C6;â&#x203A;żă˛źáşĄć&#x2020;&#x2019;ć&#x2122;&#x2030;ĺ¨źć?¸ă&#x161;?ć&#x2020;&#x2019;ä&#x2DC;Šâ&#x2019;¨ĺł&#x2018;äŹ˝ć&#x20AC;&#x2122;ă&#x203A;Şä˝ľâŽ ć&#x2020;&#x2019;â&#x;â&#x2019;¨ĺł&#x2018;ĺŠ´ĺŹ°ĺ¨&#x2018;ĺĽ˝âŚťâ&#x201C;&#x2C6; â?&#x;ă˛źć&#x2122;&#x2030;ă˛źâżâ&#x;ć&#x2122;&#x2030;ć&#x2020;&#x2019;áš˛ă Żáť?âŻ?â&#x2039;&#x20AC;ä&#x;ťäžšă&#x203A;ŞĺŹ&#x201A;âş&#x17D; â?&#x2014;â¤&#x17D;ć&#x2020;&#x2019;ć&#x2122;&#x2030;ä&#x;ťäŠ?ĺ§Żä&#x2022;&#x2019;â&#x152;ťâ?łá¸˘ă&#x2039;¨áşĄ â?&#x2014;â¤&#x17D;ć&#x2020;&#x2019;ć&#x2122;&#x2030;ä&#x;ťäŠ?â&#x20AC;&#x2019;ä?âŚťâ&#x201C;&#x2C6;ă&#x203A;ŞâŻ?ă&#x;&#x152;âŻŻâŽ? ă&#x2013;&#x2014;äŤ âˇ&#x152;ăĽ&#x201D;ă&#x2030;§ĺ şä&#x;ťäŠ?ć&#x2122;&#x2030;ä&#x;ťäŠ?ĺ§Żä&#x2022;&#x2019;â&#x152;ťâ?łá¸˘ă&#x2039;¨áşĄ á¸&#x201D;ĺ?&#x2013;ăŻ¸â&#x203A;˛ä˝ľâŽ ć&#x2020;&#x2019;â&#x;ć&#x2020;&#x2019;â&#x;ă&#x203A;Şä?áš˛ â?&#x2014;ä &#x160;ć&#x2020;&#x2019;ä&#x201D;?ć&#x203A;&#x17E;âŻŤâ&#x201E;°ć&#x203A;˘â&#x;ă&#x203A;Şä?áš˛ â?&#x2014;ä &#x160;ä&#x161;&#x2022;ĺ&#x2020; äŚ¸ć&#x2020;&#x2019;â&#x;ă&#x203A;Şă&#x2022;&#x20AC;ĺ&#x201A;&#x2122;âŚťâ&#x201C;&#x2C6;ă&#x203A;ŞâŚťâ&#x201C;&#x2C6; á¸&#x201D;ĺ?&#x2013;ăľ&#x17E;âł¤â&#x2026;?â˛&#x;ă&#x2022;&#x203A;â˝&#x2030;ä˝ľâŽ â&#x152;ťă&#x203A;ŞäŹ&#x201C;áˇ§â°â¸&#x;â&#x2039;&#x20AC;ä?áš˛ á¸&#x201D;â&#x203A;¤ă&#x2022;&#x203A;â˝&#x2030;ä˝ľâŽ â&#x152;śáź ăľ&#x17E;âł&#x2C6;á¸&#x2039;â˛&#x;â&#x2021;áź äŹ&#x201C;áˇ§â°ąâ¸&#x;â&#x2039;&#x20AC;âŚťâ&#x201C;&#x2C6;

Treatment of keloid, hypertrophic and atrophic scars with energy-based devices SessionĆ?(Aesthetic) Energy Based Device

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 13:30 to 14:00

RM 301B â&#x20AC;&#x201C; LEVEL 3 Keloid, hypertrophic and atrophic scars are common scar conditions that are difficult to treat. The dermatologists may combine multiple modalities to obtain better results. Energy-based devices (EBD) play essential parts in combined therapy. This lecture will review and update EBD's application in scar treatment with the discussion of the author's experience.

Kai-Che Wei ć¨?ă ľâ&#x17D;°

Kai-Che Wei, MD Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Dermatologist / Assistant professor CareerĆ? 2009-2011 (visiting staff) Dermatology, Hospital of National Cheng-Kung University, Tainan, Taiwan 2011-now (visiting staff) Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Study fieldsĆ? 1. Radiation dermatitis (caused by percutaneous coronary intervention) 2. Pemphigus (pathophysiology) 3. Dengue virus infection (of skin)

Trifarotene - A novel treatment for acne and rosacea SessionĆ?(Subspecialty) Acne and rosacea forum

Friday, Nov. 13, 2020 â&#x20AC;&#x201C; from 16:50 to 17:15

RM 304B â&#x20AC;&#x201C; LEVEL 3 7RSLFDO UHWLQRLGV DUH Há&#x201A;&#x2021;HFWLYH DQG UHJDUGHG DV WKH FRUQHUVWRQH RI DFQH WUHDWPHQW EXW WKHUH DUH VWLOO XQPHW QHHGV RI DFQH WUHDWPHQW DV IROORZLQJĆ? 1. Very high frequency of retinoid dermatitis /HVV Há&#x201A;&#x2021;HFWLYH IRU WUXQN OHVLRQVĆ?Approximately 50% of patients with facial acne also present with lesions on the trunk (back and/or chest). 3. Not effective for reducing hyperpigmentation 7ULIDURWHQH DV D SRWHQW DQG VHOHFWLYH UHWLQRLF DFLG UHFHSWRU 5$5 Č&#x2013; DJRQLVW LV WKH RQO\ DQG QHZHVW DSSURYHG WRSLFDO UHWLQRLGV LQ WKH past three decades, showing promising treatment effect for trunk acne and pigmentary alteration, with less side effects of irritation.

Chiao-En Wu ⋱㐗⼧ I graduated from Chang Gung University in 2007 and started my medical career at Chang Gung Memorial Hospital at Linkou after graduation. During 2014-2018, I studied “targeting regulation of p53 and MAPK pathways as a therapeutic strategy in melanoma” for a PhD degree at Newcastle University, UK. Currently, I am an associate professor of the division of hematology-oncology at Chang Gung Memorial Hospital at Linkou. My research focuses on p53 regulation in melanoma, gastrointestinal malignancies.

Current advances in melanoma treatment SessionƝ(Medical) What's new in skin tumor

Sunday, Nov. 15, 2020 – from 13:30 to 13:50

RM 305 – LEVEL 3 Melanoma is the most aggressive skin cancer. Activating mutations in BRAF are present in 40-60 % of Western melanomas but only in approximately 20% of Asian melanomas. The phase III COMBI-d/COMBI-v trials demonstrated the combination of dabrafenib and trametinib has significantly longer PFS and OS and fewer skin toxicities than BRAFi (dabrafenib and vemurafenib) alone, therefore, this combination becomes one of the standard treatment in BRAF-mutated metastatic/unresectable melanoma. . Immune checkpoint inhibitors (ICIs), nivolumab/pembrolizumab/nivolumab + ipilimumab have shown the efficacy with durable response and been approved for metastatic/unresectable melanoma regardless of BRAF status. In this talk, I will discuss latest update of immunotherapy and targeted therapy combination in the melanoma treatment.

Ching-Ying Wu ⋱昐䤌

Ching-Ying Wu, MD, PhD, is an Assistant Professor at the Department of Dermatology, Kaohsiung Medical University. Her special interests focus on hair diseases, connective tissue diseases, and aging. She has great interest in effect of sex hormones on the structure and functions of the skin in both genders. She is currently the director at Department of Dermatology, Kaohsiung Municipal Ta-Tung Hospital.

Female pattern hair loss at aglance

SessionƝ(Medical) Hair and stem cells forum

Saturday, Nov. 14, 2020 – from 16:40 to 17:00

RM 305 – LEVEL 3 Female pattern hair loss (FPHL) is a common cause of hair loss in women characterized by diffuse reduction in hair density over the crown and frontal scalp with retention of the frontal hairline. Its prevalence increases with advancing age and is associated with significant psychological morbidity. The aim of treating female pattern hair loss is to reduce hair loss and succeed in promoting hair regrowth. Various treatment methods are available. Early initiation of treatment and the combination of various modalities is the key to efficacious treatment.

Yi-Chien Yang 㠈⩚ủ

Dr. Yi-Chien Yang, MD, PHD, a physician-educator, serves as a faculty member in College of Medicine, Chang Gung University, Taoyuan, Taiwan. She received dermatology residency training in Kaohsiung Chang Gung memorial hospital in Taiwan, and obtained PhD degree in Graduate Institute of Clinical Medical Sciences, Chang Gung University. She currently is a PhD student in Graduate Institute of Adult Education at National Kaohsiung Normal University. Dr. Yang works on both field of nature and social science, including the physiological and functional significance of androgens and androgen receptor and the professional development of physicians.

Challenges in using the ACGME milestone for the dermatology resident assessments SessionƝ(Medical) Medical education

Sunday, Nov. 15, 2020 – from 09:20 to 09:45 RM 302A – LEVEL 3

Medical education is transitioning from time-based to competency-based medical education. We intended to describe the professional trajectory of a resident from the beginning of their training through the achievement of competency by utilizing milestones adapted from the dermatology milestones of the Accreditation Council for Graduate Medical Education. There are some challenges to the implementation of milestones, including increased administrative requirements, the need for faculty development, increased workload for medical teachers, lack of appropriate assessments for some competencies, work hour restrictions, and the incorporation into training programs. Because the milestones are based on observable behaviors, a key component of this system will be direct observation by faculty of residents. Faculty development in observational skills, workplace-based assessment skills, and providing formative feedback will be a important aspect.

Wei-Tai Yu ḗ䱫㮮

Wei-Tai Yu (also known as Sebastian Yu) received his M.D. degree from National Yang-Ming University. He finished his dermatology residency in Kaohsiung Medical University Hospital. Now he is an Attending Physician in Kaohsiung Medical University Hospital and an Assistant Professor in Kaohsiung Medical University. He is specialized in clinical immunology of skin diseases, including psoriasis.

Diet-induced obesity exacerbates imiquimod-mediated psoriasiform dermatitis in anti-PD-1 antibody-treated mice: Implications for patients being treated with checkpoint inhibitors for cancer

Sunday, Nov. 15, 2020 – from 13:50 to 14:30 RM 302A – LEVEL 3

SessionƝ(SDRDF) Psoriasis and PsA

We investigated the role of obesity in immune checkpoint inhibitors-exacerbated psoriasiform eruption. We fed female C57BL/6 mice a so-called Western diet (WD) or a control diet (CD). Imiquimod (IMQ) was applied topically on ears for 5 consecutive days to induce psoriasiform dermatitis (PsD). WD-fed mice showed higher baseline mRNA expression levels of psoriasis-associated cytokines such as IL-17, S100A8, and S100A9 compared to mice fed with CD. Furthermore, WD-fed mice had more gd low (GDL) T cells in the whole skin and higher expression of PD-1 on GDL Tcells than CD-fed mice. WD-fed mice receiving anti-PD-1 had more prominent ear swelling than lean mice receiving anti-PD-1 during the 5-day IMQ course (2-fold increase, P < 0.0001 on day 5)

Peter Yu Yu ẜḏ

Dr. Peter Yu Yu received his medical degree from National Taiwan University and later completed his dermatology residency at Cathay General Hospital in Taipei, Taiwan. He completed his training with fellowships in pediatric dermatology at Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University, Chicago, Illinois, USA. Dr. Peter Yu Yu has published in several medical and scientific journals. Dr. Peter Yu Yu maintains affiliations with Cathay General Hospital and Saint Mary’s Hospital Luodong. His current areas of interest include pediatric dermatology, cosmetic dermatology and atopic dermatitis. Dr. Peter Yu Yu maintains active membership in Society for Pediatric Dermatology (USA) and International Society of Pediatric Dermatology (ISPD).

Environmental factors in the pathogenesis and clinical outcome of atopic dermatitis SessionƝ(Medical) what’s new in psoriasis

Saturday, Nov. 14, 2020 – from 09:30 to 09:50 RM 305 – LEVEL 3

As the prevalence of atopic dermatitis (AD) surges worldwide in recent years, interest in the searching of underlying environmental pathogenetic and prognostic factors also rises. Among the topmost topics, hygiene, intestinal microbiota, exposure to bacterial endotoxins, outdoor living with contact to animals, atmospheric pollution, weather, and diet are most investigated. The talk aims to offer a short review of the above topics.

Speakers & Abstracts EAVA

Davinder Parsad

Professor, PGIMER, Chandigarh, India Hony Professor of Dermatology University of Rome â&#x20AC;&#x153; G.Marconiâ&#x20AC;? Rome , Italy Â&#x2021; 0DLQ DUHD RI UHVHDUFK LV YLWLOLJR SDWKRJHQHVLV DQG WUHDWPHQWDQG LQQRYDWLYH VXUJLFDO PHWKRGV Â&#x2021; 7RWDO RI SXEOLFDWLRQV DQG DERXW SXEOLFDWLRQV RQ YLWLOLJR RQO\ LQ ,QWHUQDWLRQDO MRXUQDOV ZLWK YHU\ KLJK FLWDWLRQ LQGH[ Â&#x2021; 3DVW 3UHVLGHQW Âą$VLDQ 6RFLHW\ IRU 3LJPHQW &HOO 5HVHDUFK

Holistic management of vitiligoćżŁMy Journey SessionĆ?(EAVA) Invited lectures

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 08:30 to 08:50

RM 302A â&#x20AC;&#x201C; LEVEL 3 The development of effective treatment for vitiligo depends on understanding the mechanisms of depigmentation and repigmentation. In our continued journey to find ideal treatment of vitiligo, we have definitely reached a new era with effective medical treatment and non-cultured epidermal suspension in the management of vitiligo. Vitiligo an auto-immune disease and there is need to emphasise on the early treatment of vitiligo. There are two treatment goals, one is stabilization and second is repigmentation. As vitiligo is associated with sever psycho-social stress, third goal can be to consider psychological aspects also in the management. At present combination therapy is key to the successful management of vitiligo. In the present era of post phototherapy, we have a wide spectrum of many effective treatments for vitiligoĆ&#x17E; however, we do not have ideal treatment yet. In this presentation, I will be presenting an overview of roadmaps and roadblocks to the successful treatment of vitiligo based on the experience of last 20 years. Surgical methods are emerging as an important solution for stable vitiligo refractory to medical treatment. Over the years vitiligo surgery has gained steady importance with more and more improved techniques proving their effectiveness. Non-cultured epidermal cell suspension is emerging as the first line of surgical management of stable Vitiligo.

Ichiro Katayama

Prof. Katayama has membership of European Society for Investigative Dermatology and International federation of society of Itch (IFSI)(Board Member).Other than that, he has membership nine dermatology related Japanese societies, and is playing as Board member in some of them. Prof. Katayama organized several meetings as President, in The 6th Japan-German Joint Meeting of Dermatology(2002), The 8th World Congress of Itch (WCI(2016), and The 2nd East Asia Vitiligo Association (EAVA) meeting(2017).Prof. Katayama is editorial board member of Journal of Dermatological Science, Environmental Dermatology (EIC), Journal of Environmental and Dermatology Cutaneous Allergy. He is also EIC of The Japanese Journal of Dermatology. Prof. Katayama had been appointed as board member of Japanese Society of Investigative Dermatology (JSID) from 1997 to 2008 and contributed for international communication of basic science of dermatology. Prof .Katayama has been the Board Member of International federation of society of Itch (IFSI) since 2013 to the present andcontributed for the establishment of international collaboration of itch study and publication of â&#x20AC;&#x153;Itch journalâ&#x20AC;?. Prof. Katayama has been the active members of East Asia Vitiligo Association (EAVA),since 2015 to the present and alsoVETF (Vitiligo European Task Force since 2011 to the present. Prof. Katayama published 3 peer-reviewed articles as collaborator. Certificate of AppreciationĆ?International League of Dermatological SocietyĆ&#x17E;ILDS2018

Epidermal endocrine units regulates meIanocyte function in vitiligo SessionĆ?(EAVA) Invited lectures

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 08:50 to 09:05

RM 302A â&#x20AC;&#x201C; LEVEL 3 :H KDYH UHSRUWHG WKDW HSLGHUPDO NHUDWLQRF\WHV V\QWKHVL]H FRUWLVRO WKURXJK DFWLYDWLRQ RI WKH HQ]\PH Č&#x2022; K\GUR[\VWHURLG GHK\GURJHQDVH Č&#x2022; +6' DQG DWWHQXDWH DFXWH DQG H[FHVV FXWDQHRXV LQIODPPDWLRQ LQ DGGLWLRQ WR FRQWURO FHOO JURZWK DQG survival in the epidermis (Terao m & Katayama I. J Dermatol Sci. 2016.84:11-16). Recently, we found another endocrine system, extra-gonadal production of estrogen, exists in the epidermis which regulates melanocyte survival and melanogenesis and may contribute induction and progression of vitiligo. ,Q WKH VNLQ UHVLGHQW FHOOV ZH GHPRQVWUDWHG WKDW HVWURJHQ V\QWKHWLF HQ]\PHV +6' Č&#x2022; LV PDLQO\ H[SUHVVHG E\ HSLGHUPDO keratinocytes while membranous/cytosol estrogen receptor GPER1is mainly expressed by melanocytes. We confirmed that estradiol protects melanocyte from oxidative stress and is downregulated in vitiligo lesional skin. Precise mechanisms of UHJXODWLQJ +6' Č&#x2022; H[SUHVVLRQ E\ NHUDWLQRF\WHV VKRXOG EH FODULILHG LQ WKH IXWXUH VWXG\

Sang-Ho Oh

I am an Associate professor in Yonsei University College of Medicine, Seoul, Korea. My academic interest is melanogenesis, vitiligo, pigmentary disorders and photomedicine. My main research topic is to investigate the pathogenesis of vitiligo. In addition, I am interested in finding out new mediators for melanogenesis and develop new valuable hypopigmenting agents through mechanism research. My vitiligo clinic has the best background and environment to do translational research on vitiligo using precious human samples from vitiligo patients. Very recently I am also interested in hair graying and cellular senescence as well.

ATP-P2X7- induced inflammasome activation as a new player for vitiligo development SessionĆ?(EAVA) Invited lectures

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 09:20 to 09:35 RM 302A â&#x20AC;&#x201C; LEVEL 3

In this talk, I will focus on the effect of extracellular adenosine triphosphate (ATP) as one of damage-associated molecular patterns on melanocytes because we found ATP can be released from skin cells in response to UV irradiation and ROS in our experiments. ATP is known as a molecular unit of intracellular energy source. However, ATP, which is released outside cells by damage such as injury, apoptosis and hypoxia, can act as one of danger signals. Melanocytes differently react on extracellular ATP depending on its concentration. Our previous study suggested that relatively low concentration of ATP stimulated melanogenesis through intracellular calcium and protein kinase/CREB signaling via P2X7 receptor (P2X7R). On the other hand, as extracellular ATP is a wellknown inflammasome-activating signal and emerging evidence demonstrates a critical role for inflammasome activation in vitiligo pathogenesis, we tried to investigate the specific molecular mechanism of inflammasome-dependent melanocyte degeneration in vitiligo in association with high concentration of ATP. This study presents how extracellular ATP, released from keratinocytes by oxidative stress, affects melanocyte survival in vitiligo skin. H2O2-induced oxidative injury increased ATP release from keratinocytes and skin tissues. The high concentration of extracellular ATP induced both ROS production and cell death in melanocytes. Treatment with ATP caused the activation of FDVSDVH DV ZHOO DV WKH SURGXFWLRQ RI DFWLYH IRUPV RI ,/ Č&#x2022; DQG ,/ YLD 3 ; 5 LQ NHUDWLQRF\WHV DQG PHODQRF\WHV /HVLRQDO DQG perilesional skin of vitiligo showed higher levels of ATP as well as upregulation of active caspase-1 compared to non-lesional skin, suggesting its possible role in inflammasome activation in vitiligo. Moreover, the elevated expression of CXCL9 in keratinocytes, mediated through ATP-P2X7R-dependent inflammasome activation, was responsible for CLA+CD8+ T-cell chemotaxis into the skin. These results demonstrate that extracellular ATP as a danger signal activates the inflammasome pathway and increases cutaneous chemotaxis of CD8+ T-cells via CXCL9 in vitiligo. Therefore, I propose ATP-P2X7-induced inflammasome activation could be a new player for vitiligo development from this talk and targeting ATP-P2X7 signaling may be a potential strategy for vitiligo treatment in the future.

Tamio Suzuki

My interests in dermatology are in the melanin biogenesis and metabolism in the skin of mice and humans. Our research laboratory has studied melanogenesis (melanin production), oculocutaneous albinism (congenital disorder with the loss of pigment in the skin), vitiligo (acquired skin pigment loss), color of skin, and pigmentation of skin. 1988-1991 Postdoctoral fellow, Biochemistry, Yamagata University 1991-1992 Dermatology resident, Nagoya University Hospital 1998 Staff Dermatologist, Nagoya University Hospital 1998-2001 Postdoctoral fellow, University of Colorado Health Science Center, Human Molecular Genetics Program (Prof. Spritz R.A.) 2002-2004 Assistant Professor, Department of Dermatology, Nagoya University Graduate School of Medicine 2004-200 Associate Professor, Department of Dermatology, Nagoya University Graduate School of Medicine 2007-present Professor and Chairman, Department of Dermatology, Faculty of Medicine, Yamagata University 2018Vice-president of Yamagata University Hospital 2020 President of International Pigment Cell Conference 2020 (IPCC2020)

Melanocyte behaviors during depigmentation and repigmentation processes in a chemical vitiligo mouse model SessionĆ?(EAVA) Invited lectures

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 09:35 to 09:50 RM 302A â&#x20AC;&#x201C; LEVEL 3

Vitiligo is a depigmentation disease characterized by gradual loss of melanin and melanocytes from the epidermis. The mechanism of melanocyte loss still remains unknown. In order to investigate the pathomechanism, we established a mouse modelfor rhododendrol-induced leukoderma (RIL), which is a kind of chemical vitiligo.Rhododendrol(RD), a naturally occurring phenolic compound, was developed as a tyrosinase inhibitor for skin-lightening/whitening cosmetics. In 2013, skin depigmentation was reported in consumers using RD-containing skinbrightening cosmeticsĆ&#x17E; this condition is called RIL.Here, we show melanocyte behaviors duringthe depigmentation and the repigmentation processes in the mouse model. Melanocytorrhagy has suggested that an epidermal adhesion defect may be involved in melanocyte loss in vitiligo.Previous studies have shown thatpolymorphisms of the Discoidin Domain Receptor 1 gene (DDR1) and the E-cadherin gene (CDH1)involved in melanocyte adhesion, are associated with vitiligo susceptibility.Therefore, we investigated the time-dependent expressions of DDR1 and E-cadherin during the depigmentation process. The results suggested that melanocyte damage would promote reduction of the adhesion molecules not only in melanocytes but also in keratinocytes, and would be associated with the detachment of melanocytes from the basal layer.

On the other hand, we searched for drugs that promote the repigmentation process using this mouse model. As a result, it was found that VitD3 topical application promoted the repigmentation. Therefore, we investigated in detail mechanism of action of VitD3 on melanocytes in the UHSLJPHQWDWLRQ SURFHVV DQG FODULÂżHG WKDW WKH QXPEHU RI PHODQRF\WHV LQFUHDVHG DV D UHVXOW RI SUROLIHUDWLRQ RI PHODQRF\WHV LQ WKH HSLGHUPLV

Jung-Min Bae

My name is Jung Min Bae, an Associate Professor in the Department of Dermatology at The Catholic University of Korea. Vitiligo remains one of the major challenges in dermatology because there is no definitive cure. Although recent research shed light on the pathogenesis of vitiligo, there is still a huge gap between laboratory and clinic. I am struggling to fill that gap in the clinic. Since nonsurgical treatment is not always successful in treating vitiligo, I believe surgical interventions would be viable options for patients with refractory vitiligo. Currently,the most common surgeries include micropunch grafting, suction blister grafting, and non-cultured melanocyte-keratinocyte transplantation (MKTP). Especially, noncultured MKTP has been developed to cover large areasĆ&#x17E; success rates range from 56% to 84% in recent reports. Unfortunately, noncultued MKTP has not been approved in Korea yet. I first introduced noncultured MKTP in Korea and have performed over 50 cases so far. Although there are still many obstacles that must be overcome before obtaining approval, I hope that this procedure will be widely established in Korea and other countries. For light skin patients such as Caucasians, vitiligo could be a simple matter, even though I do not believe it is a simple matter. Having met many Korean patients who profoundly suffer from vitiligo, where the white patches appear more evident on Asian skin, I thought that Asian dermatologists including me had responsibilities to study harder and find the solution for our vitiligo patients. I wish to do research that can give hope to vitiligo patients.

Surgical approaches for vitiligo SessionĆ?(EAVA) Invited lectures

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 09:50 to 10:05

RM 302A â&#x20AC;&#x201C; LEVEL 3 Since nonsurgical treatment is not always successful in treating vitiligo, surgical interventions would be viable options for patients with refractory vitiligo. Surgical treatment is a method in which melanocytes of normal skin are transplanted into vitiligo lesions and provided as a source of repigmentation. It is primarily divided into tissue grafting and cellular grafting, depending on the nature of the graft. Tissue grafting includes split-thickness skin grafting, suction blister grafting, punch grafting, hair follicle transplantation, and smashed skin grafting. Cellular grafting includes noncultured epidermal cell suspension transplantation, noncultured follicular cell suspension transplantation, and cultured epidermal cell suspension transplantation. Among them, suction blister grafting and micropunch grafting have been widely performed for localized refractory vitiligo, and noncultured epidermal cell suspension transplantation is adopted as the standard treatment for extensive vitiligo. Research on cultured cellular grafting to treat larger vitiligo areas is ongoing as well. Selecting patients with stable vitiligo that has not spread more than 12 months is the most critical factor in the surgical outcome. It is also important to choose an appropriate surgical modality for each patient, and a combination of various procedures often improves the overall outcome. In conclusion, surgical intervention can be an effective and safe option for patients with vitiligo refractory to conventional treatments.

Cheng-Che E. Lan ĺ&#x2019;&#x2039;ă?˝â&#x17D;°

Dr. Cheng-Che Lan received his MD degree from National Cheng-Kung University, (NCKU) and PhD degree from Kaohsiung Medical University (KMU). Dr. Lan is the Professor and Chair of Dermatology Department of KMU. He is also a board member of the Taiwanese Dermatological Association and Taiwanese Society for Investigative Dermatology. Currently, he is also the section editor of the Journal of Dermatological Science, the associate editor of the Photodermatology, Photoimmunology & Photomedicine, and the secretary of the International Federation of Pigment Cell Societies. Dr. Lan focuses academic research on pigmentary disorders, photomedicine, and wound healing, he published more than 150 peer-reviewed papers in academic journals. He enjoys clinical practice as much as academic research.

Use of Janus Kinase Inhibitors in dermatology: Focusing on vitiligo SessionĆ?(EAVA) Invited lectures

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 10:05 to 10:20

RM 302A â&#x20AC;&#x201C; LEVEL 3 Traditionally, the treatments for dermatologic disorders evolve from morphological and histopathological changes observed on the diseased skin. Recently, due to the advances in scientific knowledge and technology, molecular processes involved in diseased skin were more clearly defined. Clinically, targeting these specific molecules results in much improved treatment efficacy. JAK inhibitors (JAKi) function by inhibiting the activity of JAK family enzymes. These enzymes are tyrosine kinases that play a critical role in mediating the signal transduction of cytokines, particularly those that bind to and activate the type 1/2 cytokine receptors on the surface of cell. Although the only dermatologic condition that is currently approved for treatment using JAKi is PA, their potential applications within dermatology include AD, AA, and vitiligo. In this presentation, the use of JAKi on these conditions will be reviewed, and discuss our experience with JAKi in the Taiwanese vitiligo patients.

Yen-Jen Wang 䉉䛒ᵸ

Dr. Wang is a dermatologic surgeon specialized in Mohs micrographic surgery and slow-Mohs micrographic surgery, vitiligo surgery, and hidradenitis suppurativa surgery. Invited by Taiwanese Dermatological Association, she has been the person in charge of resident training program for Mohs micrographic surgery from 2018 to 2020. She has been invited to multiple national and international meetings to give lectures in the dematologic surgery field. Recently, she also developed interest for in vivo and ex vivo optical coherence tomography (OCT) and has been the principle investigator of multiple programs. She is also exploring the possibility of incorporating OCT images and deep learning, and application of in vivo OCT as an objective evaluation tool in cosmetic dermatology.

Quantitative outcome assessment of color match and the extent of repigmentation by image analysis software SessionƝ(EAVA) Treatments of vitiligo in the Dermatological surgeryThe experience of the medicalinstitutions in Taiwan

Saturday Nov. 14, 2020 – from 13:30 to 13:45 RM 302A – LEVEL 3

Atopic dermatitis (AD) is generally considered a T helper type 2-dominated disease. Pediatric AD is usually less severe than adult AD, but it may present as moderate to severe lesions that are inadequately managed by current modalities including emollients/ moisturizers, topical corticosteroids (TCSs), topical calcineurin inhibitors (TCIs), and even systemic immunosuppressants. Therefore, there is still an unmet need for a safe and effective long-term therapy for pediatric AD patients whose disease is inadequately controlled or who are intolerant to current treatments. The emerging therapeutics for AD focus on intervening in the inflammatory pathway by targeting specific cytokines/chemokines or their receptors. Accompanied by thorough characterization of different phenotype and endotype subsets, the application of precision medicine could provide new prospects for the optimal treatment of AD.

Chau Yee (Charlene) Ng 涁㓫䌚

Dr. Chau Yee (Charlene) Ng is a board-certified dermatologist, practicing in Chang Gung Memorial Hospital, Linko/ Taipei. She specializes in vitiligo and melanocyte grafting and is involved in vitiligo research including clinical and basic immunology studies.

Management of vitiligo patients with surgical interventions

SessionƝ(EAVA) Treatments of vitiligo in the Dermatological surgeryThe experience of the medical institutions in Taiwan

Saturday, Nov. 14, 2020 – from 13:45 to 14:00 RM 302A – LEVEL 3

Vitiligo is a chronic, psychologically devastating depigmentation disease that impacts patients' quality of life. Medical treatments are important for early stage of diseases when melanocyte reservoirs are still preserved. Surgical pigment grafting is the last resort for those who fail to response to medical treatment. This lecture will share the tips and tricks in evaluating vitiligo candidates, the selection of different surgical interventions, the pitfalls and methods to optimize the surgical outcome.

Jin-Bon Hong 㯨㠦彤

Attending physician in NTUH. Field of interest: genodermatoses, cancer genetics, genetic screening, dermatologic surgery, melanocyte biology.

Procedural approaches for stable vitiligo on difficult-to-treat sites SessionƝ(EAVA)Treatments of vitiligo in the Dermatological surgery The experience of the medical institutions in Taiwan

Saturday, Nov. 14, 2020 – from 14:00 to 14:15 RM302A – LEVEL 3

Various kinds of procedural and surgical approaches has been applied for treating stable vitiligo. Vitiligo on certain areas are relatively difficult to treat, including eyelids, canthus of the eyes, perioral region, hair line, areola and nipple, genitalia, hand and foot and lesions over bony prominence. Our institute utilizes suction blistering epidermal graft, microdome grafting, mini-punch grafting and cultured melanocytes for stable vitiligo on difficult-to-treat sites. These procedures will be introduced. Furthermore, we are developing new methods aimed at improving the successful rate of treating these patients.

Chao-Hsing Kao 榖䀥㓝 1978-1985 1985-1989 1990 1989-1994

Kaohsiung University, College of Medicine Residency, Kaohsiung University Hospital Department of Dermatology PhD.of Medical Science, Kaohsiung University. Fellow, Kaohsiung University Hospital, Department of Dermatology 1994-2020 Chief Doctor of Kao ChaoHsing Dermatology Clinic

Review and prospect of surgical treatment of vitiligo patients

SessionƝ(EAVA) Treatments of vitiligo in the Dermatological surgery The experience of the medical institutions in Taiwan

Saturday, Nov. 14, 2020 – from 14:15 to 14:30 RM 302A – LEVEL 3

The suitable conditions for surgical treatment of patients with vitiligo are patients in stable phase and no response to previous non-surgical treatment. Surgical treatment of patients with vitiligo is divided into preparation of donor sites and recipient sites for transplantation. Then transplant the tissue or cells containing melanocytes to the vitiliginous lesions. Surgical treatments of donor site for patients with vitiligo include (1) punch grafting (2) split-thickness skin graft with the aid of dermatome, and (3) suction blister epidermal grafting. The tissue containing melanocytes obtained from donor sites can be directly implanted onto the vitiliginous lesions or processed into non-cultured epidermal cell suspension, or purified cultured melanocytes. The future prospect of surgical treatment of vitiligo is the feasibility of implanting autologous mesenchymal stem cells into vitiliginous lesion, and the other is the improvement of wound dressing with autologous fibrin mesh.

Atsushi Tanemura

Dr. Atsushi Tanemura is Japanese dermatologist and dermato-oncologist who is currently an associate professor of the department of dermatology at Osaka University Graduate School of Medicine, Japan. He graduated Kindai University Faculty of Medicine on 1997 and received a philosophy degree at Osaka University on 2005. He was working on melanoma research as a post-doctoral fellow at John Wayne Cancer Institute from 2005 to 2007, thereafter, returned to Osaka University as an assistant professor. His research interest includes melanocyte biology influenced in oxidative stress and immunology in vitiligo and skin malignancies.

Optimal treatment for vitiligo

SessionƝ(EAVA) Free Communication

Saturday, Nov. 14, 2020 – from 15:30 to 15:45

RM 302A – LEVEL 3 The vitiligo guidelines suppose several treatments and their recommendation including topical therapy, phototherapy, systemic immune-suppressants, and surgical approach. In addition to conventional therapies, recent preclinical study provides the promising patho-mechanism of vitiligo on that the biologics targeting chemokines and signal transducers have been developed. New appearance of vitiligo treatment or intervention might contribute to increase the opportunity to manage vitiligo patients sufficiently. In order to maximize the effectiveness of these therapeutic options and to minimize the useless intervention, it is highly required to understand a heterogeneity of vitiligo patients and lesions and to apply each treatment at the best setting, so that we archive a personalized medicine. Toward an optimal treatment of vitiligo, I would like to introduce how to understand the disease heterogeneity and then discuss the choice of suitable treatments referring to representative cases.

Masahiro Hayashi

Dr. Hayashi graduated Yamagata University Faculty of Medicine got medical license in 1998. After the dermatological residency, he conducted research at the department of pathology and got Ph.D degree about the genetic analysis of cutaneous squamous cell carcinoma in 2002 (Prof. TeiichiMotoyama). He had been appointed as dermatologist in several prefectural hospitals and Yamagata University hospital from 2002-2011 (Prof. Shigeo Kondo and Tamio Suzuki) and engaged in the research about the inherited pigmentary disorders including oculocutaneous albinism and dyschromatosis symmetrica hereditaria with Prof. Suzuki. Then he worked as postdoc in human medical genetics and genomics in University of Colorado School of Medicine from 2011-2015 (Prof. Richard A Spritz). The theme in Spritz lab was functional analysis of susceptibility genes of vitiligo. After the postdoc work, he returned to Yamagata University in 2015 and has been engaged in clinical work as dermatologist and doing research. His main interest is vitiligo, inherited/ acquired pigmentary disorders and potential biomarkers for skin cancers (melanoma, SCC and so on). His hobby is sightseeing and traveling abroad (before the pandemic of covid-19). Since almost all conferences and meetings have been being cancelled because of pandemic, currently he enjoys spending the time with family (wife and two daughters) on weekends.

Pathogenesis of vitiligo from the viewpoint of genetics SessionƝ(EAVA) Invited Lecture

Saturday, Nov. 14, 2020 – from 15:45 to 16:00

RM 302A – LEVEL 3 Vitiligo is an autoimmune disease targeting cutaneous melanocytes. It is characterized by multiple white patches on the skin with occasional white hair due to loss of melanocytes. In addition to the autoimmunity to melanocytes, many factors and molecules including innate immunity, oxidative stress and cell adhesion are involved in its pathogenesisƞ however, the details are still to be elucidated. Recent advance of genetic analysis particularly Genome Wide Association Study (GWAS) revealed that the risk for vitiligo is associated with nucleotide polymorphisms located across melanocyte- and immune-related genes. Subsequent functional studies indicated these alleles defines the expression level of major histocompatibility complex genes leading to the upregulation of autoimmune response to melanocytes. Since these data are principally obtained from the studies for Caucasian population and the genetic background is different among the ethnicities, we wanted to investigate if genetics of vitiligo in Japanese is different from in Caucasian. Our preliminary data using the samples from Japanese individuals suggest that the regulatory mechanism of HLA-A expression which is important for antigen presentation of melanocyte-related molecule may be different from Caucasian. In vitiligo high risk individuals, HLA-DR/DQ expression on their unstimulated PBMC is upregulated in compared to non-high risk individuals, and they were significantly overexpressed upon microbial stimulation. High risk individuals also showed increased production of LQIODPPDWRU\ F\WRNLQHV LQFOXGLQJ ,/ ȕ DQG ,)1Ȗ RQ PLFURELDO VWLPXODWLRQ 7KLV ILQGLQJ LQGLFDWHV WKDW YLWLOLJR KLJK ULVN LQGLYLGXDOV have higher HLA-DR/DQ expression than non-high risk individuals, and they are more sensitive to microbial stimulation, suggesting excessive immune response to indigenous fungi or bacteria on the horny layer of epidermis might trigger the onset of vitiligo. In this presentation, I will talk about the vitiligo pathogenesis from the viewpoint of genetics.

Flora Xiang 朷吼䵠

Research FocusƝMelanocytes research and pigmentary skin disorders; Acne and sebaceous gland related diseases; Medical laser and photodynamic Therapy 2011.07-till now Executive deputy director, Institute of Dermatology, Fudan University 2007.10-till now Professor, Department of Dermatology, Huashan Hospital, Fudan University 2002.10-till now Vice Chair, Department of Dermatology, Huashan Hospital, Fudan University 2001.11-2007.10 Associate Professor, Department of Dermatology, Huashan Hospital, Fudan University (formerly Shanghai Medical Universtity) 2001-2002.3 Honorary Research Associate, Division of Dermatology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong 1997-2000 Attendant (senior medical officer), Department of Dermatology, Huashan Hospital, Shanghai Medical University 1992-1997 Resident (medical officer), Department of Dermatology, Huashan Hospital, Shanghai Medical University

The role of home use phototherapy in the treatment of vitiligo SessionƝ(EAVA) Invited lectures

Saturday, Nov. 14, 2020 – from 09:05 to 09:20

RM 302A – LEVEL 3 The study was to evaluate the efficacy and safety of home and outpatient NB-UVB for the treatment of non-segmental vitiligo. A total of 94 patients with non-segmental vitiligo were enrolled. Forty-eight patients were treated with home NB-UVB, and the other 46 patients were treated with outpatient NB-UVB over a period of 6 months. The efficacy, patient quality of life, and adverse events were assessed at month 3 and month 6 after treatment. It concluded that the efficacy and safety of home NB- UVB and outpatient NB- UVB phototherapy for non- segmental vitiligo were comparable. According to our results, those with long-standing vitiligo may be recommended to receive outpatient NB- UVB phototherapy. The influence factors for home phototherapy were reviewed.

Speakers & Abstracts ASD

Cheng-Hsiang Hsiao ĺ?Ťă¨Ąä Ł

Dr. Cheng-Hsiang Hsiao is the director of Dept. of Anatomical Pathology of Cheng-Hsin General Hospital in Taipei. He graduated from the School of Medicine of National Taiwan University in 1988. He completed his resident training course in the Dept. of Pathology of National Taiwan University Hospital in 1992, then he became an attending staff in his alma mater. He was in charge of dermatopathology and infectious pathology in the Dept. of Pathology in NTUH since 1995. Then he became an active member in the teaching and research activities in dermatopathology in Taiwan. In 2012, he retired from the NTUH and transferred to the Cheng-Hsing General Hospital but he still active in teaching dermatopathology.

Wei Zhang âˇ&#x17E;ć&#x161;&#x;

2010-2013 Doctor Degree in Dermatology, Institute of Dermatology, Peking Union Medical College 2006-2008 Master Degree in Dermatology, Graduate School of Kunming Medical University, 2006.3-12 Second University of Bordeaux, France, University diploma in Epidemiological Methodology and Application, ISPED 2005.9-12 Medical College of the VII University in Paris, France, university diploma in AIDS, STDs and their impact on reproductive health in the World Health Organization (WHO) and Bichat-ALFRED FOURNIER 2005.2-8 Joint Institute for Advanced Epidemiology and Clinical Trials, IRD, URI 174,Chiangmai, Thailand 2003-2005 Master Degree in Tropical Disease and Public Health,in Tropical Disease College, French Union of Colleges and Universities 2003-2007 Standardized resident training in the First Affiliated Hospital of Kunming Medical University from 2001 to 2008

Cher-Wei Liang ă&#x153;żâ&#x17D;°äąŤ

Director, Department of Pathology, Fu Jen Catholic University Hospital (2017-now) Attending physician, Department of Pathology, National Taiwan University Hospital (2012-17) Visiting scholar, Brigham and Womenâ&#x20AC;&#x2122;s Hospital, Harvard Medical School (2010-12) Attending physician, Cathay General Hospital (2005-10)

Rajiv Joshi

I am trained in clinical dermatology and dermatopathology and am practicing as Consultant in both these fields in Mumbai, India since 2000. I have been conducting teaching sessions for dermatologists and residents in dermatology and pathology in Dermatopathology since 2003 and have participated in several National and International conferences in dermatology and dermatopathology as guest speaker. Basic training in dermatology in KEM hospital Mumbai with M.D degree awarded in 1986. Training Fellowship in Dermatopathology with Dr. A Bernard Ackerman inPhiladelphia, USA in 1997. Invited speaker at many conferences in Dermatopathology in India and other places. PublicationsĆ?65 papers in peer reviewed journals.

The apoptotic keratinocyte

SessionĆ?(ASD) Clues to the diagnosis

Saturday, Nov. 14, 2020 â&#x20AC;&#x201C; from 08:30 to 09:00

RM 303A â&#x20AC;&#x201C; LEVEL 3 $SRSWRVLV LV D IRUP RI SURJUDPPHG FHOO GHDWK LQ ZKLFK FHOOV DUH GHOHWHG IURP WKH RUJDQ ZLWKRXW DQ\ DFFRPSDQ\LQJ LQĂ&#x20AC;DPPDWRU\ LQÂżOWUDWH ,Q VNLQ DSRSWRVLV LV WKH PHFKDQLVP IRU GHDOLQJ ZLWK 89 GDPDJHG '1$ LQGXFLQJ WKH FDWDJHQ SKDVH RI WKH KDLU F\FOH DQG LQ ÂżQH WXQLQJ WKH GLá&#x201A;&#x2021;HUHQWLDWLRQ RI the epidermal keratinocytes. The apoptotic cell, popularly known as the â&#x20AC;&#x2DC;Civatte cellâ&#x20AC;&#x2122; or colloid body appears as homogenous pink body with pyknotic nucleus in the early stage and loss of nucleus in the late stage when it is called a colloid body. Several skin diseases show apoptosis and observing these cells in terms of their numbers, location and distribution in the epidermis or upper dermis can give clues to the diagnosis of the various diseases. $OVR DOJRULWKPV FDQ EH GHULYHG XVLQJ WKH SUHVHQFH RI DSRSWRWLF FHOOV DQG RWKHU DVVRFLDWHG HSLGHUPDO DQG GHUPDO ÂżQGLQJV LQFOXGLQJ WKH DFFRPSDQ\LQJ LQĂ&#x20AC;DPPDWRU\ LQÂżOWUDWH IRU VSHFLÂżF GLDJQRVLV RI VNLQ GLVHDVHV WKDW VKRZ DSRSWRVLV DV RQH RI WKHLU SUHVHQWLQJ IHDWXUHV PRUSKRORJLFDOO\

Chao-Kai Hsu 壯悕₯

Dr. Chao-Kai Hsu is currently an Associate Professor in Department of Dermatology of National Cheng Kung University Hospital, Tainan. He received Dermatology residency training in National Cheng Kung University Hospital, and obtained PhD degree in Institute of Clinical Medicine in National Cheng Kung University. He has been a research fellow in Department of Dermatology, Hokkaido University Graduate School of Medicine, Japan (Feb-Apr, 2008) and St John's Institute of Dermatology, UK (Dec 2014 to Dec 2016). He has a dermpatholgy and molecular genetics background, and currently works on blistering disorders, genodermatoses and keloids.

Characteristic histopathology of genodermatoses SessionƝ(ASD) Clues to the diagnosis

Saturday, Nov. 14, 2020 – from 09:00 to 09:30

RM 303A – LEVEL 3 Researches on the underlying molecular pathology of genodermatoses has significantly increased our knowledge of genetic disorders in general. In most cases, histopathology is essential in determining the morphology of cutaneous features, and frequently facilitates establishing the correct diagnosis. In addition to the standard histopathology, special stains and immunochemistry, electron microscopy, and/or cell cultures (keratinocytes and/or fibroblasts) frequently facilitates establishing the definite molecular diagnosis. This talk will review the characteristic histopathologic features of genodermatoses, including linear and whorled nevoid hypermelanosis, Netherton syndrome, harlequin ichthyosis, skin stiffness syndrome, Darier’s disease, incontinentiapigmenti, et al. The molecular pathology will allow for a better understanding of prognosis, genetic counseling, and facilitate the development of pathogenesis-based therapies.

Shang Ian Tee

Dr Tee graduated from the National University of Singapore Faculty of Medicine in 2001. After undergoing a period of basic training in internal medicine as well as compulsory national service, he commenced specialist training in dermatology at the National Skin Centre (NSC) in 2008, and was accredited as a dermatologist in 2011. He next embarked on a 9 month fellowship training programme in Graz, Austria in dermatopathology and cutaneous lymphomas. Dr Tee still practices in NSC and is currently a Senior Consultant. His clinical appointments include being the chief of urticaria clinic, deputy chief of lymphoma clinic and deputy chief of laboratory. He is also the consultant in charge of Khoo Teck Puat Hospital dermatology service. He has received the NSC Award for Excellence in Teaching in 2011 as well as the Service Gold Award in 2017 and 2018. Dr Tee also has also served in the executive committee of the Dermatological Society of Singapore since 2013, and is presently the Vice President. He has authored or co-authored more than 20 papers in peer-reviewed journals and contributed to a book chapter.

Plasma cell infiltrates in dermatopathology SessionƝ(ASD) Clues to the diagnosis

Saturday, Nov. 14, 2020 – from 09:30 to 10:00

RM 303A – LEVEL 3 Plasma cells are activated B-lymphocytes that secrete immunoglobulins, thereby forming an essential part of humoral immunity. As such, they are commonly encountered in biopsies of a variety of skin dermatoses, especially from mucosal surfaces, which are typically plasma-cell rich. In most instances, plasma cells form a component of the reactive inflammatory infiltrate, as seen in infections (e.g. syphilis), autoimmune diseases (e.g. lupus erythematosus) and malignancies (e.g. Kaposi sarcoma). Reactive plasma cells may predominate in certain conditions such as cutaneous and systemic plasmacytosis, Rosai-Dorfman disease, cutaneous IgG4 related disease and Castleman disease. Crucially, neoplastic diseases must be considered in specimens with prominent plasmacytic infiltrates. This includes B-cell lymphomas (in particular, cutaneous marginal zone lymphoma) and multiple myeloma.

Yu-Hung Wu ⋱佰ⷖ

Dr Yu-Hung Wu is the founder and the current President of Asian Society of Dermatopathology. He has dedicated himself in the dermatopathology education for many years and has given lectures in many international meetings. He is also the Board of Directors and Chair of Education Committee of Taiwanese Dermatological Association and the Director of International Dermatopathology Fellowship program in Taipei (accredited by International Committee for Dermatopathology since 2015). He has served as the chair of the Department of Dermatology in Mackay Memorial Hospital, the Editor-in-Chief of Dermatological Sinica, and the Executive Committee member of International Society of Dermatopathologybetween 2007 to 2013. Academically, he has published more than 130 scientific articles in the peerreviewed journals and is currently an Associate Professor at the Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.

Clues to drug eruption

SessionƝ(ASD) Clues to the diagnosis

Saturday, Nov. 14, 2020 - from 10:00 to 10:30

RM 303A - LEVEL 3 Drug can induce almost every pattern of inflammatory diseases and even the deposition disorders or neoplastic process. There are many new drug-induced findings or patterns published every year. It’s important for dermatopathologists to be aware of drug reaction in certain conditions and how to make the diagnosis. In this lecture, we will summarize five conditions that we should think about drug-associated pathology and then introduce shortly about the diagnosis of drug reaction clinically. The five conditions include pathology indicating a drug reaction, non-specific pathology but has specific clinical condition, typical pathological pattern but has atypical clinical presentation, presence of multiple pathological patterns, and atypical pathological findings with atypical clinical presentation.

Daisuke Tsuruta

My name’s Daisuke Tsuruta, MD, PhD. I am a Dermatologist and current position is Professor in Medicine, Osaka City University Graduate School of Medicine. My research interest is on the pathomechanism of bullous pemphigoid and relateddiseases, and serological analyses for diagnosing autoimmune bullous diseases. I have more than 300 publications related to Dermatology and Dermatopathology. Today, I would like to inform you about the histopathology of autoimmune bullous diseases combined with other diagnostical methods related to autoimmune bullous diseases. I love to visit Taiwan, but I cannot do so, because of COVID-19. Hope the future end of it, so soon and meet with you directly in the near future!

The histopathology of autoimmune bullous diseases (AIBD) SessionƝ $6' ,QÀDPPDWRU\ VNLQ GLVRUGHUV

Saturday, Nov. 14, 2020 – from 13:30 to 14:00

RM 303A – LEVEL 3 Aim of this presentation is 1) to present representative autoimmune bullous diseases (AIBD), clinically, 2) to present typical histopathology for the AIBD, 3) and to briefly mention about direct immunofluorescence, indirect immunofluorescence using normal human skin section or salt-split skin as substrates, enzyme-linked immunosorbent assay (ELISA) and immunoblotting to diagnose AIBD. AIBD is composed of mainly two categories, a pemphigus group and a pemphigoid group. In the pemphigus group, the target antigen is in the desmosomes while in the pemphigoid group, the target antigen is in the hemidesmosomes. This talk, I present detailed histopathology for pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, bullous pemphigoid, nodular pemphigoid, mucous membrane pemphigoid, Linear IgA bullous dermatosis, epidermolysis bullosa acuquisita, and anti-laminin gamma 1 pemphigoid. To distinguish pemphigus group, the position of the cleft is important. In pemphigus foliaceus, cleft locates at subcutaneous or granular cell layer, while in pemphigus vulgaris, it lacates at suprabasilar layer. To distinguish pemphigoid group, the infiltrative cells are important. In the bullous pemphigoid and anti-laminin gamma 1 pemphigoid, most distinguishable cell infiltrates are eosinophils, while in the epidermolysis bullosa, linea IgA bullous dermatosis and mucous membrane pemphigoid, they are neutrophils. To make a correct diagnosis, enzyme-linked immunosorbent assay, chemiluminescnt enzyme immunoassay, immunoblot using epidermal or dermal extract, direct immunofluorescence and indirect immunofluorescence are equally useful.

Meenakshi Batrani

Consultant dermatopathologist in Delhi Dermpath Laboratory, a unit of Delhi Dermatology Group, an academic group practice based in New Delhi, India. A graduate of Lady Harding Medical College, New Delhi. Completed residency in Pathology from T.N. Medical College & B.Y.L. Nair Hospital, Mumbai, followed by, three years of senior residency at Post Graduate Institute of Medical Education and Research & R.M.L. Hospital, New Delhi. Trained as a fellow in dermatopathology at Boston University School of Medicine, Boston. Hold ICDP-UEMS certification in dermatopathology. Member of Dermatopathology Society of India, Indian Association of Pathologists and Microbiologists and International Academy of Pathology- Indian division. Served as editorial board member of Indian Journal of Dermatopathology and Diagnostic Dermatology for two years and have been reviewing for several dermatopathology, dermatology and pathology journals. Principal interests include clinic-pathological correlation of inflammatory dermatoses and immunofluorescence based diagnosis of bullous disorders.

Unusual clinico-pathological variants of sarcoidosis and diagnostic challenges SessionƝ(ASD) Inflammatory skin disorders

Saturday, Nov. 14, 2020 – from 14:00 to 14:30 RM 303A – LEVEL 3

Sarcoidosis is a chronic multisystem granulomatous disease that can involve almost any organ. Cutaneous manifestations of sarcoidosis are protean mimicking clinically and histologically various other cutaneous diseases, hence, aptly entitled as “great imitator”. Most frequent and characteristic clinical presentations of cutaneous sarcoidosis include maculo-papular lesions, nodulo-plaque lesions, scar sarcoidosis and lupus pernio. Albeit, less frequent, a wide variety of atypical clinical manifestations are known such

asƝsubcutaneous panniculitic, angiolupoid, hypopigmented, psoriasiform, ichthyosiform, lichenoid/micropapular, ulcerative, atrophic/ necrobiosis lipoidica-like, erythrodermic, morpheaform, palmer erythema, rosacea like, photodistributed, cellulitis-like, verrucous, granulomatous cheilitis, bullous, perforating, livedoid, pigmented purpuric dermatosis-likeƞ and localization to unusual special sites including oral cavity, genital, scalp alopecia. The histological hallmark of sarcoidosis is tissue infiltration with sarcoidal granuloma defined as non-caseating epithelioid cell granuloma surrounded by sparse lymphocytes- so called “naked granuloma”. Notwithstanding, neither sarcoidal granuloma is exclusive for sarcoidosis, nor all cases of sarcoidosis display the characteristic sarcoidal granuloma. Cases of cutaneous sarcoidosis showing histomorphological deviation to variable extent from the prototypical histopathology are not so uncommon. The pivotal histological aberrations described areƝsignificant lympho-plasmacytic infiltrate, necrosis within granuloma, small and/or medium vessel vasculitis, perineural leprosy-like pattern, syringotropic granulomas, and granuloma annulare-like pattern Given the remarkable heterogeneous clinico-pathological appearances of cutaneous sarcoidosis, the diagnosis can be challenging with a large number of infectious and non-infectious diseases entering as differential diagnosis. Clinico-pathological correlation is the key to the correct diagnosis. The focus of the presentation is to discuss some of the unusual clinico-pathological manifestations of cutaneous sarcoidosis with their respective diagnostic challenges.

Jun Asai

I received my MD from Kyoto Prefectural University of Medicine in 2001, which was followed by 2 years of residency at the Department of Dermatology, University Hospital at Kyoto Prefectural University of Medicine. I obtained my PhD in 2006, having trained at the Department of Dermatology, Graduate School of Medical Science Kyoto Prefectural University of Medicine in Kyoto under Professor Saburo Kishimoto, and at the Cardiovascular Research Department at St. Elizabeth’s Medical Center, Tufts University School of Medicine, in Boston under Professor Douglas W. Losordo. During my PhD, I predominantly investigated the molecular mechanisms and pathology of diabetic ulcers and the contribution of endothelial progenitor cells and macrophages to neovascularization in cutaneous wound healing. In 2006, I began working as an Assistant Professor at the Department of Dermatology, Graduate School of Medical Science at Kyoto Prefectural University of Medicine focusing on research and patient care in the field of dermatosurgery. My recent research interests involve the molecular biology and pathology of macrophages in wound healing and other skin diseases. To date, I have authored/co-authored over 80 peer-reviewed scientific articles regarding wound healing, granulomatous diseases, skin cancers, and other topics. Currently, I am a principal investigator at the Department of Dermatology, Graduate School of Medical Science Kyoto Prefectural University of Medicine and mentor young investigators.

Recent understandings of granulomatous skin diseases SessionƝ(ASD) Inflammatory skin disorders

Saturday, Nov. 14, 2020 – from 14:30 to 15:00

RM 303A – LEVEL 3 A granuloma is a form of inflammation, which predominantly consists of macrophages. It typically develops when the immune system attempts to enclose substances that are usually insoluble and cannot be eliminated to prevent the spread of these substances to the other body compartments. According to the source of the substances, granulomatous diseases can be divided into two groupsă infectious and non-infectious. Non-infectious granulomas can be further divided into six subgroups according to the histopathology. In this lecture, I talk about the basic histopathology of granulomatous dermatitis along with histopathological classification of granulomatous diseases. Next, I’m going to talk about recent understandings of histogenesis of granulomas, especially focusing on macrophage polarization. I also want to introduce our recent research regarding macrophage polarization in sarcoidosis.

Wayne Grayson

Wayne Grayson was born in Johannesburg, South Africa. He obtained his undergraduate medical degree from the University of the Free State in 1989. Wayne received his specialist training in Anatomical Pathology at the University of the Witwatersrand (WITS) and the South African Institute for Medical Research (S.A.I.M.R.), and became a Fellow of the College of Anatomical Pathologists of South Africa in 1995. He was a recipient of the James Gear prize and the Neville Proctor prize of the S.A.I.M.R. In 2001 Wayne was awarded a PhD from WITS University. He headed the Dermatopathology service in the Division of Anatomical Pathology at WITS University and the National Health Laboratory Service in Johannesburg until 2008, when he joined AMPATH Laboratories. His main areas of interest include infectious diseases of the skin, HIV/AIDS-related cutaneous pathology, melanoma and Kaposi sarcoma. Wayne is a former Executive Committee member of the International Society of Dermatopathology, an Executive Committee member of the African Dermatopathology Society, nominated Secretary of the International Committee for Dermatopathology, Course Director of the annual Johannesburg Dermatopathology Symposium, and Chairman of the local organizing committee of the upcoming 2021 XLI Symposium of the I.S.D.P. He is a co-author of the chapters on infectious diseases of the skin and HIV-associated cutaneous pathology in McKee’s Pathology of the Skin with Clinical Correlations, author of the chapter on histologic variants of Kaposi sarcoma in the book entitled Kaposi SarcomaƝA Model of Oncogenesis, a contributing author of the fourth edition of the W.H.O. “blue book” publication on Tumours of the Skin, and author of the chapter on HIV-associated dermatoses and neoplasia in Hospital-Based DermatopathologyƝAn Illustrated Guide to Evaluation. He serves on the Editorial Board of the American Journal of Dermatopathology. Wayne is an Honorary Professor in the School of Pathology at WITS University, where he remains actively involved in postgraduate teaching. He is a passionate car lover and loves to travel.

Cutaneous infectious diseases濣An update SessionƝ(ASD) Infection

Saturday, Nov. 14, 2020 – from 15:30 to 16:00

RM 303A – LEVEL 3 The spectrum of infectious diseases with potential skin involvement, either primary or secondary to systemic disease, is vast. Unusual host inflammatory responses may be elicited by certain pathogens, including reactions with an inherent capacity for misdiagnosis as neoplasia. Current, emerging, re-emerging and/or recently recognized pathogens or infections of major significance 68

include SARS-CoV-2,carbapenem-resistant gram-negative bacterial infections, Ebola virus disease, measles, Mycobacterium lepromatosisas a second aetiological agent of leprosy, and Emergomyces africanusi nfection among those living with HIV/AIDS. The era of molecular microbiology has also seen recent changes in taxonomy, including Talaromyces marneffei (formerly Penicillium marneffei) and Cutibacterium acnes (formerly Propionobacterium acnes). Precise speciation by PCR on formalin-fixed, paraffin embedded tissue, however, remains a challenge despite recent advances in molecular microbiology. Finally, one must remain cognizant of the wide range of potential infective manifestations of the immune reconstitution inflammatory syndrome in HIV-infected individuals receiving antiretroviral therapy.

Panitta Sitthinamsuwan

Associate Professor of Pathology I worked at Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand I am interested in Dermatopathology and Breast Pathology 2006-Present Associate Professor Department of Pathology Faculty of Medicine Siriraj Hospital Mahidol University July 2010- June 2012 Visiting scholar Department of Dermatopathology, UCSF April 2012- May 2012 Visiting scholar Breast Pathology, Department of Pathology MD Anderson Cancer Center

Monsters in the skin

SessionƝ(ASD) Infection

Saturday, Nov. 14, 2020 – from 16:00 to 16:30

RM 303A – LEVEL 3 An approach of parasitic infestation in skin included nematode infection and cestode infection in Thailand .The presentation included morphological approach and also molecular techniques.

Norain Karim

MBBS, MPath, FRCPA, FRCPath Professor ( Pathology) University Kuala Lumpur, Royal College of Medicine Perak Dr Norain Karim received her Master of Pathology (Anatomical Pathology) from the University of Malaya in 1988. She is a Fellow of the Royal College of Pathologists (UK) 2003 and the Royal College of Australasia 2007. She was a former Chief of Pathology Services, Ministry of Health Malaysia from 2005 to 2010. Under her headship, she has provided high-level expert advice to the Ministry of Health Malaysia and had played a crucial role in the planning and development of pathology services. She was the consultant pathologist and Head of Pathology Department of Hospital Raja PermaisuriBainun Ipoh, Perak Malaysia till 2019. Her special interests are in Dermatopathology, Infectious diseases and Digital Pathology. At present, she is the Vice President of International Academy of Pathology Malaysian Division (IAPMD), dedicated to promoting the advancement of Pathology through educational exchanges and she is also the expert panel of QAP (Anatomical Pathology) organized by IAPMD. Currently, she is lecturer in University Kuala Lumpur, Royal College of Medicine Perak

Perianal Tuberculosis and Crohn’s disease濣a diagnostic challenge SessionƝ(ASD) Infection

Saturday, Nov. 14, 2020 – from 16:30 to 17:00

RM 303A – LEVEL 3 Perianal ulcer is a rare form of extrapulmonary Tuberculosis (TB) and extraintestinal Crohn’s disease (CD). Diagnosis and treatment can be delayed in this type of disease as the differential diagnosis include a large spectrum of diagnosis and even more, difficult when the perianal involvement is the first presentation without pulmonary symptoms of TB or intestinal lesion for both. Distinguishing the two can be very challenging because both are a chronic granulomatous disease. We present two cases of persistent non-healing perianal ulcers for 2 years that were seen by many doctors and treated with multiple topical and oral antibiotics. These cases are to emphasize the importance of considering TB and CD aetiology in the workup of persistent perianal ulcer and to be aware that extrapulmonary TB and extraintestinal CD can manifest as the first presentation of the diseases. Furthermore, it is to highlights the role of histopathological, microbiological investigations together with its limitation in differentiating the two diseases. We found that the characteristic of granulomas of TB are confluent, numerous, large with Langhan’s giant cells, and central caseation necrosis in contrast to granulomas in CD which are occasional, small, and non-caseous. The presence of Schaumann bodies within the cytoplasm of giants cells can be seen in CD. Positive acid-fast staining for bacilli and growth of M tuberculosis on tissue culture and clinical response to therapy confirms the final diagnosis. However, the histopathological features may overlap. Therefore, an accurate diagnosis should be made based on the clinical, radiological and pathological findings as well as the response to treatment. Extrapulmonary TB, metastatic Crohn and ancillary method in the diagnosis of TB and CD including molecular techniques, immunohistochemistry method for M Tuberculosis and ACE are briefly mentioned. Diagnosis of perianal TB and CD is difficult and needs a high index of suspicion, especially in patients with no active pulmonary infection of TB and gastrointestinal lesion. Histopathological in particular the characteristic of granuloma and microbiological 69

investigations are mandatory to confirm the diagnosis along with clinical response to treatment in unclear cases since treatment with anti TB and anti-CD provides complete recovery.

Eduardo Calonje

Dr Eduardo Calonje is a council member of the section of Dermatology of the Royal Society of Medicine, the council of the British Division of the International Academy of Pathology, President of the British Society of Dermatopathology and examiner for the Diploma in Dermatopathology for the Royal College of Pathologists. He has contributed multiple chapters to major textbooks in Dermatology and Dermtopathology including Fletcherâ&#x20AC;&#x2122;s Diagnostic Histopathology of Tumours (since the 1st ed), Leverâ&#x20AC;&#x2122;s Histolopathology of the skin (from the seventh edition), Rookâ&#x20AC;&#x2122;s Textbook of Dermatology (since the 6th ed) and is a co-editor of the 4th edition of McKeeâ&#x20AC;&#x2122;s Pathology of the Skin. He is co-editor of Clinical and Experimental Dermatology, Histopathology and The British Journal of Dermatology. He has been involved in over 200 publications in the fields of dermatology, dermatopathology and soft tissue tumours.

Seok-Jong Lee

POSITION TITLE Department of Dermatology & Pathology Professor, Department of Dermatology, Adjunctive Professor, Department of Pathology Vice Director, Vascular Anomalies Center Director, Cutaneous Melanoma Clinic Kyungpook National University Hospital, Daegu, South Korea ACADEMIC & PROFESSIONAL CAREER 1998.5-Present KNUH (Daegu), Instructor-Professor (Dermatology) 2005.3-2006.3 Providence college (USA), Visiting Scholar 2000.9-2000.12 Free University of Berlin(Germany), Clinical Fellow (Phlebology) 1995.2-1995.5 National Skin Centre (Singapore), Clinical Fellow (Dermatology) 1991.3-1995.2 Kyungpook National University Hospital, Resident (Dermatology), KNUH (Daegu) 1987.2 Kyungpook National University, School of Medicine (Graduation) MAIN INTEREST Hemangioma & vascular malformation Skin cancer (esp. malignant melanoma) Dermatosurgery Dermatopathology

Vascular tumors & vascular malformations reviewed from KNUH vascular anomalies files SessionĆ?(ASD) Soft tissue and nail tumor

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 09:15 to 09:40 RM 303Aâ&#x20AC;&#x201C; LEVEL 3

7KH FODVVLÂżFDWLRQ RI FRQJHQLWDO YDVFXODU OHVLRQV VR FDOOHG YDVFXODU PDUNV LV YHU\ FRPSOLFDWHG DQG TXLWH GLá&#x201A;&#x2021;HUHQW GHSHQGLQJ RQ WKH WH[WERRNV or relevant academic societies. Furthermore, infantile hemangioma shows rather typical clinical feature but another disease of vascular tumor and even vascular malformation shows similar clinical and/or radiological characteristics. So correct diagnosis and subsequent management could be somewhat misdirected in reality. As a result, about 10% of â&#x20AC;&#x153;hemangiomaâ&#x20AC;? patients referred from outer clinics and even resident-training KRVSLWDOV ZHUH UH FODVVLÂżHG DV ERWK WXPRUV FRQJHQLWDO KHPDQJLRPD S\RJHQLF JUDQXORPD WXIWHG DQJLRPD HWF DQG PDOIRUPDWLRQV O\PSKDWLF YHQRXV DQG DUWHULRYHQRXV PDOIRUPDWLRQ HWF IURP SUHYLRXV VWXG\ &RQVLGHULQJ WKH LQQRYDWLYH FODVVLÂżFDWLRQ RI YDVFXODU ELUWKPDUN E\ YDVFXODU tumors and malformations according to proliferation ability of mainly endothelial cells (1980â&#x20AC;&#x2122;V 'U 0XOOLNHQ SUHFLVH GLDJQRVWLF FODVVLÂżFDWLRQ EHFDPH SRVVLEOH EHFDXVH RI WKH LQWURGXFWLRQ RI QHZO\ GHYHORSHG GLá&#x201A;&#x2021;HUHQWLDO PDUNHUV RI HQGRWKHOLDO FHOOV RI YDVFXODU ELUWKPDUN DQG PROHFXODU works by ISSVA (International Society for the Study of Vascular Anomalies, httpĆ?//www.issva.org). I will talk of histopathological aspect of them with a faint hue of clinical features depending on ISSVA scheme here (Table 1).

Ikmal Hisham Bakrin

Dr Ikmal Hisyam Bakrin is a Consultant Histopathologist and Medical Lecturer at the Department of Pathology Faculty of Medicine and Health Sciences, Universiti Putra Malaysia with special interest in Dermatopathology. He graduated from Universiti Kebangsaan Malaysia with an MD in 2005 and subsequently obtained his Master of Pathology from UniversitiSains Malaysia in 2014. He was a Visiting Fellow in the Department of Dermatopathology, St Johnâ&#x20AC;&#x2122;s Institute of Dermatology, St Thomasâ&#x20AC;&#x2122; Hospital, London UK, from July 2018 till January 2019. He is one of the expert persons for skin pathology in Malaysia and actively involved in Dermatopathology clinicopathological conferences (CPCs), seminars and workshops. Apart from that, he is also a referred person for skin referral cases from all over Malaysia. His research is mainly on prostate cancer working on gene expression profiling and mutation screening study. Currently, he is part of an atopic dermatitis research group looking into potential therapeutic medication.

Genetic characterisation of cutaneous mesenchymal neoplasms SessionĆ?(ASD) Update in soft tissue tumor and nail tumor

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 09:40 to 10:05

RM 303Aâ&#x20AC;&#x201C; LEVEL 3 &XWDQHRXV PHVHQFK\PDO QHRSODVPV SRVH VLJQLÂżFDQW GLDJQRVWLF FKDOOHQJHV LQ GD\ WR GD\ SUDFWLFH RI 'HUPDWRORJ\ DQG 'HUPDWRSDWKRORJ\ 7KH GLá&#x201A;&#x2C6;FXOWLHV DULVH GXH WR WKH UDUH HQWLWLHV RI PRVW RI WKH FXWDQHRXV PDOLJQDQW DQG EHQLJQ PHVHQFK\PDO QHRSODVPV DV ZHOO DV WKHLU RYHUODSSLQJ clinical & histologic features. &XUUHQW DGYDQFHG LQ JHQHWLF PROHFXODU DQDO\VLV DQG VWXG\ KDYH KHOSHG WR GHÂżQH XQLTXH SDWKRORJLF HQWLWLHV IXUWKHU FODVVLI\LQJ DQG LQFUHDVLQJ the understanding of their behaviors. Having said that, molecular studies (e.g. FISH and PCR) are not routinely used as they are rather expensive and required well trained personnel. However, recent molecular discoveries have resulted in the development of new & useful immunohistochemistry markers such as FOS-B and CAMTA1 to help in making a correct diagnosis. The principal of this application relies on the Genogenic immunohistochemistry, where knowledge on the molecular basis of tumours is used in immunohistochemistry study to identify underlying molecular changes or the presence RI VSHFLÂżF PROHFXODU PDUNHUV LQ WXPRXUV DLG IRU GLDJQRVLV JXLGH IRU WDUJHWHG WKHUDS\ Here, defined molecular signature of cutaneous mesenchymal neoplasms will be discussed together with their clinical and morphological IHDWXUHV IRFXVLQJ RQ WKH VSHFLÂżF LPPXQRKLVWRFKHPLVWU\ SDQHO DQG PROHFXODU ÂżQGLQJV

Dong-Youn Lee

Dong-Youn Lee is a professor and chair of the Department of Dermatology at Samsung Medical Center Sungkyunkwan University, Seoul, Korea. Dr. Lee graduated from Seoul National University (M.D., Ph.D.) and completed his dermatology residency and fellowship at the Seoul National University Hospital. In 2004, he received International Board of Dermatopathology. As a clinical dermatologist, he has focused on skin cancer, nail, hair and vitiligo. His strong interests are melanoma and nail disorders. Every year he has seen several hundred foreign patients coming from abroad at international health services of Samsung Medical Center. In addition, he has been doing skin research. He has been publishing more than200 English-written articles. In the past, he defined specialized nail mesenchyme and mesenchymal cells in the nail unit and proposed to call them onychofibroblasts and onychodermis respectively. He has presented many times at international dermatology meetings including WCD, AAD and ASDP meetings.

Malignant and benign nail tumors

SessionĆ?(ASD) Update in soft tissue tumor and nail tumor

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 10:05 to 10:30

RM 303A â&#x20AC;&#x201C; LEVEL 3 Nail tumors include all tumors occurring in the nail or periungual tissue. While some nail tumorscan be similar to tumors located on the skin, others are unique. Both benign and malignant lesions can affect thenail apparatus. In particular, early malignant tumors like melanoma and squamous cell carcinoma can presentsimilarly to benign lesions and frequently missed by clinicians. Therefore, physiciansshould be aware of nail structures and the clinicopathologic features of nail tumors. In this presentation, I will talk about normal nail unitand malignant tumors including melanoma and squamous cell carcinoma, and nail-specific benign tumors.

David Elder

I was trained in pathology primarily in New Zealand and have had several important mentors including Vincent McGovern M.D. and Wallace H Clark Jr. M.D., who were pioneers in the histopathologic diagnosis and classification of malignant melanoma. In my current position, I am responsible primarily for diagnosis of skin biopsy specimens, including inflammatory conditions and skin tumors including melanomas and other skin cancers, and also for teaching and research. I am associated with the Penn Pigmented Lesion Group which has been a referral center for patients with these tumors for many years. I recently served as Lead Editor for the WHO 2018 Classification of Skin Tumours. I have also served as Editor-In-Chief for the dermatopathology textbook "Levers Histopathology of the Skin" for the last four editions. I have published widely in matters relating especially to the diagnostic pathology, clinical presentation and management, prognosis, biology, epidemiology, and genomic aspects of these conditions, and these activities are ongoing.

The 2018 WHO Classification of Melanomas and Nevi SessionĆ?(ASD) Update in the melanoma and lymphoma

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 13:30 to 14:10

RM 303A â&#x20AC;&#x201C; LEVEL 3 ,Q WKH :+2 &ODVVLÂżFDWLRQ RI 6NLQ 7XPRUV PDOLJQDQW PHODQRPDV DQG EHQLJQ PHODQRF\WLF QHYL ZHUH FODVVLÂżHG LQWR QLQH GLá&#x201A;&#x2021;HUHQW SDWKZD\V DOVR including ocular melanoma). Three of these pathways (superficial spreading, lentigomaligna and desmoplastic melanoma) occur in skin with high cumulative solar damage (CSD) and are responsible for the epidemic of melanomas in people with susceptible skin that is exposed to the sun. The other pathways are not related to sun exposure and include Spitz, acral, mucosal, and congenital nevus and blue nevus-related melanomas, whose incidence PD\ EH VLPLODU LQ GLá&#x201A;&#x2021;HUHQW SRSXODWLRQV DURXQG WKH ZRUOG (VSHFLDOO\ IRU WKH &6' PHODQRPDV EHQLJQ WXPRUV QHYL PD\ EH UHODWHG WR PHODQRPDV DV potential precursors (usually low risk), as risk markers and as simulants, and these need to be distinguished from the melanomas for accurate diagnosis.

Ye-Qiang Liu â&#x192;&#x2013;áł&#x2DC;âˇ¸

Dr. Liu was graduated from Department of dermatology, Tongji Medical College, Huazhong University of Science and Technology, P.R.China. And He was a VRF in ackerman academy of dermatopathology during 2015-2016 and a member of dermatopathology in Chinese Society of Dermatology now. Investigator, he has held 4 grants including China National Natural Science Foundation program (NSFC) grant than 25 peer-reviewed papers have been published in the recent years. And shanghai health develop center grants. More Dr. Liuâ&#x20AC;&#x2122;s research interests evolve from Melanoma and Psoriasis. As principle

Malignant Melanoma and its Simulators from shanghai SessionĆ?(ASD) Update in soft tissue tumor and nail tumor

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 14:10 to 14:35 RM 303A â&#x20AC;&#x201C; LEVEL 3

I will give 8 cases and use criteria to help differentiate melanoma from benign mimics.

Jisun Cha

I am an associate professor of dermatology at Thomas Jefferson University in Philadelphia Pennsylvania. I am a dermatology trained dermatopathologist and am interested in Cutaneous Lymphoma Pathology. I graduated from Ewha Womenâ&#x20AC;&#x2122;s University, Seoul Korea in 2001 and did my Dermatology residency and Dermatopathology fellowship at Roger Williams Medical Center in Providence RI, USA. It is my honor to be invited to 2020 ASD meeting and I am excited to share my presentation and to learn in this meeting.

Update on cutaneous lymphoma pathology

SessionĆ?(ASD) Update in soft tissue tumor and nail tumor

Sunday, Nov. 15, 2020 â&#x20AC;&#x201C; from 14:35 to 15:00

RM 303A â&#x20AC;&#x201C; LEVEL 3 In this presentation, we will review some recent updates on cutaneous lymphoma including â&#x20AC;&#x153;6XSHULRU &OLQLFDO %HQHÂżW RI %UHQWX[LPDE9HGRWLQ LQ Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Statusâ&#x20AC;?, â&#x20AC;&#x153;Importance of distinguishing EHWZHHQ IROOLFXODU FHQWHU FHOO O\PSKRPD GLá&#x201A;&#x2021;XVH W\SH DQG GLá&#x201A;&#x2021;XVH ODUJH % FHOO O\PSKRPDâ&#x20AC;? DQG RWKHU XSGDWHG FKDQJHV LQ :+2 FODVVLÂżFDWLRQ

Chi-Shun Yang ă &#x2C6;â??ć&#x203A;&#x201E;

Chi-shun yang is currently serving as the attending pathologist at Taichung Veterans General Hospital. Dr. Yang graduated from Kaohsiung Medical University in 2001 and then completed his anatomic and clinical pathology training at the department of pathology and laboratory medicine in Taichung Veterans General Hospital. In 2015, he went abroad to Indiana University Health for the fellowship training of dermatopathology and cytopathology.

Free Papers

The 46th Annual Meeting of Taiwanese Dermatological Association Free Paper (12 minutes per person included discussion time) Date濣November 14th, 2020

Location濣RM303B, Kaohsiung Exhibition Center (KEC)

Free Paper- Original List Moderators濣Din-Dar Lee ( 㘌⩘弒 , Taiwan), Su-Ying Wen ( 㵩䯞䌧 , Taiwan) 01

08:30-08:42 A Machine-learning Approach to Predict Risk of Psoriatic Arthritis in Patients with Psoriasis 弉䏦㤝┦⨶亐㑷㮓ⶸ㢉ᴼ䔪䒃⽡丷⽡ᴼ䔪⻥撚䩾㽌ᴉ杦敨曎㳪㣟♉ Leon Tsung-Ju Lee,1,2ƞJack Yu-Chuan Li, 2,3,4 Department of Dermatology, Taipei Medical University Hospital, Taipei, Taiwan 2 Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei, Taiwan 3 Department of Dermatology, Taipei Medical University - Wanfang Hospital, Taipei, Taiwan 4 College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan 㜵⭾⃹ 1,2 㜵⎲⯯ 2,3,4

08:42-08:54 Metformin Therapy for Acne in Patients with Polycystic Ovary Syndrome濣 A Systematic Review and Meta-analysis Hsuan Yen, 1ƞYa-Wen Hsiao, 1ƞYu-Tung Chang, 2ƞFui-Jun Yee, 2ƞYu-Chen Huang, 1,3,4 Department of Dermatology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 2 Department of Medical Education, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 3 Research center of big data and meta-analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 4 Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 栶䐫 1 啔暬㕮 1 ⼜媅⽋ 2 ὀデ␂ 2 溪ヰ䜆 1,3,4

08:54-09:06 Platelet-rich plasma and its utility in the treatment of acne scars濣A systematic review and meta-analysis I-Hsin Huang, 1ƞYu-Chen Huang, 2,3,4 Department of Education, Taipei Medical University Hospital, Taipei, Taiwan 2 Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 3 Department of Dermatology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 4 Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 溪㗺㬊 1 溪ヰ䜆 2,3,4

09:06-09:18 Intralesional vitamin D3 injection in the treatment of warts濣A systematic review and meta-analysis Marvin Chia-Han Yeh, 1ƞTsung-Yu Tsai, 1ƞYu-Chen Huang, 1 1 Wan Fang Hospita

09:18-09:30 Is genital psoriasis correlated to impairment in quality of sexual function? The first study in Taiwan I-Lun Tseng, 1ƞChaw-Ning Lee,1,2ƞLi Jhang, 1ƞTak-Wah Wong, 1,3 Departments of Dermatology, National Cheng Kung University Hospital,College of Medicine, National Cheng Kung University, Tainan, Taiwan 2 School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan 3 Biochemistry and Molecular Biology, Center of Applied Nanomedicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan 㛥〈‒ 1 㜵ℭ䔖 1,2 ⼜䪲 1 䍲⾞取 1,3 1

09:30-09:42 Pityriasisrubra pilaris in Taiwan濣A retrospective clinical and management analysis from a single medical center Hsi Yen, 1ƞChun-Bing Chen,1,2,3ƞChun-Hsien Huang,.1ƞWen-Hung Chung,1,2,3ƞ 1 Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 2 Drug Hypersensitivity Clinical and Research Center, Department of Dermatology, Chang Gung Memorial Hospitals, Linkou, Taipei, and Keelung, Taiwan 3 Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan 栶䒤 1 晚ᾱ岺 1,2,3 溪ᾱ㆙ 1 揿㕮⭶ 1,2,3

09:42-09:54 Health-related quality of life in people with androgenetic alopecia濣a systemic review and meta-analysis Chun-Hsien Huang, 1ƞYun Fu, 1ƞChing-Chi Chi1,2 Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 2 College of Medicine, Chang Gung University, Taoyuan 溪ᾱ㆙ 1 ⁬䭇 1 䳧㙖䐑 1,2

09:54-10:06 Impact of vitiligo on life quality of patients濣Assessment of currently available tools Ting-Ting Yang, 1ƞCheng-Che E. Lan,1,2ƞ 1 Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan 2 Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 㤱ẔẔ 1 喴㔦ⓙ 1,2

Moderators濣Tak-Wah Wong ( 䉉⹵劭 , Taiwan), Chao-Kai Hsu ( 壯悕₯ , Taiwan) 09

13:30-13:42 The dermoscopic features and differential diagnosis of sebaceous carcinoma 䕬偘䕬俀倸䔊䒃䋄僅䕬偘抟圦䊼ᴉ䖶撚⻥⃄㙎僅挏⃣壸㑵ᴉ䖶撚䛒䤴 Chun-Yu, Cheng,1,2,3ƞHsing-Jou, Su, 1ƞTseng-Tong, Kuo, 4 Department of Dermatology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan 2 Department of Cosmetic Science, Chang Gung University of Science and Technology, Taoyuan, Taiwan 3 Center of tissue engineering, Chang Gung Memorial Hospital, Taoyuan, Taiwan 4 Department of Pathology, Chang Gung Memorial Hospital, Taipei, Taiwan 愔㤦㘘 1,2,3 嗮´㞻 1 惔㉦䵘 4

13:42-13:54 A novel dual approach medial epicanthoplasty Yu-Hsin Wang, 1ƞShyue-Luen Chang,1,2ƞMei-Ching Lee, 2ƞSindy Hu, 2ƞChun-Yu Cheng, 2ƞChing-Sheng Yang, 3ƞYau-Li Huang,1,2 Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan 2 Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan 3 ℰ⽐妑⬷䚕冁䦸偖⏯娡㈧䍲Ἰ摒 1 ⼜⭟‒ 1,2 㜵併朹 2 僈‐⩞ 2 愔㤦㘘 2 㤱ㅝ⌮ 3 溪俧䪲 1,2

13:54-14:06 Steroid pulse therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN)濣 A prospective pilot study in Taiwan and Japan Ting-Yu Yeh, 1ƞEishin Morita, 2ƞChun-Bing Chen, 1,3ƞWen-Hung Chung, 1,3 Department of Dermatology, Chang-Gung Memorial Hospital, Linkou, Taiwan 2 Department of Dermatology, Shimane University Faculty of Medicine, Japan 3 Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan 吰Ẕ⦋ 1 㣕䔗㟫἟ 2 晚ᾱ岺 1,3 揿㕮⭶ 1,3

14:06-14:18 Systemic Immunomodulants For Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Yen-Chun Lin, 1ƞSew-Min Lew, 1ƞChun-Bing Chen, 1ƞWen-Hung Chung, 1ƞChing-Chi Chi,1 Chang Gung Memorial Hospital, Linkou, Taiwan 㝾⽌✮ 1 ≰㶸㔶 1 晚ᾱ岺 1 捥㕮⭶ 1 䳧㙖䐑 1

14:18-14:30 Atenolol Treatment for Infantile Hemangiomas濣 a Single Center Observational Study Pei-Rong, Gao, 1ƞChin-Yi Yang,2 Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 2 New Taipei Municipal TuCheng Hospital, TuCheng, New Taipei, Taiwan 檿䏕⮠ 1 㤱权⮃ 2

14:30-14:42 Can dermoscopy help to diagnose Stevens-Johnson syndrome/toxic epidermal necrolysis? Meng-Han Shen, 1ƞChun-Bing Chen, 2 Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan 2 Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 㱯⭆㚜 1 晚ᾱ岺 2

Moderators濣Yu-Ping Hsiao ( 含䉇⬍ , Taiwan), Chung-Yang Yen ( 摹⺞㊘ , Taiwan) 15

15:30-15:42 Clinical and epidemiological characteristics of tinea capitis in northern Taiwan during 2014-2019 2014 傱 2019 ⴲ⇕⊮㼡曫䔪ᴉ傦ⵈ僅㯿圊䒃⨶䄷儰 Hsuan Ning Wang,1,2ƞChuin-Shee Shang, 3ƞShih-Jyun Yang,1,2ƞI-Hsin Shih,1,2ƞChung-Yee Rosaline Hui,1,2ƞChin-Yi Yang,1,2ƞ Chun-Wei Lu,1,2ƞPei-Lun Sun,1,2,4 1 Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taipei and Keelung, Taiwan 2 College of Medicine, Chang Gung University, Taoyuan, Taiwan 3 Center for Ecology and Environment, Tunghai University, Taichung, Taiwan 4 Research Laboratory of Medical Mycology, Chang Gung Memorial Hospital, Linkou Branch, Taiwan 䍲⮊䔖 1,2 Ⰱ␂䒤 3 㤱᷽戅 1,2 㖤ᷧ㖗 1,2 娘ộ䑋 1,2 㤱权⮃ 1,2 䛎ᾱ䐲 1,2 ⭒⟠‒ 1,2,4

15:42-15:54 Overlapping DRESS and Stevens Johnson syndrome/TEN syndrome濣Clinicopathological characteristics and prognosis 咣䄧⊋ょᷲ敦⒚᷈䯃⻥䔻图䋁❜⟘䒅ḳ⊰區兪ⷵ㞬䒅ỗ乢⊈㪐⻥圦䕬㵴墡䱚⋆䔣濣傦ⵈ䒃䋄僅曎⹊圦䊼 Lai-Ying Lu,1ƞChung-Bing Chen,1,2ƞWen-Hung Chung,1,2 Department of Dermatology, Chang Gung Memorial hospital, Linkou, Taoyuan, Taiwan 2 Colledge of Medicine, Chang Gung University, Taoyuan, Taiwan ␩峛䨵 1 晚ᾱ岺 1,2 揿㕮⭶ 1,2

15:54-16:06 Experience of diphenylcyclopropenone in the treatment of alopecia areata濣 a 10-year observation study of 92 cases in a single center in Taiwan ḽ䏦ᵊ冭⚸䍮᳗㾭怬㭹䔀◑䡽䕂䱑椕濣⊮㼡⑬Ჾᳫ⺁ᴛ⇿ᵊḋ⽡仃䕂⇿ⴲ塾⪝⻥䛒䤴 Chang-Ming Huang,1ƞTsen-Fang Tsai,1,2 Department of Dermatology, National Taiwan University Hospital, Taiwan 2 Department of Dermatology, National Taiwan University College of Medicine, Taipei, Taiwan 溪⸟承 1 唈␯劚 1,2

16:06-16:18 Association of antineutrophil cytoplasmic antibodies with cutaneous and other organ-specific manifestations in eosinophilic granulomatosis with polyangiitis濣A systematic review and meta-analysis Hua-Ching Chang,1ƞPai-Chien Chou, 2ƞChun-Yu Lai,1ƞHsiou-Hsin Tsai,1,3 Department of Dermatology, Taipei Medical University Hospital, Taipei, Taiwan 2 Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan 3 Dpartment of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan ⼜取㙖 1 ⑏䙥嬀 2 峛ᾱἸ 1 唈䦧㬊 1,3

16:18-16:30 The incidence and predictors of malignancy in dermatomyositis濣 A retrospective study of 88 patients in Northern Taiwan Hsing-Jou Su,1ƞMeng-Han Shen,1ƞWen-Hung Chung,1,2,3ƞChien-Yio Lin,1,2,3 1 Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Linkou, and Keelung, Taiwan 2 College of Medicine, Chang Gung University, Taoyuan, Taiwan 3 Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan 嗮´㞻 1 㱯⭆㚜 1 揿㕮⭶ 1,2,3 㝾〉⎯ 1,2,3

16:30-16:42 Association of Psoriasis with Colorectal Cancer濣A Systematic Review and Meta-Analysis Yun Fu,1ƞCheng-Han Lee, 2ƞChing-Chi Chi,1,3 1 Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 2 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 3 College of Medicine, Chang Gung University, Taoyuan, Taiwan ⁬䭇 1 㜵㉦俗 2 䳧㙖䐑 1,3

The 3rd Meeting of the East Asia Vitiligo Association (3rd EAVA) EAVA Free Communication (10 minutes per person included discussion time) Date濣November 14th, 2020 Location濣RM302A, Kaohsiung Exhibition Center (KEC) Moderators濣Cheng-Che E. Lan ( 咋㏽⎰ , Taiwan), Chau Yee Ng ( 涁㓫䌚 , Taiwan) 16:00-16:10 Functional genomic screening for identification of therapeutic targets of vitiligo JimyungSeo,1ƞEun Jung Lee,1ƞSang Ho Oh,1 Department of Dermatology and Cutaneous Biology Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea Jimyung Seo1Eun Jung Lee1 Sang Ho Oh1 1

16:10-16:20 Evaluation of low-dose tofacitinib combining narrowband UVB therapy for treating vitiligo patients who had failed previous therapy濣A pilot study Wei-Cheng Fang,1ƞSzu-Hao Chiu,1ƞSheng-Yiao Lin,1ƞShu-Mei Huang,1,2ƞCheng-Che E. Lan,1,2 Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan 2 Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 㖠䄹䧲 1 悘〄屑 1 㝾倽⠖ 1,2 喴㔦ⓙ 1,2

16:20-16:30 Feasibility of Oral Tranexamic acid (TA) for vitiligo patients with melasma Chiang Pin-Hsuan,1ƞChau Yee NG,1 Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Linko and Keelung, Taiwan 㱆⒨吘 1 溪㘔䑃 1

16:30-16:40 Proposal of a New Classification of Segmental Vitiligo and Evaluation of Its Clinical Courses濣 A Retrospective Review of 956 Patients Jongwook Oh,1ƞRo Woo Lee,2ƞHee Ra Lee,3ƞSeon Bok Lee,4ƞHyun Jeong Ju,2ƞJeonghyun Shin,4ƞHee Young Kang,3ƞ Jung Min Bae, 2ƞSang Ho Oh,1 1 Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea 2 Department of Dermatology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 3 Department of Dermatology, Ajou university school of medicine, Suwon, Korea 4 Department of Dermatology, Inha University, School of Medicine, Incheon, Republic of Korea

16:40-16:50 Efficacy and safety of intravenous methylprednisolone pulse therapy for progressive vitiligo濣 a retrospective study of 33 therapy experiences from a single institute. Moyuka Irimada,1ƞKenshi Yamasaki,1ƞRui Sasaki,1ƞNaokazu Hatchome,1ƞKenichiro Tsuchiyama,1ƞSetsuya Aiba,1 Department of Dermatology, Tohoku University Graduate School of Medicine

The 2nd Annual Meeting of Asian Society of Dermatopathology Free paper (10 minutes per person included discussion time) Date濣November 15th, 2020

Location濣RM303A, Kaohsiung Exhibition Center (KEC)

Moderator濣Bai-Yao Wu ( ⋱䔼⛭ , Taiwan) 12:30-12:40 Azacytidine-induced localized Sweets Syndrome in Myelodysplastic Syndrome Pankhuri Dudani,1ƞTanvi Dev,1ƞNeetu Bhari,1 1 Department of Dermatology & Venereology, All India Institute of Medical Sciences, New Delhi, India

12:40-12:50 A Case of Neutrophil-rich, Anaplastic Large Cell Lymphoma(ALCL) Showing Relapsing Course Jung EunSeol,1ƞSeong Min Hong,1ƞSang Woo Ahn,1ƞJong Uk Kim,1ƞGyeong Je Cho,1ƞWoo Jung Jin,1ƞ So Hee Park,1ƞHyojin Kim,1 1 Department of Dermatology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea

12:50-13:00 A study of the clinico-histopathological features of panniculitis presenting to a tertiary care centre in India. A Narayanan,1ƞNeetu Bhari,1 1 All India Institute of Medical Sciences, New Delhi

13:00-13:10 Primary Cutaneous Extranodal NK-/T-Cell Lymphoma, Nasal Type濣A Rare Case Report Huy Q. Nguyen,1ƞTho Quynh Ngoc Le, 2ƞGiang Huong Tran, 2 1 Detroit Medical Center/Wayne State University, Detroit, Michigan, USA 2 University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam

13:10-13:20 Primary anetoderma and acquired cutis laxa associated with glomerulonephritis in a 37-year old Filipino male濣 a case report Val Constantine Cua,1ƞEileen LieslCubillan, 2 1 Resident Physician, Department of Dermatology, Philippine General Hospital, University of the Philippines Manila 2 Associate Professor 3, Department of Dermatology, College of Medicine and Philippine General Hospital, University of the Philippines Manila

13:20-13:30 Generalized purpuric lichen nitidus in a 32-year old Filipino male濣a case report Soraya Elisse E. Escandor,1ƞNicole Marella G. Tan,1ƞVal Constantine S. Cua,1ƞEileen Leisl A. Cubillan,2 Resident Physician, Department of Dermatology, Philippine General Hospital, University of the Philippines Manila 2 Associate Professor 3, Department of Dermatology, College of Medicine and Philippine General Hospital, University of the Philippines Manila

Case Reports

The 46th Annual Meeting of Taiwanese Dermatological Association Case Report (8 minutes per person included discussion time) Date濣November 15th, 2020

Location濣RM303B, Kaohsiung Exhibition Center (KEC)

Case Report List Moderators濣Po-Yuan Wu ( ⋱ᷭ , Taiwan), Sheng-Yiao Lin ( 㙕伔⛭ , Taiwan) 21

08:30-08:38 Nivolumab, a checkpoint inhibitor, may accentuate Sorafenib-related drug eruption An-Yu, Cheng,1ƞJui, Lan, 2ƞYu wen, Cheng,1ƞYi-Chien, Yang,1 Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan 2 Department of Pathology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan 愔⭰⦋ 1 喴⏈ 2 愔墼㕮 1 㤱⮃‐ 1

08:38-08:46 A case of superficial epidermolytic ichthyosis Yen-Ju, Kuo,1ƞMin-Hsin, Lin,1ƞJen-Jung, Cheng,1ƞPo-Ju, Lai,1 Chung Shan Medical University hospital 惔㘶⥩ 1 㝾㗢㖗 1 愔ạ㥼 1 峛㞶⥩ 1

08:46-08:54 Recurrent pigmented papule in young patients as the diagnostic clue for nevoid basal cell carcinoma syndrome濣 a case report with novel mutation of PTCH1 gene Chien Lin,1ƞHsuan Chen,1ƞSheau-Chiou Chao,1ƞJulia Yu-Yun Lee,1ƞChao-Chun Yang,1 National Cheng Kung University Hospital 㝾嬀 1 晚吘 1 嶀㚰䦲 1 㜵䍰曙 1 㤱㜄戅 1

08:54-09:02 A rare diagnosis of superficial spreading capillary hemangioma濣a case report Cian-Hao Ye,1ƞYan-Yun Tsai,1ƞHui-Ting Hsu,2ƞKuo-Chia Yang,1 Department of Dermatology, Changhua Christian Hospital, Changhua, Taiwan 2 Department of pathology, Changhua Christian Hospital, Changhua, Taiwan 吰〉屑 1 唈⥴䭇 1 娘デ⩞ 2 㤱⛲㜷 1

09:02-09:10 A Taiwanese patient with granuloma faciale improved with colchicine ᶣ䢉㫲ᶗ䯞ノ⅝㭹䔀丷⽡服徦佇养倩ᴉ⊮㼡㗪◝䒃⽡ Ya-Tang Yang,1ƞYang Lo,1ƞChen-Yu Wu,1ƞShiou-Hwa Jee,1,2ƞHsien-Ching Chiu, 2ƞYi-Teng Tseng,1 Department of Dermatology, Cathay General Hospital 2 Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine 㤱暬㣇 1 佬晤 1 ␚掕⭮ 1 䳧䦧取 1,2 悘桖㷬 2 㛥⤼樗 1

09:10-09:18 Necrolytic Migratory Erythema-like Eruption Associated with Erlotinib in a Patient with Lung Adenocarcinoma Sheng-Hsiang Ma,1,2ƞCheng-Yuan Li,1,2 Department of Dermatology, Taipei Veterans General Hospital 2 Department of Dermatology, National Yang-Ming University 榓倽侻 1,2 㜵㔦㹷 1,2

09:18-09:26 Lichen striatus in an adult after contrast media injection Li-Wen Chiu,1,2ƞStephen Chu-Sung Hu,1,2 Division of Dermatology, Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 2 Division of Dermatology, Department of Dermatology, Kaohsiung Medical University, Kaohsiung, Taiwan 悘印曖 1,2 僈㥁㝥 1,2

09:26-09:34 Microcystic Adnexal Carcinoma of the axilla濣an unusual location ⹬█倩⻥攂⬪┦䔊濣昜‶♉ḋ丬 Wu Kuan-Jou,1ƞHong Chien-Hui,1 1 Kaohsiung Veterans General Hospital ␚ↇ㞻 1 㴑〉デ 1

09:34-09:42 Rupioid erythema multiforme major associated with a combination use of pembrolizumab and lenvatinib 䄟囡㩺䅾╲悋♉⟘♉⻥䯃㑏⍊ pembrolizumab, lenvatinib ‧咣䄧ḳ䏦ᴉ撚伭⻥ Yi-Hsuan Wu,1ƞYi-Hsien Shih ,1ƞ Tzu-Yu Weng ,1 1 Department of Dermatology, Shuang Ho Hospital ␚⤼吘 1 㖤〈峉 1 侨⬷䍰 1

09:42-09:50 Poikilodermatous mycosis fungoides. Sheng-Wen Liu,1ƞYi-Hsien Chen,1ƞChih-Tzung Hung,1ƞHong-Wei Gao, 2ƞChien-Ping Chiang,1ƞWei-Ming Wang,1 Department of Dermatology, Tri-Service General Hospital, National Defense Medical Center 2 Department of Pathology, Tri-Service General Hospital, National Defense Medical Center ≰㗮曖 1 晚⤼ℯ 1 㴑婳偗 1 檿洢‰ 2 㱆⻡⹚ 1 䍲‰承 1

09:50-09:58 Rapid occurrence and deterioration of interstitial lung disease in a case of anti-MDA-5 positive dermatomyositis Chia-Jui, Su,1ƞLai-San, Wong,1ƞYu wen, Cheng,1 1 Kaohsiung Chang Gung Memorial Hospital 嗮⮝䝦 1 溪湾䎱 1 愔墼㕮 1

09:58-10:06 Novel ADAR1 mutations in three cases of psoriasis coexisting with dyschromatosis symmetrica hereditaria Ro-Wei Wu,1ƞHui-Ying Weng, 2ƞYen-Ting Chen,1ƞYung-Feng Lin, 3ƞYen-Ming Liu, 3ƞWei-Wen Song,1ƞTing-Hua Wu,1ƞ Shih-Feng Tsai, 3ƞChung-Hsing Chang,1,4 1 Skin Institute, Department of Dermatology, Buddhist Tzu-Chi General Hospital, Hualien, Taiwan 2 Biomedical Industry PhD Program, National Yang-Ming University, Taipei, Taiwan. 3 Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan. 4 Doctoral Degree Program in Translational Medicine, Tzu Chi University and Academia Sinica, College of Medicine, Tzu Chi University, Hualien, Taiwan. ␚勌啮 1 侨デ䑐 2 晚⽌⩞ 1 㝾㰟尷 3 ≰⽌㗵 3 ⭲䶔㕮 1 ␚Ẕ㨡 1 唈᷽Ⳗ 3 ⼜Ḕ凯 1,4

10:06-10:14 Effects of risankizumab in patients with psoriasis previously treated with guselkumab濣a case series study risankizumab 䏦㑺 ℋᶣ guselkumab 㭹䔀䕂ᴼ䔪䒃ᵸ䔀㐆濣Ჾ㜆ṉ䮹⃕⛯⌈ Pin-Hsin Lin,1ƞTsen-Fang Tsai,1 Department of Dermatology, National Taiwan University Hospital 㝾⒨榏 1 唈␯劚 1

10:14-10:22 Immune-related adverse event presented as eruptive keratoacanthomas Hsu TsunHao,1,2ƞChun-Bing Chen,1,2,3 Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospitals, Linkou, Taipei, and Keelung, Taiwan 2 College of Medicine, Chang Gung University, Taoyuan, Taiwan 3 Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan 娘㷚䙺 1,2 晚ᾱ岺 1,2,3

10:22-10:30 How to Treat Complications of thread lift about skin dimpling and thread extrusion Cheng-Kun Wang,1 E-Champ Dermatology Clinic 䍲㭊❋ 1

Moderators濣Kai-Che Wei ( 樍㠵⎰ , Taiwan), Chien-Ping Chiang ( 㬝ⶸⴱ , Taiwan) 36

13:30-13:38 Etanercept as steroid-sparing treatment in a case of generalized bullous fixed drug eruption (GBFDE) Yu-Han Hsueh1ƞChun-Bing Chen1 1 Department of Dermatology, Chang Gung Memorial Hospital 喂偦㶜 1 晚ᾱ岺 1

13:38-13:46 Clinical experience of guselkumab in the treatment of patients with history of chronic erythrodermic psoriasis濣 a case series Guselkumab ◦㭹䔀‵㗇〠⻥䯃䕬⻥ᴼ䔪䒃ᵸ䕂傦ⵈ䱑椕 - 䒃ṉ䮹⃕⛯⌈ Cheng-Ying Chiang,1ƞTsen-Fang Tsai,1,2 Department of Dermatology, National Taiwan University Hospital, Taiwan 2 Department of Dermatology, National Taiwan University College of Medicine, Taipei, Taiwan 㱆㔦䨵 1 唈␯劚 1,2

13:46-13:54 Epidermolysis bullosa simplex with mottled pigmentation濣a case report 㑏桿儰䯞⻥⑬䯒⻥㫲䑯⻥圦䕬槄墡䒅濣㜆ṉ⛯⌈ Jen-Ping Chao,1ƞCheng-Ying Chiang,1ƞJin-Bon Hong,1ƞSung-Jan Lin,1 1 Department of Dermatology, National Taiwan University Hospital and College of Medicine 嶀ạ⹚ 1 㱆㔦䨵 1 㴑㥏悍 1 㝾柳䄝 1

13:54-14:02 Two different cutaneous presentations in one case of eosinophilic granulomatosis with polyangiitis Ჾỉ‵‧䣬᳋⋊䕬偘圦䊼䕂⒚᷈䯃⻥佇养倩⟘䔺⻥图䩟㽌ỉ㜆 Chun-Yu Lai,1ƞI-Jing Chang,1 Department of Dermatology, Taipei medical university hospital, Taipei, Taiwan 峛ᾱἸ 1 ⼜⮃厨 1

14:02-14:10 A case of pemphigus foliaceus with atypical clinical features due to malnutrition Kana HIRAYAMA,1ƞAtsushi FUJIMOTO,1ƞKanade SHIMADA,1ƞYuka TSUTSUI,1ƞShingo TAKEI,1ƞAyano ISHIWATARI,1ƞ Tatsuya KATSUMI,1ƞAmi SATO,1ƞAkito HASEGAWA,1ƞYudai KABATA,ƞNatsuimi HAMA,1ƞRiichiro ABE,1ƞAtsuko AIZAWA,2ƞ Norito ISHII, 3ƞHiroshi KOGA, 3 1 Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan 2 Kazama Clinic, Niigata, Japan 3 Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan

14:10-14:18 Ultra-low Dose Rituximab for Pemphigus Vulgaris濣A Case Report 㠳Ḍ⅏悍 Rituximab 䏦㑺㭹䔀⫉⳶♉⟧䕮䓟濣䒃ṉ⛯⌈ Yu-An Wang,1ƞJulia Yu-Yun Lee,1ƞChao-Chun Yang,1,2 Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 2 International Center for Wound Repair and Regeneration, National Cheng Kung University, Tainan, Taiwan 䍲侤⭰ 1 㜵䍰曙 1 㤱㜄戅 1,2

14:18-14:26 Actinomycetoma caused by Nocardiabrasiliensis濣a case report Ⲳ堽⠲∟㫍劊傲山劊倩濣䒃ṉ⛯⌈ Yi-Teng Hung,1ƞTing-Shu Wu, 2ƞYu-Han Hsueh,1ƞHsuan-Ning Wang,1ƞPei-Lun Sun,1 1 Department of Dermatology, Chang Gung Memorial Hospital LinkouBracnh, Taoyuan, Taiwan 2 Division of Infectious Diseases, Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan 㴑侱樗 1 ␚ᷨ㨠 2 喂偦㶜 1 䍲⮊䔖 1 ⭒⟠‒ 1

14:26-14:34 Disseminated Cutaneous Gout濣Two Case Reports 㻮㷩⻥䒙杦䚱濣‧ṉ㜆ṉ⛯⌈ Woon Chai Ng,1ƞShu-Hui Wang,1ƞYung-Ling Su,1 1 Department of Dermatology, Far Eastern Memorial Hospital, New Taipei City, Taiwan 溪㙏㗱 1 䍲㶸デ 1 嗮婇䔖 1

14:34-14:42 Folliculotropic mycosis fungoides with concurrent presentation of tumors, eyebrow loss and follicular keratosis濣 a case report Mei-Yi Tsui,1ƞJin-Bon Hong,1 1 National Taiwan University Hospital ⳻併〈 1 㴑㥏悍 1

14:42-14:50 Paget’s disease of ectopic mammary tissue on the abdominal wall with underlying ductal carcinoma in situ with microinvasion in a Taiwanese woman濣case report and review of literature Ჾ⊮㼡⠱⻥ᴉ倷徦䐮ḋᴱヽ㚍⎰⹵㫍䒅⊈‴ᴱヽ䰂䴒ᴉ䩟‥≝ḋ䔊⋆ḳ⹬⫍ṳ䅭濣ỉ㜆⛯⌈⊈㑅䈹▜朥 Wei-Ting Liu,1ƞChao-Kai Hsu,1ƞHui-Wen Chen, 2ƞKung-Chao Chang, 2ƞYang-Cheng Lee, 3ƞJulia Yu-Yun Lee,1 Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 2 Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 3 Division of Hematology and Oncology, Tainan Municipal Hospital, Tainan, Taiwan ≰⧨⻞ 1 娘憾⇘ 1 晚ㅎ曖 2 ⼜⬻㘔 2 㜵㤱ㇷ 3 㜵䍰曙 1

14:50-14:58 Gustatory Hemifacial Hyperhidrosis Induced by Thoracic Sympathectomy and Augmented by Ipsilateral Insular Stroke Rosie Hsu,ƞChou-Ching Lin,ƞShuan Chen,ƞWei-Ting Liu,ƞChao-Chun Yang, 1 National Cheng Kung University Hospital 娘⮝功 1 㝾⮀㙛 1 晚吘 1 ≰⧨⻞ 1 㤱㜄戅 1

Moderators濣Hui-Wen Tseng ( 㖼〥㑅 , Taiwan), Tsu-Man Chiu ( 彯山㶽 , Taiwan) 47

15:30-15:38 Disseminated eruption of ectopic sebaceous glands after TEN ᳫ㪐⻥圦䕬➜㨹䒅ỗ乢⹊ⶡ䅭䔺䑷⻥䐮ḋ䕬俀倸 Yu-Han Fang,1ƞKai-Che Wei,1 1 Kaohsiung Veterans General Hospital 㖠㮺㶜 1 欶㥞ⓙ 1

15:38-15:46 Autosomal dominant familial acanthosis nigricans caused by a nonsense mutation of FGFR3 in two families Umi Tahara,1ƞMasahito Yasuda, 2ƞYozo Yamada, 3ƞSatomi Aoki,1ƞShowbu Sato,1ƞMasayuki Amagai,1ƞAkiharu Kubo,1 Department of Dermatology, Keio University School of Medicine, Tokyo, Japan 2 Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan 3 Department of Dermatology, Kakogawa Central City Hospital, Kakogawa, Japan

15:46-15:54 Acrokeratosis Paraneoplastica (Bazex syndrome) with Feature of Bullous Pemphigoid and Thyroid Cancer A case presentation and review of literature 䏰䅾倸䔊ⷓ尵䕂ᷲ倩䓢⻥你䦭墐⇔䒅濕ỉ㜆⛯⌈⊈㑅䈹▜朥 Po-Huan, Ko,1ƞHsiou-Hsin Tsai,1,2 Department of Dermatology, Taipei Medical University Hospital 2 Department of Dermatology, School of Medicine, Taipei Medical University 㟖⍁㠺 1 唈䦧㬊 1,2

15:54-16:02 Scrotal tumor with features of epidermolytic hyperkeratosis and multifocal p16 positive staining濣a case report 攮█倩䓢ᶣ圦䕬槄墡⻥墐⇔弌ⵤḳ⟘⇾ p16 㚑儰攻⻥圦䊼濣㜆ṉ⛯⌈ Jenny Chiang,1ƞYu Ting, Hung,1ƞConnie Liu 唊㉦凢 1 㴑您⩞ 1 ≰⺞䎙

16:02-16:10 Merkel cell carcinoma with squamous cell carcinoma濣a case report Yu-Ting Hung,1ƞMeng-Sui Lee,1ƞRuey-yi Lin,1 1 Taipei city hospital 㴑您⩞ 1 㜵⭆䨾 1 㝾䑅⮃ 1

16:10-16:18 Combined photodynamic therapy and imiquimod local treatment for the perianal extramammary Paget's disease濣 a successful case report Jia-Di Lin,1ƞChung-Hsing Chang,1ƞTing-Hua Wu,1 Skin Institute, Department of Dermatology, Buddhist Tzu-Chi General Hospital, Hualien, Taiwan. 㝾䎯呩 1 ⼜Ḕ凯 1 ␚Ẕ㨡 1

16:18-16:26 A case of squamous cell carcinoma arising within a lesion of subacute cutaneous lupus erythematosus. ◦ᵜ⻣⻥䕬偘䯃㑏䆺䓟䒃㼴ᳫ₸䊼欕䅾䯮侜䔊ᴉ䒃ṉ⛯⌈ Yao Yu Leu,1ƞYi-Hsien Shih,1 1 Department of dermatology, Taipei Medical University Shuang Ho Hospital ␩㛃⭮ 1 㖤〈峉 1

16:26-16:34 Cutaneous manifestations reflecting disease progression in a patient with myeloproliferative neoplasm Yng Sun,1ƞCheng-Che Lan,1 Kaohsiung Medical University Chung-Ho Memorial Hospital ⭒䅹 1 喴㔦ⓙ 1

16:34-16:42 Splenic marginal zone lymphoma with cutaneous involvement濣a case report Jim-Yih Chen,1ƞWei-Hsin Wu,1 National Taiwan University Hospital 晚Ⳣ㮬 1 䂶テ㖗 1

16:42-16:50 Tocilizumab-induced psoriasis in a patient with rheumatoid arthritis濣a case report and literature review Yen-Ting, Chen,1ƞChung-Hsing, Chang,1,2 Skin Institute, Hualian Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan 2 Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan 晚⽌⩞ 1 ⼜Ḕ凯 1,2

16:50-16:58 Kikuchi disease, ischemic stroke and macular lymphocytic arteritis in a young woman濣A case report ◦ⴲ巓⠱⻥㗇劈◮㫍䒅濕䷸图⻥ᳫ杦ᶣ⊈㑏涜䅾㲉Ⲳ䯮侜↓俆㽌ᴉ䒃ṉ⛯⌈ Chi-Hsuan Chen,1ƞCheng-Lin Wu, 2ƞYu-Yun Lee,1ƞChia-Bao Chu,1 Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 2 Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 晚湹ṿ 1 ⷒ㔦曽 2 㜵䍰曙 1 㜘⮝吭 1

E-posters

The 46th Annual Meeting of Taiwanese Dermatological Association The 2nd Annual Meeting of Asian Society of Dermatopathology The 3rd Meeting of the East Asia Vitiligo Association (3rd EAVA) Date濣November 13-15th, 2020 Location濣E-poster Area, Kaohsiung Exhibition Center (KEC)

e-Poster List P01

The Clinicopathological Manifestations of Acute Generalized Exanthematous Pustulosis in a Taiwanese female with a de novo KRT1 Mutation-induced Epidermolytic Hyperkeratosis ◦Ჾḋ⊮㼡ᵸ⠱⻥▞ KRT1 ⚸▞㑮䏝䤿婈⫌傲圦䕬槄墡⻥弌ⵤ墐⇔䒅ᴉ䒃⽡䔺䏝⻣⻥ⶡ㮙⻥䔺䑷⻥偽䕮䒅ᴉ傦ⵈ䒃䋄圦䊼 Han-Tang Wang,1ƞHsing-San Yang,1ƞJing-Yu Wang,1ƞHsin-Yu Huang,1ƞYu-Rong Lee,1ƞSheau-Chiou Chao,1ƞJulia Yu-Yun Lee,1ƞ Ken Natsuga,2ƞChao-Kai Hsu,1,3 1 Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan (R.O.C.) 2 Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan 3 International Research Center of Wound Repair and Regeneration, National Cheng Kung University, Tainan, Taiwan (R.O.C.) 䍲䀁㣇 1 㤱䛨ᷰ 1 䍲㙖䍰 1 溪Ὲ䕓 1 㜵㘘坴 1 嶀㚰䦲 1 㜵䍰曙 1 ⣶岧⁌ 2 娘憾⇘ 1,3

P02

The customer satisfaction and loyalty in medical aesthetic service 乌⩷恩⨶㗋↗ᳫ䕂朥⩠㶽⿍ⵤ僅⺞奞ⵤ Tsai,wen-chien,1,3ƞLiu,kwei-lan,2ƞTsai,hsiu-fen,3 Huang PH Dermatology and Aesthetics, Kaohsiung, Taiwan 2 Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan 3 Department of Fragrance and Cosmetic Science, Kaohsiung Medical University, Kaohsiung, Taiwan 唈㕮樒 1,3 ≰⤵嘔 2 唈䦧劓 3

P03

Extra-urogenital cutaneous malakoplakia limited to the forearm濣Case report and literature review Yu-An Wang,1ƞTzu-Chien Hsu,1ƞJulia Yu-Yun Lee,1 1 Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 䍲侤⭰ 1 ⽷ㄯ嬀 1 㜵䍰曙 1

P04

Cutaneous plasmacytosis濣a clinicopathologic report and treatment outcome of a series of 3 cases in south Taiwan Huei-Jing Wang,1,2ƞYang-Yi Chen,1,2ƞSzu-Hao Chiu,1,2ƞYng Sun,1,2ƞCheng-Che E. Lan,1,2 Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan 2 Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 䍲㙰㙖 1,2 晚㳘ự 1,2 悘〄屑 1,2 ⭒䅹 1,2 喴㔦ⓙ 1,2

P05

Effective treatment of Dupilumab in a Hyper Immunoglobulin E Syndrome Patient ⟧⻥䑩䋁喉䔻 E 弌榖䒅ỗ乢⽡仃㉣⊕㘚弽㽌ᴉ䔀㐆ノ⅝㜆ṉ Han-Chi Tseng,1ƞChia-Jui Su,1 Department of dermatology, Kaohsiung Chang-Gung Memorial Hospital 㛥㶜䐑 1 嗮⮝䝦 1

P06

Excellent Cosmesis for Ear Helix Keloid after Keloid Fillet Flap Yu-An Wang,1ƞTak-Wah Wong,1,2,3 Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 2 Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan 3 Center of Applied Nanomedicine, National Cheng Kung University 䍲侤⭰ 1 䍲⾞取 1,2,3

P07

Erythema Multiforme Induced by Ostamivir濣A Case Report Wei-Yao Wang,1ƞChing-Ying Wu,2 Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 2 Department of Dermatology, Kaohsiung-Municipal Ta-Tung Hospital, Kaohsiung, Taiwan 䍲‰俧 1 ␚朹䨵 2

P08

Naphtho [1,2-b] furan-4,5-dione nanofibers濣physicochemical properties and anti-skin cancer activity Stephen Chu-Sung Hu,1,2,3ƞChi-Ling Lin,1ƞFeng-Lin Yen, 4 1 Department of Dermatology, Kaohsiung Medical University Hospital 2 Department of Dermatology, Kaohsiung Municipal Siaogang Hospital 3 Department of Dermatology, College of Medicine, Kaohsiung Medical University 4 Department of Fragrance and Cosmetic Science, College of Pharmacy, Kaohsiung Medical University 僈㥁㝥 1,2,3 㝾嵞侵 1 栶ⳗ曽 4

P09

Acitretin-induced photosensitivity in a young female with generalized annular pustular psoriasis Chi-Ling Lin,1ƞGwo-Shing Chen,1,2ƞStephen Chu-Sung Hu,1,2,3 Department of Dermatology, Kaohsiung Medical University Hospital 2 Department of Dermatology, College of Medicine, Kaohsiung Medical University 3 Department of Dermatology, Kaohsiung Municipal Siaogang Hospital 㝾嵞侵 1 晚⛲䅶 1,2 僈㥁㝥 1,2,3

P10

Transient bullous dermolysis of the newborn with de novo mutation in the COL7A1 gene COL7A1 ⚸▞㑮䏝䤿婈廞ノ䕂㑮䏝‐㕩㔀⻥䕬偘垀墡㫲䕮䒅 Yang-Yi Chen,1ƞChao-Kai Hsu,2ƞPei-Ling Chi,3ƞTzu-Hung Huang, 4ƞCheng-Che Lan,1 1 Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 2 Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 3 Huang PH Dermatology and Aesthetics, Kaohsiung, Taiwan 4 Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan 晚㳘ự 1 娘憾⇘ 2 㱇䏕䶥 3 溪⬷洢 4 喴㔦ⓙ 1

P11

Lymphomatoid Papulosis with DUSP22 - IRF4 Rearrangement on 6p25.3濣A case report 㲉Ⲳ䓢㣡᳖䑷䒅⋆ḳ DUSP22 - IRF4 ⚸▞悋䰂濣㜆ṉ⛯⌈ Yi-Ning Mao,1ƞYu-Hung Wu,1 Department of Dermatology, Mackay Memorial Hospital, Taipei, Taiwan 㯂⤼䔖 1 ␚備⻿ 1

P12

A10-year-old girl with Buschke-Ollendorff Syndrome Kuanyu Chen,1ƞChin-Yi Yang,2ƞMeng-Han Shen,3 Department of Dermatology, Chang Gung Memorial Hospital, Linko, Taiwan 2 Department of Dermatology, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan 3 Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan 晚ↇỪ 1 㤱权⮃ 2 㱯⭆㚜 3

P13

Identification of a Novel KITLG Mosaic Mutation in a Taiwanese Female with Linear and Whorled Nevoid Hypermelanosis Hsuan Chen,1ƞYi-Ting Huang,1ƞHsing-San Yang,1ƞYing-Yo Ho,1ƞJulia Yu-Yun Lee,1ƞChao-Kai Hsu,1,2 Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 2 International Center for Wound Repair and Regeneration, National Cheng Kung University, Tainan, Taiwan 晚吘 1 溪栾⺔ 1 㤱䛨ᷰ 1 Ἴ勘⏚ 1 㜵䍰曙 1 娘憾⇘ 1,2

P14

UVA-induced photoaging was reduced after 755nm Picosecond laser treatment in mice skin Shu-Mei Huang,1ƞChing-Shuang Wu,2ƞCheng-Che E. Lan,1,3 Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 2 Department of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan 3 Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 溪㶸併 1 ␚ㅝ庹 2 喴㔦ⓙ 1,3

P15

IgE level changes as a possible biomarker in treatment of atopic dermatitis with Dupilumab Tzu-Hung Huang,1ƞCheng-Che E. LAN,2,3 1 Kaohsiung Municipal Siao-Gang Hospital 2 Department of Dermatology, Kaohsiung Medical University Hospital 3 Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 溪⬷洢 1 喴㔦ⓙ 2,3

P16

A rare case of linear lichen planus pigmentosus Yung-Wei Chang,1ƞHsin-Wei Huang,2 Department of Dermatology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan 2 Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan ⼜婇䂡 1 溪榏呍 2

P17

Daily visit counts of patients with urticaria and the exposure of ambient air pollutants in Kaohsiung city 榖斂Ⳁ叿浹䑷⽡仃㪍㒣⫯壸㐶⍊⌦○䤸㫡㬟㚑䄧䕂㕲旰䕂撚伭⻥ Hui-Wen Tseng,1,2ƞLing-Yin Lu,3 Department of Dermatology, Kaohsiung Veterans General Hospital 2 Institute of Biomedical Sciences, National Sun Yat-Sen University 3 Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital 㛥ㅎ㕮 1,2 ␩倭柚 3

P18

Compression fracture in psoriasis patient Yuichi Nakayama,1ƞKentoMizutani,1ƞMai Ishikawa,1ƞTomoko Akeda,1ƞKeiichi Yamanaka,1 Department of Dermatology, Mie University Graduate School of medicine

P19

Perioral dermatitis-like demodicosis in a patient receiving epidermal growth factor receptor-tyrosine kinase inhibitor Ჾḋ䒃⽡◦㉣⊕䏝搵▞⨎⊕榒怨侸怶怴ㅏ⃴⅏㭹䔀⹊䏠䏝䕂⊡⌦䕬偘㽌㣡䕂囓⸠噦嚰⿝㚑 Jian-Wei Lee,1ƞChia-Bao Chu,1 Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 㜵⻡䷖ 1 㜘⮝吭 1

P20

Bullous pemphigoid masquerading as erythema annularecentrifugum Shiang-Yu Yang,1,2 1 Department of Dermatology, Kaohsiung Municipal Siaogang Hospital 2 Department of Dermatology, College of Medicine, Kaohsiung Medical University 㤱侻⭮ 1,2

P21

In vitro proliferation of human epidermal melanocytes biopsied from multiple anatomical sites Hui-Ju Yang,1,2ƞChung-Hao Hsu,1ƞKuo-Chia Yang,1ƞYu-Fen Wang,3ƞTzu-Hsuan Liu,1,4ƞYuan-Ting Yang,2ƞJiunn-Liang Ko,2 Department of Dermatology, Changhua Christian Hospital, Changhua, Taiwan 2 Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan 3 Cancer Research Center, Department of Research, Changhua Christian Hospital, Changhua, Taiwan 4 Feng-chi dermatology clinic, Taiwan 㤱啀⥩ 1,2 ⽷ⳮ屑 1 㤱⛲㜷 1 䍲㮺劓 3 ≰⧦䍫 1,4 㤱⪂⩞ 2 㟖ᾱ剖 2

P22

Expression of type II transmembrane serine proteases and endogenous inhibitors in mycosis fungoides 䧪ᵊ♉Ⰺ做䰰侸怶喉䔻怴僅‥䏝⻥ㅏ⃴⅏◦吆䅾佇养倩ᴉ圦䊼 Chien-Ping Chiang,1,2ƞSheng-Wen Liu,1ƞHong-Wei Gao,3ƞJehng-Kang Wang,2 Department of Dermatology, Tri-Service General Hospital 2 Department of Biochemistry, National Defense Medical Center 3 Department of Pathology, Tri-Service General Hospital 㱆⻡⹚ 1,2 ≰㗮曖 1 檿洢‰ 3 䍲㭊⺞ 2

P23

Poststeroid panniculitis Chun-Sheng Chen,1ƞPo-Yuan Wu,1,2 1 Department of Dermatology, China Medical University Hospital, Taichung, Taiwan 2 School of Medicine, China Medical University, Taichung, Taiwan 晚槦⌮ 1 ␚἖K 1,2

P24

Will a keloid resolve spontaneously? A case series study and review of the literature Yu-Chen Lin,1ƞTak-Wah Wong,2,3 Department of Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan 2 Department of Dermatology, National Cheng Kung University Hospital, Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan 3 Center of Applied Nanomedicine, National Cheng Kung University, Tainan 70101, Taiwan 㝾㘘得 1 䍲⾞取 2,3

P25

Generalized morphea and monoclonal gammopathy濣A rare association Yolanka Lobo,1,2ƞRuby Lee,2ƞSarathBodapati,3ƞNerilee Wall,1 Department of Dermatology, Mater Misericordiae Health Services, Brisbane, Queensland, Australia 2 Veracity Clinical Research, Brisbane, Queensland, Australia 3 Department of Dermatology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia

P26

Association of psoriatic disease with hearing loss濣a systematic review and meta-analysis 䮹䰯⻥▜朥⍊䰯⋆⃄㙎㗇撚ᴼ䔪僅伻⅙㋋⟯䕂撚伭 Tzong-Yun Ger,1ƞKuang-Hsu Lien,2,3ƞChing-Chi Chi,1,3 Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 2 Department of Otolaryngology - Head & Neck Surgery, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 3 College of Medicine, Chang Gung University, Taoyuan, Taiwan 呂⭾㗧 1 怊䎽㗔 2,3 䳧㙖䐑 1,3

P27

Increased Risk of Herpes Zoster in Individuals with Stroke Chieh-Hsin Wu,1,2ƞYing-Yi Lu,3,4 Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 2 Department of Surgery, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 3 Department of Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan 4 Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan ␚䔳㬊 1,2 ␩䨵〈 3,4

P28

UVB induces the proliferation of BRAFV600E-mutated melanocytes (nevi) via p16 downregulation. Ting-Hua Wu,1,2ƞYu-Ya Su,1ƞWei-Wen Sung,1ƞChung-Hsing Chang,1,2 Skin institute, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan 2 Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan ␚Ẕ㨡 1,2 嗮您暬 1 ⭲䶔㕮 1 ⼜Ḕ凯 1,2

P29

The effects of hyperbaric oxygen therapy (HBOT) in melanoma mice Wei-Ping Huang,1,2ƞChien-Hsing Wang,1ƞShyh-Jer Huang,1ƞTing-Hua Wu,1,2ƞChung-Hsing Chang,1,2 Skin institute, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan 2 Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan 溪䐲嗲 1,2 䍲⁌凯 1 溪⣒ⓙ 1 ␚Ẕ㨡 1,2 ⼜Ḕ凯 1,2

P30

Development of Dermatitis Herpetiformis in Chronic Plaque Psoriasis Ruby Lee,1ƞYolanka Lobo,1ƞLynda Spelman,1,2 Veracity Clinical Research, Brisbane, Queensland, Australia 2 Gabba Dermatology, Brisbane, Queensland, Australia

P31

Cutaneous adverse events and psychological status in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitor 佸䔊䒃ᵸ㉣⊕圦䕬䏝搵▞⨎⊕榒㣗昴咣䄧㭹䔀ⷓ尵ᴉ䕬偘᳋儭ᵉᶴ僅‴⾃䲐䅾〉ᴉ㉠壌 Hui-Te Hsu,1ƞChu-Chun Yu,2ƞChia-Yu Chu,1 Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan 2 School of Nursing, National Taiwan University College of Medicine, Taipei, Taiwan 娘ㅎ⽾ 1 㸟䫠␂ 2 㜘⮝䑃 1

P32

Losartan/hydrochlorothiazide-induced pemphigus foliaceus in an elderly patient. Wei-En Wang,1ƞRo-Wei Wu,1ƞChung-Hsing Chang,1,2 Department of Dermatology, Skin Institute, Buddhist Tzu-Chi General Hospital, Hualien, Taiwan 2 Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan 䍲‰ぐ 1 ␚勌啮 1 ⼜Ḕ凯 1,2

P33

Erythema palmarehereditarium濣a case report 弸ά⻥ㄉ㉊䯃㑏濣䒃ṉ⛯⌈ XIAO-FENG YAO,1ƞYu-Hung Wu,1 Taipei Mackay Memorial Hospital ⧁䭘㤺 1 ␚備⻿ 1

P34

Efficacy and Safety of Automated Epidermal Micrograft Harvesting System in Patients with Stable and Segmental Vitiligo Chi-Hui Wang,1,2ƞYa-Ching Chang,1ƞWen-Hung Chung,1,2,3ƞChau Yee Ng,1,3,4 Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 2 Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan 3 School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan 4 Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan 䍲湹デ 1,2 ⼜暬厨 1 揿㕮⭶ 1,2,3 溪㘔䑃 1,3,4

P35

Angiosarcoma of the scalp濣a case report with unusual clinical lesion Ching-Hao Chang,1ƞChia-Wen Shih,2 1 Department of Dermatology, LotungPoh-Ai Hospital, Yilan, Taiwan 2 Department of Pathology, LotungPoh-Ai Hospital, Yilan, Taiwan ⼜㙖䙺 1 㖤㴤曖 2

P36

Pigmented clear cell acanthosis of nipple and areola濣a case report ᴱ曫⊈ᴱ㕆ᴉ儰䯞⻥廍㓌䯮侜㞖䕬䒅濣Ჾ䒃ṉ⛯⌈ Chia-Shuen Lin,1ƞRo-Wei Wu,1ƞChung-Hsing Chang,1,2 Skin Institute, Department of Dermatology, Buddhist Tzu-Chi General Hospital, Hualien, Taiwan 2 Doctoral Degree Program in Translational Medicine, Tzu Chi University and Academia Sinica, College of Medicine, Tzu Chi University, Hualien, Taiwan 㝾὚吘 1 ␚勌啮 1 ⼜Ḕ凯 1,2 1

P37

A top-100 most cited articles in “psoriasis vulgaris and biological agents” (1991-2020)濣a bibliometric analysis Chieh-Hsun Chen,1ƞTsair-Wei Chien,2ƞFeng-Jie Lai,3,4 Medical Education Center, Chi-Mei Medical Center, Tainan, Taiwan 2 Medical Research Department, Chi-Mei Medical Center, Tainan, Taiwan 3 Department of Dermatology, Chi Mei Medical Center, Tainan, Taiwan 4 Center for General Education, Southern Taiwan University of Science and Technology, Tainan, Taiwan 晚䎇⋚ 1 按㈴䐲 2 峛尷⁸ 3,4

P38

Cutaneous Norcardiosis 䕬偘⠲∟㫍劊⿝㚑 Chia-Ling Hsieh,1ƞChin-Yin Liu,1ƞPo-Ju Lai,1ƞShiou-Jiuan Wei,1 Chung Shan Medical University Hospital 嬄὚晜 1 ≰妑䨵 1 峛㞶⥩ 1 欶䦧⨆ 1

P39

Eccrine porocarcinoma, clinicopathologic analysis of nine cases in Taiwan Yi-Hsiang Yu,1ƞChih-Hung Lee,1ƞJi-Chen Ho,1 Department of Dermatology, Kaohsiung Chang-Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, R.O.C. Ⰻ⤼侻 1 㜵⾾⭶ 1 Ἴ⮃㉦ 1 1

P40

Localized bullous pemphigoid induced by Dipeptidyl peptidase-4 (DPP-4) inhibitor in a middle-aged woman Chiau Sheng Jang,1,2ƞKuanJou Wu,2 Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University,100,Shih-Chuan1st Road, Kaohsiung, 80708, Taiwan 2 Department of Dermatology, Veterans General Hospital, Kaohsiung, Taiwan ⼜▓⋄ 1,2 ␚ↇ㞻 2

P41

Paraneoplastic Dermatoses濣Dermatomyositis associated with testicular malignancy ℭ倩䓢䕬偘䒃婈濣䕬佊㽌⋆ḳ䘨ᳶ䔊 Szu-Hao Chiu,1,2ƞWei-Cheng Fang,,1,2ƞCheng-Che E. Lan,1,2ƞYue-Chiu Su,1,3 Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan 2 Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 3 Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan 悘〄屑 1,2 㖠䄹䧲 1,2 喴㔦ⓙ 1,2 嗮㛯䦲 1,3

P42

Papular granuloma annulare in a previous traumatized area on the face, an isotopic response in a 50 y/o womana case report ᳖䑷㣡䍮⸠佇养倩䔺䏝◦Ჾỉ傇徦⊕ή䕂ᵒ⇿㨰⠱⻥ - Ჾỉ䒃ṉ⛯⌈ HSU JEN HAO,1 Mackay Memorial Hospital 娘Ẩ䁄 1

P43

Early generalized morphea mimicking cutaneous T cell lymphoma濣A case report 朜᷺䕬偘 T 䯮侜㲉Ⲳ䔊䕂㒧㗝⟘䔺⻥⫾攎⻥䜪䕬䒃濣Ჾ䒃ṉ⛯⌈ Che-Hao Chang,1ƞYu-Hung Wu,1ƞChia-Yu Chu,2ƞHsien-Ching Chiu,2 1 Department of Dermatology, Mackay Memorial Hospital 2 Department of Dermatology, National Taiwan University Hospital ⼜ⓙ䙺 1 ␚備⻿ 1 㜘⮝䑃 2 悘桖㷬 2

P44

Alopecia and generalized maculopapular eruption in a patient with Vogt-Koyanagi-Harada (VKH) disease ≝䏮㫍䒅 (VKH disease)濣ᶣ䡽榬⊈…嵩㑏⻥᳖䅾䔺䑷㽸䕬偘圦䊼ᴉỉ㜆⛯⌈ Chia-Hsien Yen,1ƞShang-Hung Lin,1 Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan 栶◰峉 1 㝾Ⰱ⭶ 1

P45

Serial punch excisions followed by secondary intention healing for acne keloidalis Tzu-Kun Lo,1ƞChao-Chung Yang,1,2ƞJulia Yu-Yun Lee,1ƞChao-Kai Hsu,1,2,3 Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 2 International Research Center of Wound Repair and Regeneration (iWRR), National Cheng Kung University, Tainan, Taiwan 3 Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan 佬⬷䄃 1 㤱㜄戅 1,2 㜵䍰曙 1 娘憾⇘ 1,2,3

P46

Bilateral auricular ossificans with stenosis of external ear canals and hearing loss caused by primary hyperparathyroidism濣A case report 䒃ṉ⛯⌈濣ℭ䏰䅾倸ᵠ廰奖䔺ᴉ仱㩺䜪⇔䒅ḳ⟔伻弑䥂䳬⊈伻⅙⑨⟯ Tzu Kun Lo,1ƞChao Kai Hsu,1ƞSu Ting Hsin,2ƞJiunn Liang Wu,3ƞJulia Yu Yun Lee,.1 Department of Dermatology, National Cheng Kung University Hospital, Tainan, Taiwan 2 College of Medicine, National Cheng Kung University, Tainan, Taiwan 3 Department of Otolaryngology, National Cheng Kung University Hospital 佬⬷䄃 1 娘憾⇘ 1 徂⤀⩞ 2 ␚ᾱ剖 3 㜵䍰曙 1

P47

Leuprorelin Acetate Granuloma濣A Case Report and Successfully Treated with Intralesional Triamcinolone Acetonide Leuprorelin Acetate 佇养倩濣ᶣ䒃㼴㮦⫂ Triamcinolone Acetonide 㭹䔀䕂㜆ṉ⛯⌈ Pai-Shan Cheng,1 Department of Dermatology, Chi Mei Medical Center 愔䙥䎱 1

P48

Early antihistamine exposure is not associated with an increased attention deficit and hyperactivity disorder (ADHD) risk in atopic dermatitis (AD) patients 㒧㗝ㅕ䰂䴒侸㕲旰᳋㗁❜⅞䐮ḋ⻥䕬偘㽌䒃䦣丷⽡㮦⿍⅙᳋山弌↓䒅䕂杦敨 Chia-Jung Hsu,1ƞWen-Ting Hsieh,2ƞTom C. Chan, MD., PhD1ƞYung-Tsu Cho, MD.1ƞChao-Hsiun Tang, PhD2ƞChia-Yu Chu, MD., PhD1 Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan 2 School of Health Care Administration, Taipei Medical University, Taipei, Taiwan 娘◰⮠ 1 嬄㕮⩞ 2 婠㙡⁸ 1 ⌺暴ⓙ 1 㹖㾈喗 2 㜘⮝䑃 1

P49

Various skin manifestations related to inflammatory bowel disease濣 A nationwide cross-sectional study on the Korean population UiHyeon Jo,1ƞJin Yong Lee,2ƞHanjae Lee,1ƞDo-Yeop Kim,1ƞSungchan Kang,3ƞSeong-Joon Koh, 4ƞHyunsun Park,1 Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, South Korea 2 Department of Health Policy and Management, Seoul National University College of Medicine, Seoul, Korea 3 Graduate School of Public Health, Seoul National University, Seoul, South Korea 4 Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea

Chronic graft-versus-host disease presenting as lichen planus-like skin eruptions濣a case report and literature review P50

Ting-Jung Hsu,1ƞLai-San Wong,1 Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine 娘⺔㥼 1 溪湾䎱 1

P51

Successful treatment of Kaposi sarcoma by everolimus and dose reduction of immunosuppressants in a kidney transplant recipient YANG, HSING-SAN,1ƞShen-Shin Chang,2ƞCheng-Lin, Wu,3ƞPo-Chang Lee,3ƞJulia Yu-Yun Lee,1ƞChao-Kai Hsu,1,4 Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 2 Division of Transplantation, Department of Surgery, National Chung Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 3 Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan 4 Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan 㤱䛨ᷰ 1 ⼜⋄⋂ 2 ⷒ㔦曽 3 㜵἖䑲 3 㜵䍰曙 1 娘憾⇘ 1,4

P52

Plaque form syphilis with non-reactive RPR, a case report Yuan-Hsin Lo,1,2ƞRuey-Yi Lin,1,3ƞCher-Wei Liang,2,4 Department of Dermatology, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan 2 School of medicine, Fu Jen Catholic University, New Taipei City, Taiwan 3 Department of Dermatology, Taipei City Hospital, Taipei, Taiwan 4 Department of Pathology, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan

P53

A Large Eccrine Porocarcinoma of the Perianal Region濣A Case Report and Review of the Literature Giang Huong Tran,1ƞNhanThi Ai Le,1ƞHuy Q. Nguyen,2ƞThuy Phung,3 University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam 2 Detroit Medical Center/Wayne State University, Detroit, Michigan, USA 3 University of South Alabama College of Medicine, Mobile, Alabama, USA

P54

Trichotillomania masked by diffuse alopecia areata濣a case report Val Constantine Cua,1ƞFelix Paolo Lizarondo,1ƞClaudine Yap-Silva,2 Resident Physician, Department of Dermatology, Philippine General Hospital, University of the Philippines Manila 2 Clinical Associate Professor, Department of Dermatology, College of Medicine and Philippine General Hospital, University of the Philippines Manila

P55

IgA Pemphigus in Childhood with Oral Mucosal Involvement濣A Rare Case Report NhanThi Ai Le,1ƞGiang Huong Tran,1ƞThi Anh Minh Nguyen,2ƞHuy Q. Nguyen,3ƞThuy Phung, 4 1 University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam 2 Ho Chi Minh City Hospital of Dermatology and Venereology, Ho Chi Minh City, Vietnam 3 Detroit Medical Center/Wayne State University, Detroit, Michigan, USA 4 University of South Alabama College of Medicine, Mobile, Alabama, USA

P56

Asymptomatic dark reddish variable sized plaques and nodules on the face, neck, abdomen in a 58-year-old woman Jun Hyeong Park,1ƞSook Jung Yun,1 Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea

P57

A Patient with an Eruptive Nodule Over the Mandibular Area Ro-Wei Wu,1ƞChung-Hsing Chang,1,2 1 Skin Institute, Department of Dermatology, Buddhist Tzu-Chi General Hospital, Hualien, Taiwan 2 Doctoral Degree Program in Translational Medicine, Tzu Chi University and Academia Sinica, College of Medicine, Tzu Chi University, Hualien, Taiwan ␚勌啮 1 ⼜Ḕ凯 1,2

P58

Non-cultured Melanocyte-Keratinocyte Transplantation using Suction Blisters to Treat Refractory Vitiligo濣 A Retrospective Study of 41 Cases in Korea Jung Min Bae,1,2ƞSeoGyeong Lee,1 Department of Dermatology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea 2 Heal House Skin Clinic, Suwon, Korea

P59

Differential diagnosis of childhood hypopigmentation濣A retrospective study of1,783 patients Hyun Jeong Ju,1ƞJung Min Bae,1,2 1 Department of Dermatology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 2 Heal House Skin Clinic, Suwon, Korea

P60

An Identification of Potential Therapeutics for Vitiligo by Mass Screening for1732 Medicines in Korean National Health Insurance Database Solam Lee,1ƞMiri Kim,2ƞJu Hee Han,2ƞHyun Jeong Ju,3ƞJung Min Bae,3,4 Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea 2 Department of Dermatology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 3 Department of Dermatology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea 4 Heal House Skin Clinic, Suwon, Korea

P61

Mass screening on comorbidities of vitiligo濣A nationwide population-based study JuHee Han,1ƞMiri Kim,1ƞJung Min Bae,2,3 Department of Dermatology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 2 Department of Dermatology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 3 Heal House Skin Clinic, Suwon, Korea

NOTE